{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "uaGnb0-r5hcw"
      },
      "source": [
        "\n",
        "#Predicting Market Reactions to Earnings Calls Using Financial Language Models\n",
        "\n",
        "*Ahmad Alshikh Menou, Risha Baid*"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "mhS2ah96RDt6"
      },
      "outputs": [],
      "source": [
        "##if the first code block does not run, make sure to uncomment this and run.\n",
        "!pip install --no-cache-dir --force-reinstall -U numpy"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "7jIpZqZT6Hff",
        "outputId": "87d300d9-b3c2-4b7f-b72b-21c7dabf9e18"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "[nltk_data] Downloading package punkt_tab to /tmp/nltk...\n",
            "[nltk_data]   Package punkt_tab is already up-to-date!\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\u001b[38;5;10m______      __           _    ______      _        \n",
            "|  _  \\    / _|         | |   | ___ \\    | |       \n",
            "| | | |___| |_ ___  __ _| |_  | |_/ / ___| |_ __ _ \n",
            "| | | / _ \\  _/ _ \\/ _` | __| | ___ \\/ _ \\ __/ _` |\n",
            "| |/ /  __/ ||  __/ (_| | |_  | |_/ /  __/ || (_| |\n",
            "|___/ \\___|_| \\___|\\__,_|\\__| \\____/ \\___|\\__\\__,_|\u001b[0m\n",
            "\u001b[1;38;5;10mðŸ“ˆ:: Data Update Time ::\u001b[0m\t2025-12-12 \u001b[1;38;5;10m::\u001b[0m\n",
            "\u001b[1;38;5;10mðŸ“ˆ:: Software Version ::\u001b[0m\t0.0.27      \u001b[1;38;5;10m::\u001b[0m\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.12/dist-packages/transformers/utils/generic.py:441: FutureWarning: `torch.utils._pytree._register_pytree_node` is deprecated. Please use `torch.utils._pytree.register_pytree_node` instead.\n",
            "  _torch_pytree._register_pytree_node(\n",
            "/usr/local/lib/python3.12/dist-packages/huggingface_hub/file_download.py:942: FutureWarning: `resume_download` is deprecated and will be removed in version 1.0.0. Downloads always resume when possible. If you want to force a new download, use `force_download=True`.\n",
            "  warnings.warn(\n",
            "/usr/local/lib/python3.12/dist-packages/huggingface_hub/utils/_auth.py:94: UserWarning: \n",
            "The secret `HF_TOKEN` does not exist in your Colab secrets.\n",
            "To authenticate with the Hugging Face Hub, create a token in your settings tab (https://huggingface.co/settings/tokens), set it as secret in your Google Colab and restart your session.\n",
            "You will be able to reuse this secret in all of your notebooks.\n",
            "Please note that authentication is recommended but still optional to access public models or datasets.\n",
            "  warnings.warn(\n",
            "/usr/local/lib/python3.12/dist-packages/transformers/utils/generic.py:309: FutureWarning: `torch.utils._pytree._register_pytree_node` is deprecated. Please use `torch.utils._pytree.register_pytree_node` instead.\n",
            "  _torch_pytree._register_pytree_node(\n",
            "/usr/local/lib/python3.12/dist-packages/transformers/utils/generic.py:309: FutureWarning: `torch.utils._pytree._register_pytree_node` is deprecated. Please use `torch.utils._pytree.register_pytree_node` instead.\n",
            "  _torch_pytree._register_pytree_node(\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "BertForSequenceClassification(\n",
              "  (bert): BertModel(\n",
              "    (embeddings): BertEmbeddings(\n",
              "      (word_embeddings): Embedding(30522, 768, padding_idx=0)\n",
              "      (position_embeddings): Embedding(512, 768)\n",
              "      (token_type_embeddings): Embedding(2, 768)\n",
              "      (LayerNorm): LayerNorm((768,), eps=1e-12, elementwise_affine=True)\n",
              "      (dropout): Dropout(p=0.1, inplace=False)\n",
              "    )\n",
              "    (encoder): BertEncoder(\n",
              "      (layer): ModuleList(\n",
              "        (0-11): 12 x BertLayer(\n",
              "          (attention): BertAttention(\n",
              "            (self): BertSelfAttention(\n",
              "              (query): Linear(in_features=768, out_features=768, bias=True)\n",
              "              (key): Linear(in_features=768, out_features=768, bias=True)\n",
              "              (value): Linear(in_features=768, out_features=768, bias=True)\n",
              "              (dropout): Dropout(p=0.1, inplace=False)\n",
              "            )\n",
              "            (output): BertSelfOutput(\n",
              "              (dense): Linear(in_features=768, out_features=768, bias=True)\n",
              "              (LayerNorm): LayerNorm((768,), eps=1e-12, elementwise_affine=True)\n",
              "              (dropout): Dropout(p=0.1, inplace=False)\n",
              "            )\n",
              "          )\n",
              "          (intermediate): BertIntermediate(\n",
              "            (dense): Linear(in_features=768, out_features=3072, bias=True)\n",
              "            (intermediate_act_fn): GELUActivation()\n",
              "          )\n",
              "          (output): BertOutput(\n",
              "            (dense): Linear(in_features=3072, out_features=768, bias=True)\n",
              "            (LayerNorm): LayerNorm((768,), eps=1e-12, elementwise_affine=True)\n",
              "            (dropout): Dropout(p=0.1, inplace=False)\n",
              "          )\n",
              "        )\n",
              "      )\n",
              "    )\n",
              "    (pooler): BertPooler(\n",
              "      (dense): Linear(in_features=768, out_features=768, bias=True)\n",
              "      (activation): Tanh()\n",
              "    )\n",
              "  )\n",
              "  (dropout): Dropout(p=0.1, inplace=False)\n",
              "  (classifier): Linear(in_features=768, out_features=3, bias=True)\n",
              ")"
            ]
          },
          "metadata": {},
          "execution_count": 2
        }
      ],
      "source": [
        "import subprocess\n",
        "import sys\n",
        "\n",
        "#Install all dependencies with compatible versions\n",
        "subprocess.run([\n",
        "    sys.executable, \"-m\", \"pip\", \"install\", \"-q\",\n",
        "    \"requests\", \"pandas\", \"numpy\", \"yfinance\",\n",
        "    \"defeatbeta-api\", \"nltk\"\n",
        "], check=True)\n",
        "\n",
        "#Install PyTorch and compatible transformers\n",
        "subprocess.run([\n",
        "    sys.executable, \"-m\", \"pip\", \"install\", \"-q\",\n",
        "    \"torch\", \"torchvision\", \"torchaudio\"\n",
        "], check=True)\n",
        "\n",
        "subprocess.run([\n",
        "    sys.executable, \"-m\", \"pip\", \"install\", \"-q\",\n",
        "    \"transformers==4.36.2\", \"sentencepiece\", \"protobuf\"\n",
        "], check=True)\n",
        "\n",
        "#Import everything\n",
        "import requests\n",
        "import re\n",
        "import numpy as np\n",
        "import pandas as pd\n",
        "import time\n",
        "from datetime import datetime, timedelta\n",
        "import yfinance as yf\n",
        "from defeatbeta_api.data.ticker import Ticker\n",
        "import nltk\n",
        "from nltk.sentiment import SentimentIntensityAnalyzer\n",
        "import torch\n",
        "from transformers import AutoTokenizer, AutoModelForSequenceClassification\n",
        "\n",
        "#Download VADER\n",
        "nltk.download('vader_lexicon', quiet=True)\n",
        "sia = SentimentIntensityAnalyzer()\n",
        "\n",
        "#Load FinBERT\n",
        "tokenizer = AutoTokenizer.from_pretrained(\"ProsusAI/finbert\")\n",
        "model = AutoModelForSequenceClassification.from_pretrained(\"ProsusAI/finbert\")\n",
        "model.eval()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "pGsctYwg7a_D"
      },
      "outputs": [],
      "source": [
        "import requests\n",
        "import re\n",
        "import numpy as np\n",
        "import pandas as pd\n",
        "import time\n",
        "import readline\n",
        "from datetime import datetime, timedelta\n",
        "import yfinance as yf"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "GJp9Y3D62fpW"
      },
      "source": [
        "#Objective\n",
        "\n",
        "To build and evaluate predictive models that use linguistic features from corporate earnings calls, combined with firm characteristics to predict short-term stock market reactions following earnings announcements."
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "jO-y_XFG2q_j"
      },
      "source": [
        "#Goals\n",
        "\n",
        "- Transform unstructured earnings call text into predictive numerical features using VADER and FinBERT.\n",
        "\n",
        "- Evaluate whether language alone contains predictive information about short-term market reactions.\n",
        "\n",
        "- Compare traditional sentiment metrics (VADER) with financial language models (FinBERT).\n",
        "\n",
        "- Assess which linguistic dimensions-tone, confidence, disagreement, or complexityâ€”matter most for prediction."
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "CR1U2amw3H8h"
      },
      "source": [
        "#Sample Size\n",
        "\n",
        "\n",
        "This study focuses on the top 2 companies (by market cap) for 5 main sectors i.e. Technology, Communication Services, Consumer Discretionary,  Health Care, Financials"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "iUsEfCtH6Rjy"
      },
      "source": [
        "#Data Sources\n",
        "\n",
        "- Constituents List: The list of S&P 500 companies was obtained from  \n",
        "  https://datahub.io/core/s-and-p-500-companies/r/constituents.csv.\n",
        "- Transcripts: `defeatbeta_api` â†’ `Ticker(...).earning_call_transcripts()` and `get_transcript(year, quarter)`; `content_full` concatenated per call.  \n",
        "- Prices & Benchmark: `yfinance` â†’ daily prices and volumes for firm tickers + SPY; used to compute 1-day, 3-day, and 5-day post-earnings returns and CAR5.  \n",
        "- Firm Metadata: `yfinance.info` â†’ sector, industry, company name, and `market_cap_billion`.  \n",
        "- Baseline Sentiment: `nltk.sentiment.VADER` â†’ sentence-level polarity scores aggregated into `vader_mean`, `vader_pos_share`, `vader_neg_share`, and `vader_neu_share`.  \n",
        "- Financial NLP Model: Hugging Face Transformers â†’ `ProsusAI/finbert`; used to extract financial sentiment scores, confidence, entropy, and dispersion measures from earnings call text.\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "R0w549dx0l5S"
      },
      "source": [
        "# Data Collection"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "ztMo5InL8PF9"
      },
      "source": [
        "**Finding the top 2 companies (by market cap) from 5 main sectors through the S&P500 market data.**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "FInp7pg27bdN",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 323
        },
        "outputId": "92272491-cb1a-4789-d336-0c048b8b7c0e"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<Response [200]>\n",
            "Symbol,Security,GICS Sector,GICS Sub-Industry,Headquarters Location,Date added,CIK,Founded\n",
            "MMM,3M,Industrials,Industrial Conglomerates,\"Saint Paul, Minnesota\",1957-03-04,66740,1902\n",
            "AOS,A. O. Smith,Industrials,Building Products,\"Milwaukee, Wisconsin\",2017-07-26,91142,1916\n",
            "ABT,Abbott Laboratories,Health Care,Health Care Equipment,\"North Chicago, Illinois\",1957-03-04,1800,1888\n",
            "ABBV,AbbVie,Health Care,Biotechnology,\"North Chicago, Illinois\",2012-12-31,1551152,2013 (1888)\n",
            "ACN,Accenture,Information Te\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "  Symbol             Security             GICS Sector  \\\n",
              "0    MMM                   3M             Industrials   \n",
              "1    AOS          A. O. Smith             Industrials   \n",
              "2    ABT  Abbott Laboratories             Health Care   \n",
              "3   ABBV               AbbVie             Health Care   \n",
              "4    ACN            Accenture  Information Technology   \n",
              "\n",
              "                GICS Sub-Industry    Headquarters Location  Date added  \\\n",
              "0        Industrial Conglomerates    Saint Paul, Minnesota  1957-03-04   \n",
              "1               Building Products     Milwaukee, Wisconsin  2017-07-26   \n",
              "2           Health Care Equipment  North Chicago, Illinois  1957-03-04   \n",
              "3                   Biotechnology  North Chicago, Illinois  2012-12-31   \n",
              "4  IT Consulting & Other Services          Dublin, Ireland  2011-07-06   \n",
              "\n",
              "       CIK      Founded  \n",
              "0    66740         1902  \n",
              "1    91142         1916  \n",
              "2     1800         1888  \n",
              "3  1551152  2013 (1888)  \n",
              "4  1467373         1989  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-fd468e39-7071-4009-a8ea-dda5c3556d4f\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Symbol</th>\n",
              "      <th>Security</th>\n",
              "      <th>GICS Sector</th>\n",
              "      <th>GICS Sub-Industry</th>\n",
              "      <th>Headquarters Location</th>\n",
              "      <th>Date added</th>\n",
              "      <th>CIK</th>\n",
              "      <th>Founded</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>MMM</td>\n",
              "      <td>3M</td>\n",
              "      <td>Industrials</td>\n",
              "      <td>Industrial Conglomerates</td>\n",
              "      <td>Saint Paul, Minnesota</td>\n",
              "      <td>1957-03-04</td>\n",
              "      <td>66740</td>\n",
              "      <td>1902</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>AOS</td>\n",
              "      <td>A. O. Smith</td>\n",
              "      <td>Industrials</td>\n",
              "      <td>Building Products</td>\n",
              "      <td>Milwaukee, Wisconsin</td>\n",
              "      <td>2017-07-26</td>\n",
              "      <td>91142</td>\n",
              "      <td>1916</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>ABT</td>\n",
              "      <td>Abbott Laboratories</td>\n",
              "      <td>Health Care</td>\n",
              "      <td>Health Care Equipment</td>\n",
              "      <td>North Chicago, Illinois</td>\n",
              "      <td>1957-03-04</td>\n",
              "      <td>1800</td>\n",
              "      <td>1888</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>ABBV</td>\n",
              "      <td>AbbVie</td>\n",
              "      <td>Health Care</td>\n",
              "      <td>Biotechnology</td>\n",
              "      <td>North Chicago, Illinois</td>\n",
              "      <td>2012-12-31</td>\n",
              "      <td>1551152</td>\n",
              "      <td>2013 (1888)</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>ACN</td>\n",
              "      <td>Accenture</td>\n",
              "      <td>Information Technology</td>\n",
              "      <td>IT Consulting &amp; Other Services</td>\n",
              "      <td>Dublin, Ireland</td>\n",
              "      <td>2011-07-06</td>\n",
              "      <td>1467373</td>\n",
              "      <td>1989</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-fd468e39-7071-4009-a8ea-dda5c3556d4f')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-fd468e39-7071-4009-a8ea-dda5c3556d4f button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-fd468e39-7071-4009-a8ea-dda5c3556d4f');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-bcf7833a-129d-46d7-83a3-72ca923bfeee\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-bcf7833a-129d-46d7-83a3-72ca923bfeee')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-bcf7833a-129d-46d7-83a3-72ca923bfeee button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "sp500",
              "summary": "{\n  \"name\": \"sp500\",\n  \"rows\": 503,\n  \"fields\": [\n    {\n      \"column\": \"Symbol\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 503,\n        \"samples\": [\n          \"KVUE\",\n          \"BRO\",\n          \"LYV\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Security\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 503,\n        \"samples\": [\n          \"Kenvue\",\n          \"Brown & Brown\",\n          \"Live Nation Entertainment\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"GICS Sector\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 11,\n        \"samples\": [\n          \"Materials\",\n          \"Industrials\",\n          \"Consumer Staples\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"GICS Sub-Industry\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 129,\n        \"samples\": [\n          \"Health Care Distributors\",\n          \"Automotive Retail\",\n          \"Tobacco\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Headquarters Location\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 252,\n        \"samples\": [\n          \"Eagle, Idaho\",\n          \"Arlington, Virginia\",\n          \"Newtown, Pennsylvania\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Date added\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 374,\n        \"samples\": [\n          \"2020-12-21\",\n          \"1982-11-30\",\n          \"1995-07-13\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"CIK\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 574268,\n        \"min\": 1800,\n        \"max\": 2041610,\n        \"num_unique_values\": 500,\n        \"samples\": [\n          1590955,\n          14693,\n          1126328\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Founded\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 197,\n        \"samples\": [\n          \"2015 (1869)\",\n          \"1956\",\n          \"1917\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 4
        }
      ],
      "source": [
        "sp500_url = \"https://datahub.io/core/s-and-p-500-companies/r/constituents.csv\" #getting top marketcap companies from s&p500 csv file\n",
        "\n",
        "response = requests.get(sp500_url)\n",
        "print(response)                  # <Response [200]>\n",
        "print(response.text[:500])       # preview first 500 chars\n",
        "\n",
        "#read the CSV text into a DataFrame\n",
        "from io import StringIO\n",
        "sp500 = pd.read_csv(StringIO(response.text))\n",
        "sp500.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "S_B76y-i8b0j",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 204
        },
        "outputId": "57fdf0aa-41fd-476d-cc85-999178a63b65"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "  ticker             gics_sector chosen_sector\n",
              "2    ABT             Health Care   Health Care\n",
              "3   ABBV             Health Care   Health Care\n",
              "4    ACN  Information Technology    Technology\n",
              "5   ADBE  Information Technology    Technology\n",
              "6    AMD  Information Technology    Technology"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-680d6cf8-f8a8-4baa-9fcb-5841f646492f\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>ticker</th>\n",
              "      <th>gics_sector</th>\n",
              "      <th>chosen_sector</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>ABT</td>\n",
              "      <td>Health Care</td>\n",
              "      <td>Health Care</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>ABBV</td>\n",
              "      <td>Health Care</td>\n",
              "      <td>Health Care</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>ACN</td>\n",
              "      <td>Information Technology</td>\n",
              "      <td>Technology</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>ADBE</td>\n",
              "      <td>Information Technology</td>\n",
              "      <td>Technology</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>AMD</td>\n",
              "      <td>Information Technology</td>\n",
              "      <td>Technology</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-680d6cf8-f8a8-4baa-9fcb-5841f646492f')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-680d6cf8-f8a8-4baa-9fcb-5841f646492f button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-680d6cf8-f8a8-4baa-9fcb-5841f646492f');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-2b384bee-3c04-489e-8b5d-8cd40571629f\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-2b384bee-3c04-489e-8b5d-8cd40571629f')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-2b384bee-3c04-489e-8b5d-8cd40571629f button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"sp500[[\\\"ticker\\\",\\\"gics_sector\\\",\\\"chosen_sector\\\"]]\",\n  \"rows\": 5,\n  \"fields\": [\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"ABBV\",\n          \"AMD\",\n          \"ACN\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"gics_sector\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Information Technology\",\n          \"Health Care\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chosen_sector\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Technology\",\n          \"Health Care\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 5
        }
      ],
      "source": [
        "#Rename the columns and prep tickers\n",
        "sp500 = sp500.rename(columns={\"Symbol\": \"ticker\", \"GICS Sector\": \"gics_sector\"})\n",
        "sp500[\"ticker\"] = sp500[\"ticker\"].astype(str).str.replace(\".\", \"-\", regex=False)  # BRK.B -> BRK-B for Yahoo\n",
        "\n",
        "#Keep only these main 5 sectors\n",
        "target_map = {\n",
        "    \"Information Technology\": \"Technology\",\n",
        "    \"Communication Services\": \"Communication Services\",\n",
        "    \"Consumer Discretionary\": \"Consumer Discretionary\",\n",
        "    \"Health Care\": \"Health Care\",\n",
        "    \"Financials\": \"Financials\"\n",
        "}\n",
        "\n",
        "sp500 = sp500[sp500[\"gics_sector\"].isin(target_map.keys())].copy()\n",
        "sp500[\"chosen_sector\"] = sp500[\"gics_sector\"].map(target_map)\n",
        "\n",
        "sp500[[\"ticker\",\"gics_sector\",\"chosen_sector\"]].head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "yeWLudO38eHF",
        "outputId": "f10ea095-f542-4fa2-a972-540e513ed10d"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "ABT 217766232064\n",
            "ABBV 393808642048\n",
            "ACN 178268864512\n",
            "ADBE 150934601728\n",
            "AMD 327334035456\n",
            "AFL 59077484544\n",
            "A 38811205632\n",
            "ABNB 82033459200\n",
            "AKAM 12730634240\n",
            "ALGN 11702199296\n",
            "ALL 54000144384\n",
            "GOOGL 3663432253440\n",
            "GOOG 3666819416064\n",
            "AMZN 2424113201152\n",
            "AXP 261317689344\n",
            "AIG 47749591040\n",
            "AMP 45975302144\n",
            "AMGN 174693892096\n",
            "APH 158649843712\n",
            "ADI 134615711744\n",
            "AON 76120498176\n",
            "APO 84915830784\n",
            "AAPL 4039405731840\n",
            "AMAT 201948856320\n",
            "APTV 16895982592\n",
            "ACGL 35997093888\n",
            "ANET 156932112384\n",
            "AJG 64879214592\n",
            "AIZ 12010806272\n",
            "T 173468352512\n",
            "ADSK 63738118144\n",
            "AZO 56830328832\n",
            "BAC 401900961792\n",
            "BAX 9803043840\n",
            "BDX 55806365696\n",
            "BRK-B 1085980803072\n",
            "BBY 15076867072\n",
            "TECH 8896905216\n",
            "BIIB 24926183424\n",
            "BLK 165234163712\n",
            "BX 188635742208\n",
            "XYZ 39251111936\n",
            "BK 80714809344\n",
            "BKNG 173246087168\n",
            "BSX 142477492224\n",
            "BMY 108566716416\n",
            "AVGO 1557813788672\n",
            "BRO 27678984192\n",
            "CDNS 85861597184\n",
            "CZR 4987636736\n",
            "COF 155274805248\n",
            "CAH 47305175040\n",
            "KMX 5903838720\n",
            "CCL 38425698304\n",
            "CBOE 26021951488\n",
            "CDW 18752172032\n",
            "COR 66070282240\n",
            "CNC 19277336576\n",
            "CRL 9540419584\n",
            "SCHW 176493789184\n",
            "CHTR 28206039040\n",
            "CMG 50457501696\n",
            "CB 123976736768\n",
            "CI 73192472576\n",
            "CINF 26257164288\n",
            "CSCO 304036708352\n",
            "C 207708520448\n",
            "CFG 25195094016\n",
            "CME 95930359808\n",
            "CTSH 40908046336\n",
            "COIN 64502095872\n",
            "CMCSA 111763095552\n",
            "COO 16393784320\n",
            "GLW 74487463936\n",
            "CPAY 21627066368\n",
            "CRWD 120316502016\n",
            "CVS 98749153280\n",
            "DHR 160646184960\n",
            "DRI 22488825856\n",
            "DDOG 48494256128\n",
            "DVA 8304724992\n",
            "DECK 14915924992\n",
            "DELL 82394415104\n",
            "DXCM 25846953984\n",
            "DPZ 14644545536\n",
            "DASH 99534798848\n",
            "DHI 44217966592\n",
            "EBAY 38232621056\n",
            "EW 49786085376\n",
            "EA 50996637696\n",
            "ELV 77596442624\n",
            "ENPH 4313136128\n",
            "EPAM 11530375168\n",
            "ERIE 15114385408\n",
            "EG 13958542336\n",
            "EXPE 35331932160\n",
            "FFIV 15051599872\n",
            "FDS 10335994880\n",
            "FICO 42280280064\n",
            "FIS 34424750080\n",
            "FITB 31505395712\n",
            "FSLR 28092198912\n",
            "FI 34314950656\n",
            "F 53073522688\n",
            "FTNT 61109719040\n",
            "FOXA 31635359744\n",
            "FOX 29860573184\n",
            "BEN 12451196928\n",
            "GRMN 38922276864\n",
            "IT 18901383168\n",
            "GEHC 37675499520\n",
            "GEN 17076869120\n",
            "GM 77280157696\n",
            "GPC 17518184448\n",
            "GILD 150720823296\n",
            "GPN 19922896896\n",
            "GL 11221420032\n",
            "GDDY 17537337344\n",
            "GS 265274490880\n",
            "HIG 38747615232\n",
            "HAS 11511845888\n",
            "HCA 109172006912\n",
            "HSIC 9340091392\n",
            "HPE 31561246720\n",
            "HLT 67658190848\n",
            "HOLX 16704518144\n",
            "HD 353396621312\n",
            "HPQ 21918758912\n",
            "HUM 31351582720\n",
            "HBAN 27700789248\n",
            "IBM 280841224192\n",
            "IDXX 55771271168\n",
            "INCY 19104161792\n",
            "PODD 20616566784\n",
            "INTC 173055590400\n",
            "ICE 91627773952\n",
            "IPG 8999164928\n",
            "INTU 186216185856\n",
            "ISRG 201424371712\n",
            "IVZ 11809120256\n",
            "IQV 37895155712\n",
            "JBL 23187974144\n",
            "JKHY 13398009856\n",
            "JNJ 501880258560\n",
            "JPM 860672950272\n",
            "KEY 22961041408\n",
            "KEYS 34290479104\n",
            "KKR 122193928192\n",
            "KLAC 160969850880\n",
            "LH 20943693824\n",
            "LRCX 207692021760\n",
            "LVS 45964935168\n",
            "LEN 26754363392\n",
            "LLY 947447201792\n",
            "LYV 32249221120\n",
            "LKQ 7641607680\n",
            "L 21958158336\n",
            "LOW 138953293824\n",
            "LULU 25509713920\n",
            "MTB 31825805312\n",
            "MKTX 6764710912\n",
            "MAR 83288694784\n",
            "MMC 91309326336\n",
            "MA 511860572160\n",
            "MTCH 7846688256\n",
            "MCD 228103651328\n",
            "MCK 100821008384\n",
            "MDT 126312030208\n",
            "MRK 251501805568\n",
            "META 1674764615680\n",
            "MET 54339276800\n",
            "MTD 28620718080\n",
            "MGM 10056832000\n",
            "MCHP 34621022208\n",
            "MU 279705681920\n",
            "MSFT 3597503823872\n",
            "MRNA 12093206528\n",
            "MHK 6802823168\n",
            "MOH 8819424256\n",
            "MPWR 44528599040\n",
            "MCO 89265004544\n",
            "MS 276102250496\n",
            "MSI 62266535936\n",
            "MSCI 43510206464\n",
            "NDAQ 54344146944\n",
            "NTAP 22057832448\n",
            "NFLX 398308376576\n",
            "NWSA 15289074688\n",
            "NWS 16581063680\n",
            "NKE 97014349824\n",
            "NTRS 26374080512\n",
            "NCLH 9847219200\n",
            "NVDA 4239786770432\n",
            "NVR 20893542400\n",
            "NXPI 55989608448\n",
            "ORLY 77657309184\n",
            "OMC 25913919488\n",
            "ON 22223646720\n",
            "ORCL 517249597440\n",
            "PLTR 442580303872\n",
            "PANW 129558364160\n",
            "PSKY 14352203776\n",
            "PYPL 56787693568\n",
            "PFE 142370127872\n",
            "PNC 82320302080\n",
            "POOL 8820484096\n",
            "PFG 19902132224\n",
            "PGR 131812933632\n",
            "PRU 40667009024\n",
            "PTC 21071536128\n",
            "PHM 24003223552\n",
            "QCOM 187951022080\n",
            "DGX 19697698816\n",
            "RL 22440681472\n",
            "RJF 31945299968\n",
            "REGN 79353856000\n",
            "RF 24529555456\n",
            "RMD 35404124160\n",
            "RVTY 11173146624\n",
            "ROP 48491741184\n",
            "ROST 59376562176\n",
            "RCL 78194991104\n",
            "SPGI 154698563584\n",
            "CRM 245473198080\n",
            "STX 63618637824\n",
            "NOW 159268372480\n",
            "SWKS 9669001216\n",
            "SOLV 13993748480\n",
            "SBUX 101679480832\n",
            "STT 36134273024\n",
            "STE 24775313408\n",
            "SYK 135037607936\n",
            "SMCI 17533042688\n",
            "SYF 31133773824\n",
            "SNPS 87306010624\n",
            "TMUS 225387675648\n",
            "TROW 22700980224\n",
            "TTWO 45575696384\n",
            "TPR 25958490112\n",
            "TEL 66561302528\n",
            "TDY 23684894720\n",
            "TER 30295554048\n",
            "TSLA 1607601225728\n",
            "TXN 160180879360\n",
            "TMO 211294470144\n",
            "TJX 172371951616\n",
            "TKO 17380986880\n",
            "TTD 18232680448\n",
            "TSCO 27651360768\n",
            "TRV 66110550016\n",
            "TRMB 19016110080\n",
            "TFC 64394387456\n",
            "TYL 19702294528\n",
            "USB 83831922688\n",
            "ULTA 26634436608\n",
            "UNH 297241903104\n",
            "UHS 14302159872\n",
            "VRSN 22828126208\n",
            "VZ 170385752064\n",
            "VRTX 114704056320\n",
            "VTRS 13784337408\n",
            "V 667763736576\n",
            "WRB 26430474240\n",
            "DIS 201134866432\n",
            "WBD 68428591104\n",
            "WAT 22403518464\n",
            "WFC 293050810368\n",
            "WST 19328315392\n",
            "WDC 59992641536\n",
            "WSM 22605932544\n",
            "WTW 32156694528\n",
            "WDAY 58227359744\n",
            "WYNN 13154070528\n",
            "YUM 42952892416\n",
            "ZBRA 12849078272\n",
            "ZBH 17915613184\n",
            "ZTS 54405206016\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "    ticker           chosen_sector     market_cap\n",
              "12    GOOG  Communication Services  3666819416064\n",
              "11   GOOGL  Communication Services  3663432253440\n",
              "169   META  Communication Services  1674764615680\n",
              "186   NFLX  Communication Services   398308376576\n",
              "235   TMUS  Communication Services   225387675648"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-c277afa5-f23d-4979-81c7-64190a9858aa\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>ticker</th>\n",
              "      <th>chosen_sector</th>\n",
              "      <th>market_cap</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>GOOG</td>\n",
              "      <td>Communication Services</td>\n",
              "      <td>3666819416064</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>GOOGL</td>\n",
              "      <td>Communication Services</td>\n",
              "      <td>3663432253440</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>169</th>\n",
              "      <td>META</td>\n",
              "      <td>Communication Services</td>\n",
              "      <td>1674764615680</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>186</th>\n",
              "      <td>NFLX</td>\n",
              "      <td>Communication Services</td>\n",
              "      <td>398308376576</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>235</th>\n",
              "      <td>TMUS</td>\n",
              "      <td>Communication Services</td>\n",
              "      <td>225387675648</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-c277afa5-f23d-4979-81c7-64190a9858aa')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-c277afa5-f23d-4979-81c7-64190a9858aa button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-c277afa5-f23d-4979-81c7-64190a9858aa');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-4d2b00bb-2e70-44cd-87d4-9a60c1ed221b\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-4d2b00bb-2e70-44cd-87d4-9a60c1ed221b')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-4d2b00bb-2e70-44cd-87d4-9a60c1ed221b button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "mktcaps",
              "summary": "{\n  \"name\": \"mktcaps\",\n  \"rows\": 277,\n  \"fields\": [\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 277,\n        \"samples\": [\n          \"LOW\",\n          \"HBAN\",\n          \"LRCX\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chosen_sector\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Consumer Discretionary\",\n          \"Technology\",\n          \"Financials\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"market_cap\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 556933346068,\n        \"min\": 4313136128,\n        \"max\": 4239786770432,\n        \"num_unique_values\": 277,\n        \"samples\": [\n          138953293824,\n          27700789248,\n          207692021760\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 6
        }
      ],
      "source": [
        "#Pull market caps from Yahoo finance\n",
        "rows = []\n",
        "for i in range(len(sp500)):\n",
        "    t = sp500.iloc[i][\"ticker\"]\n",
        "    s = sp500.iloc[i][\"chosen_sector\"]\n",
        "    try:\n",
        "        info = yf.Ticker(t).info\n",
        "        mc = info.get(\"marketCap\", None)\n",
        "    except Exception:\n",
        "        mc = None\n",
        "    print(t, mc)\n",
        "    rows.append({\"ticker\": t, \"chosen_sector\": s, \"market_cap\": mc})\n",
        "    time.sleep(0.05)\n",
        "\n",
        "#Create DataFrame, remove missing market caps, and clean formatting\n",
        "mktcaps = pd.DataFrame(rows).dropna(subset=[\"market_cap\"]).copy()\n",
        "mktcaps[\"market_cap\"] = mktcaps[\"market_cap\"].astype(\"int64\")\n",
        "\n",
        "#Sort by sector and descending market cap for easy comparison\n",
        "mktcaps = mktcaps.sort_values([\"chosen_sector\",\"market_cap\"], ascending=[True, False])\n",
        "mktcaps.head()\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 359
        },
        "id": "AGNDqSi98gls",
        "outputId": "8507cede-8f49-4cf0-e33d-f132acdb6748"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "            chosen_sector ticker     market_cap  market_cap_bn\n",
              "0  Communication Services   GOOG  3666819416064         3666.8\n",
              "1  Communication Services  GOOGL  3663432253440         3663.4\n",
              "2  Consumer Discretionary   AMZN  2424113201152         2424.1\n",
              "3  Consumer Discretionary   TSLA  1607601225728         1607.6\n",
              "4              Financials  BRK-B  1085980803072         1086.0\n",
              "5              Financials    JPM   860672950272          860.7\n",
              "6             Health Care    LLY   947447201792          947.4\n",
              "7             Health Care    JNJ   501880258560          501.9\n",
              "8              Technology   NVDA  4239786770432         4239.8\n",
              "9              Technology   AAPL  4039405731840         4039.4"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-5d579fdd-17a2-4f50-b9f7-bce62f19ce4a\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>chosen_sector</th>\n",
              "      <th>ticker</th>\n",
              "      <th>market_cap</th>\n",
              "      <th>market_cap_bn</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Communication Services</td>\n",
              "      <td>GOOG</td>\n",
              "      <td>3666819416064</td>\n",
              "      <td>3666.8</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Communication Services</td>\n",
              "      <td>GOOGL</td>\n",
              "      <td>3663432253440</td>\n",
              "      <td>3663.4</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Consumer Discretionary</td>\n",
              "      <td>AMZN</td>\n",
              "      <td>2424113201152</td>\n",
              "      <td>2424.1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Consumer Discretionary</td>\n",
              "      <td>TSLA</td>\n",
              "      <td>1607601225728</td>\n",
              "      <td>1607.6</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Financials</td>\n",
              "      <td>BRK-B</td>\n",
              "      <td>1085980803072</td>\n",
              "      <td>1086.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>Financials</td>\n",
              "      <td>JPM</td>\n",
              "      <td>860672950272</td>\n",
              "      <td>860.7</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>Health Care</td>\n",
              "      <td>LLY</td>\n",
              "      <td>947447201792</td>\n",
              "      <td>947.4</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>Health Care</td>\n",
              "      <td>JNJ</td>\n",
              "      <td>501880258560</td>\n",
              "      <td>501.9</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>Technology</td>\n",
              "      <td>NVDA</td>\n",
              "      <td>4239786770432</td>\n",
              "      <td>4239.8</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>Technology</td>\n",
              "      <td>AAPL</td>\n",
              "      <td>4039405731840</td>\n",
              "      <td>4039.4</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-5d579fdd-17a2-4f50-b9f7-bce62f19ce4a')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-5d579fdd-17a2-4f50-b9f7-bce62f19ce4a button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-5d579fdd-17a2-4f50-b9f7-bce62f19ce4a');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-502ff506-a582-4a82-9328-c4707fe73975\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-502ff506-a582-4a82-9328-c4707fe73975')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-502ff506-a582-4a82-9328-c4707fe73975 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "  <div id=\"id_1822b485-6035-4e36-a2e5-863aaa9e8be9\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('top2_display')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_1822b485-6035-4e36-a2e5-863aaa9e8be9 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('top2_display');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "top2_display",
              "summary": "{\n  \"name\": \"top2_display\",\n  \"rows\": 10,\n  \"fields\": [\n    {\n      \"column\": \"chosen_sector\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Consumer Discretionary\",\n          \"Technology\",\n          \"Financials\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 10,\n        \"samples\": [\n          \"NVDA\",\n          \"GOOGL\",\n          \"JPM\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"market_cap\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1476417160876,\n        \"min\": 501880258560,\n        \"max\": 4239786770432,\n        \"num_unique_values\": 10,\n        \"samples\": [\n          4239786770432,\n          3663432253440,\n          860672950272\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"market_cap_bn\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1476.4104363474119,\n        \"min\": 501.9,\n        \"max\": 4239.8,\n        \"num_unique_values\": 10,\n        \"samples\": [\n          4239.8,\n          3663.4,\n          860.7\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 7
        }
      ],
      "source": [
        "#Pick the top 2 companies per sector\n",
        "top2 = []\n",
        "\n",
        "#Filter companies in the current sector and take the top 2 largest by market cap\n",
        "for sector in mktcaps[\"chosen_sector\"].unique():\n",
        "    top2.append(mktcaps[mktcaps[\"chosen_sector\"] == sector].head(2))\n",
        "    #Combine all sector subsets into one DataFrame\n",
        "top2 = pd.concat(top2, ignore_index=True)\n",
        "\n",
        "top2_display = top2[[\"chosen_sector\",\"ticker\",\"market_cap\"]].copy()\n",
        "top2_display[\"market_cap_bn\"] = (top2_display[\"market_cap\"]/1e9).round(1)\n",
        "top2_display\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "I7mhqWYK8iy1",
        "outputId": "0258e71b-04cb-4e1e-da55-a4bb3b3dc686"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'Communication Services': ['GOOG', 'GOOGL'],\n",
              " 'Consumer Discretionary': ['AMZN', 'TSLA'],\n",
              " 'Financials': ['BRK-B', 'JPM'],\n",
              " 'Health Care': ['LLY', 'JNJ'],\n",
              " 'Technology': ['NVDA', 'AAPL']}"
            ]
          },
          "metadata": {},
          "execution_count": 8
        }
      ],
      "source": [
        "#dictionary to reuse later\n",
        "sector_tickers = {}\n",
        "for sec in top2[\"chosen_sector\"].unique():\n",
        "    sector_tickers[sec] = top2[top2[\"chosen_sector\"] == sec][\"ticker\"].tolist()\n",
        "sector_tickers"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 359
        },
        "id": "6CbZf6dS8lhC",
        "outputId": "5ef838f9-ce4a-455d-c7f3-83f92e106ca6"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "            chosen_sector ticker               yf_sector  \\\n",
              "0  Communication Services   GOOG  Communication Services   \n",
              "1  Communication Services  GOOGL  Communication Services   \n",
              "2  Consumer Discretionary   AMZN       Consumer Cyclical   \n",
              "3  Consumer Discretionary   TSLA       Consumer Cyclical   \n",
              "4              Financials  BRK-B      Financial Services   \n",
              "5              Financials    JPM      Financial Services   \n",
              "6             Health Care    LLY              Healthcare   \n",
              "7             Health Care    JNJ              Healthcare   \n",
              "8              Technology   NVDA              Technology   \n",
              "9              Technology   AAPL              Technology   \n",
              "\n",
              "                      yf_industry                    shortName     market_cap  \\\n",
              "0  Internet Content & Information                Alphabet Inc.  3666819416064   \n",
              "1  Internet Content & Information                Alphabet Inc.  3663432253440   \n",
              "2                 Internet Retail             Amazon.com, Inc.  2424113201152   \n",
              "3              Auto Manufacturers                  Tesla, Inc.  1607601225728   \n",
              "4         Insurance - Diversified  Berkshire Hathaway Inc. New  1085980803072   \n",
              "5             Banks - Diversified        JP Morgan Chase & Co.   860672950272   \n",
              "6    Drug Manufacturers - General        Eli Lilly and Company   947447201792   \n",
              "7    Drug Manufacturers - General            Johnson & Johnson   501880258560   \n",
              "8                  Semiconductors           NVIDIA Corporation  4239786770432   \n",
              "9            Consumer Electronics                   Apple Inc.  4039405731840   \n",
              "\n",
              "   market_cap_billion  \n",
              "0             3666.82  \n",
              "1             3663.43  \n",
              "2             2424.11  \n",
              "3             1607.60  \n",
              "4             1085.98  \n",
              "5              860.67  \n",
              "6              947.45  \n",
              "7              501.88  \n",
              "8             4239.79  \n",
              "9             4039.41  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-34e83b28-ca3c-4d30-9170-698410959e13\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>chosen_sector</th>\n",
              "      <th>ticker</th>\n",
              "      <th>yf_sector</th>\n",
              "      <th>yf_industry</th>\n",
              "      <th>shortName</th>\n",
              "      <th>market_cap</th>\n",
              "      <th>market_cap_billion</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Communication Services</td>\n",
              "      <td>GOOG</td>\n",
              "      <td>Communication Services</td>\n",
              "      <td>Internet Content &amp; Information</td>\n",
              "      <td>Alphabet Inc.</td>\n",
              "      <td>3666819416064</td>\n",
              "      <td>3666.82</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Communication Services</td>\n",
              "      <td>GOOGL</td>\n",
              "      <td>Communication Services</td>\n",
              "      <td>Internet Content &amp; Information</td>\n",
              "      <td>Alphabet Inc.</td>\n",
              "      <td>3663432253440</td>\n",
              "      <td>3663.43</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Consumer Discretionary</td>\n",
              "      <td>AMZN</td>\n",
              "      <td>Consumer Cyclical</td>\n",
              "      <td>Internet Retail</td>\n",
              "      <td>Amazon.com, Inc.</td>\n",
              "      <td>2424113201152</td>\n",
              "      <td>2424.11</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Consumer Discretionary</td>\n",
              "      <td>TSLA</td>\n",
              "      <td>Consumer Cyclical</td>\n",
              "      <td>Auto Manufacturers</td>\n",
              "      <td>Tesla, Inc.</td>\n",
              "      <td>1607601225728</td>\n",
              "      <td>1607.60</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Financials</td>\n",
              "      <td>BRK-B</td>\n",
              "      <td>Financial Services</td>\n",
              "      <td>Insurance - Diversified</td>\n",
              "      <td>Berkshire Hathaway Inc. New</td>\n",
              "      <td>1085980803072</td>\n",
              "      <td>1085.98</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>Financials</td>\n",
              "      <td>JPM</td>\n",
              "      <td>Financial Services</td>\n",
              "      <td>Banks - Diversified</td>\n",
              "      <td>JP Morgan Chase &amp; Co.</td>\n",
              "      <td>860672950272</td>\n",
              "      <td>860.67</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>Health Care</td>\n",
              "      <td>LLY</td>\n",
              "      <td>Healthcare</td>\n",
              "      <td>Drug Manufacturers - General</td>\n",
              "      <td>Eli Lilly and Company</td>\n",
              "      <td>947447201792</td>\n",
              "      <td>947.45</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>Health Care</td>\n",
              "      <td>JNJ</td>\n",
              "      <td>Healthcare</td>\n",
              "      <td>Drug Manufacturers - General</td>\n",
              "      <td>Johnson &amp; Johnson</td>\n",
              "      <td>501880258560</td>\n",
              "      <td>501.88</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>Technology</td>\n",
              "      <td>NVDA</td>\n",
              "      <td>Technology</td>\n",
              "      <td>Semiconductors</td>\n",
              "      <td>NVIDIA Corporation</td>\n",
              "      <td>4239786770432</td>\n",
              "      <td>4239.79</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>Technology</td>\n",
              "      <td>AAPL</td>\n",
              "      <td>Technology</td>\n",
              "      <td>Consumer Electronics</td>\n",
              "      <td>Apple Inc.</td>\n",
              "      <td>4039405731840</td>\n",
              "      <td>4039.41</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-34e83b28-ca3c-4d30-9170-698410959e13')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-34e83b28-ca3c-4d30-9170-698410959e13 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-34e83b28-ca3c-4d30-9170-698410959e13');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-5ec3be83-e731-4e4c-b4ad-3d409bc2c68d\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-5ec3be83-e731-4e4c-b4ad-3d409bc2c68d')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-5ec3be83-e731-4e4c-b4ad-3d409bc2c68d button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "  <div id=\"id_12ca7a90-8c2e-44a0-9f8d-066f5ccaf8f2\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('universe')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_12ca7a90-8c2e-44a0-9f8d-066f5ccaf8f2 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('universe');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "universe",
              "summary": "{\n  \"name\": \"universe\",\n  \"rows\": 10,\n  \"fields\": [\n    {\n      \"column\": \"chosen_sector\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Consumer Discretionary\",\n          \"Technology\",\n          \"Financials\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 10,\n        \"samples\": [\n          \"NVDA\",\n          \"GOOGL\",\n          \"JPM\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"yf_sector\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Consumer Cyclical\",\n          \"Technology\",\n          \"Financial Services\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"yf_industry\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 8,\n        \"samples\": [\n          \"Internet Retail\",\n          \"Drug Manufacturers - General\",\n          \"Internet Content & Information\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"shortName\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 9,\n        \"samples\": [\n          \"NVIDIA Corporation\",\n          \"Amazon.com, Inc.\",\n          \"Eli Lilly and Company\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"market_cap\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1476417160876,\n        \"min\": 501880258560,\n        \"max\": 4239786770432,\n        \"num_unique_values\": 10,\n        \"samples\": [\n          4239786770432,\n          3663432253440,\n          860672950272\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"market_cap_billion\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1476.4181969226893,\n        \"min\": 501.88,\n        \"max\": 4239.79,\n        \"num_unique_values\": 10,\n        \"samples\": [\n          4239.79,\n          3663.43,\n          860.67\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 9
        }
      ],
      "source": [
        "#Flatten to a DataFrame and verify sectors from Yahoo Finance\n",
        "rows = []\n",
        "for sector, tickers in sector_tickers.items():\n",
        "    for t in tickers:\n",
        "        info = yf.Ticker(t).info  #metadata call\n",
        "        market_cap = info.get(\"marketCap\", None)\n",
        "        rows.append({\n",
        "            \"chosen_sector\": sector,\n",
        "            \"ticker\": t,\n",
        "            \"yf_sector\": info.get(\"sector\"),\n",
        "            \"yf_industry\": info.get(\"industry\"),\n",
        "            \"shortName\": info.get(\"shortName\"),\n",
        "            \"market_cap\": market_cap,\n",
        "            \"market_cap_billion\": round(market_cap / 1e9, 2) if market_cap else None\n",
        "        })\n",
        "\n",
        "universe = pd.DataFrame(rows)\n",
        "universe"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "CG8jF6ib9hFZ"
      },
      "source": [
        "**Extracting earnings-call transcripts from the DefeatBeta API [https://github.com/defeat-beta/defeatbeta-api/].**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "sQtHNH0S8qCH"
      },
      "outputs": [],
      "source": [
        "#import the Ticker class from Earnings Call transcript API\n",
        "from defeatbeta_api.data.ticker import Ticker"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "tJiBiUEX8sId",
        "outputId": "cecc14e2-9432-4964-c681-a5b7e63edf65"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['GOOG', 'GOOGL', 'AMZN', 'TSLA', 'BRK-B', 'JPM', 'LLY', 'JNJ', 'NVDA', 'AAPL']"
            ]
          },
          "metadata": {},
          "execution_count": 11
        }
      ],
      "source": [
        "#Flatten dictionary into a simple list of tickers\n",
        "tickers = [t for tickers_list in sector_tickers.values() for t in tickers_list]\n",
        "tickers"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 204
        },
        "id": "SIv_E976_G7d",
        "outputId": "ccfb09b0-7aff-49a0-93f5-e873d6f8b5bd"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "  symbol  fiscal_year  fiscal_quarter report_date  \\\n",
              "0   AAPL         2025               4  2025-10-30   \n",
              "1   AAPL         2025               3  2025-07-31   \n",
              "2   AAPL         2025               2  2025-05-01   \n",
              "3   AAPL         2025               1  2025-01-30   \n",
              "4   AAPL         2024               4  2024-10-31   \n",
              "\n",
              "                                         transcripts  transcripts_id  \n",
              "0  [{'paragraph_number': 1, 'speaker': 'Suhasini ...            <NA>  \n",
              "1  [{'paragraph_number': 1, 'speaker': 'Suhasini ...            <NA>  \n",
              "2  [{'paragraph_number': 1, 'speaker': 'AI Insigh...            <NA>  \n",
              "3  [{'paragraph_number': 1, 'speaker': 'Suhasini ...          506955  \n",
              "4  [{'paragraph_number': 1, 'speaker': 'Suhasini ...          455679  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-5346e7ab-b6c4-499a-824d-107e4cb0cd44\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>symbol</th>\n",
              "      <th>fiscal_year</th>\n",
              "      <th>fiscal_quarter</th>\n",
              "      <th>report_date</th>\n",
              "      <th>transcripts</th>\n",
              "      <th>transcripts_id</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>2025</td>\n",
              "      <td>4</td>\n",
              "      <td>2025-10-30</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'Suhasini ...</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>2025</td>\n",
              "      <td>3</td>\n",
              "      <td>2025-07-31</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'Suhasini ...</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>2025</td>\n",
              "      <td>2</td>\n",
              "      <td>2025-05-01</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'AI Insigh...</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>2025</td>\n",
              "      <td>1</td>\n",
              "      <td>2025-01-30</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'Suhasini ...</td>\n",
              "      <td>506955</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>2024</td>\n",
              "      <td>4</td>\n",
              "      <td>2024-10-31</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'Suhasini ...</td>\n",
              "      <td>455679</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-5346e7ab-b6c4-499a-824d-107e4cb0cd44')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-5346e7ab-b6c4-499a-824d-107e4cb0cd44 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-5346e7ab-b6c4-499a-824d-107e4cb0cd44');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-ecdebeeb-4b23-452a-81ca-86e12d9b0b46\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-ecdebeeb-4b23-452a-81ca-86e12d9b0b46')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-ecdebeeb-4b23-452a-81ca-86e12d9b0b46 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "meta_10y",
              "summary": "{\n  \"name\": \"meta_10y\",\n  \"rows\": 353,\n  \"fields\": [\n    {\n      \"column\": \"symbol\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 9,\n        \"samples\": [\n          \"NVDA\",\n          \"AMZN\",\n          \"JPM\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"fiscal_year\",\n      \"properties\": {\n        \"dtype\": \"int32\",\n        \"num_unique_values\": 10,\n        \"samples\": [\n          2017,\n          2024,\n          2020\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"fiscal_quarter\",\n      \"properties\": {\n        \"dtype\": \"int32\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          3,\n          1,\n          4\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"report_date\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2015-05-07\",\n        \"max\": \"2025-10-30\",\n        \"num_unique_values\": 254,\n        \"samples\": [\n          \"2023-11-21\",\n          \"2024-05-02\",\n          \"2021-04-27\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcripts\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcripts_id\",\n      \"properties\": {\n        \"dtype\": \"Int32\",\n        \"num_unique_values\": 328,\n        \"samples\": [\n          198100,\n          431759,\n          198046\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 12
        }
      ],
      "source": [
        "#Pull the transcripts list (includes transcripts + transcripts_id)\n",
        "all_meta = []\n",
        "\n",
        "for tk in tickers:\n",
        "    tr = Ticker(tk).earning_call_transcripts()\n",
        "    df = tr.get_transcripts_list()\n",
        "    df[\"symbol\"] = tk\n",
        "    all_meta.append(df)\n",
        "\n",
        "meta_df = pd.concat(all_meta, ignore_index=True)\n",
        "\n",
        "#Clean report date\n",
        "meta_df[\"report_date\"] = pd.to_datetime(\n",
        "    meta_df[\"report_date\"], errors=\"coerce\"\n",
        ").dt.date\n",
        "\n",
        "#Keep last 10 fiscal years\n",
        "current_year = pd.Timestamp.today().year\n",
        "meta_10y = meta_df[\n",
        "    meta_df[\"fiscal_year\"].astype(int).between(current_year - 9, current_year)\n",
        "].copy()\n",
        "\n",
        "#Drop duplicates per symbol / year / quarter\n",
        "meta_10y = (\n",
        "    meta_10y\n",
        "    .sort_values([\"symbol\",\"fiscal_year\",\"fiscal_quarter\"], ascending=[True, False, False])\n",
        "    .drop_duplicates(subset=[\"symbol\",\"fiscal_year\",\"fiscal_quarter\"])\n",
        "    .reset_index(drop=True)\n",
        ")\n",
        "\n",
        "meta_10y.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 204
        },
        "id": "THKnliy3_pK3",
        "outputId": "852de249-4dd6-4e30-8bf5-7285c208b642"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "  symbol  fiscal_year  fiscal_quarter report_date  \\\n",
              "0   AAPL         2025               4  2025-10-30   \n",
              "1   AAPL         2025               3  2025-07-31   \n",
              "2   AAPL         2025               2  2025-05-01   \n",
              "3   AAPL         2025               1  2025-01-30   \n",
              "4   AAPL         2024               4  2024-10-31   \n",
              "\n",
              "                                         transcripts transcripts_id  \\\n",
              "0  [{'paragraph_number': 1, 'speaker': 'Suhasini ...           <NA>   \n",
              "1  [{'paragraph_number': 1, 'speaker': 'Suhasini ...           <NA>   \n",
              "2  [{'paragraph_number': 1, 'speaker': 'AI Insigh...           <NA>   \n",
              "3  [{'paragraph_number': 1, 'speaker': 'Suhasini ...         506955   \n",
              "4  [{'paragraph_number': 1, 'speaker': 'Suhasini ...         455679   \n",
              "\n",
              "                                        content_full  \n",
              "0  Good afternoon, and welcome to the Apple Q4 Fi...  \n",
              "1  Good afternoon, and welcome to the Apple Q3 Fi...  \n",
              "2   Good afternoon, and welcome to the Apple Q2 F...  \n",
              "3  Good afternoon, and welcome to the Apple Q1 Fi...  \n",
              "4  Good afternoon, and welcome to the Apple Q4 Fi...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-ef0283c1-9b72-4f03-859e-6f7d06aeaa2d\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>symbol</th>\n",
              "      <th>fiscal_year</th>\n",
              "      <th>fiscal_quarter</th>\n",
              "      <th>report_date</th>\n",
              "      <th>transcripts</th>\n",
              "      <th>transcripts_id</th>\n",
              "      <th>content_full</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>2025</td>\n",
              "      <td>4</td>\n",
              "      <td>2025-10-30</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'Suhasini ...</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>Good afternoon, and welcome to the Apple Q4 Fi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>2025</td>\n",
              "      <td>3</td>\n",
              "      <td>2025-07-31</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'Suhasini ...</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>Good afternoon, and welcome to the Apple Q3 Fi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>2025</td>\n",
              "      <td>2</td>\n",
              "      <td>2025-05-01</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'AI Insigh...</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>Good afternoon, and welcome to the Apple Q2 F...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>2025</td>\n",
              "      <td>1</td>\n",
              "      <td>2025-01-30</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'Suhasini ...</td>\n",
              "      <td>506955</td>\n",
              "      <td>Good afternoon, and welcome to the Apple Q1 Fi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>2024</td>\n",
              "      <td>4</td>\n",
              "      <td>2024-10-31</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'Suhasini ...</td>\n",
              "      <td>455679</td>\n",
              "      <td>Good afternoon, and welcome to the Apple Q4 Fi...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-ef0283c1-9b72-4f03-859e-6f7d06aeaa2d')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-ef0283c1-9b72-4f03-859e-6f7d06aeaa2d button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-ef0283c1-9b72-4f03-859e-6f7d06aeaa2d');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-ac264b78-d9d1-4a71-87ee-0d0007a53f66\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-ac264b78-d9d1-4a71-87ee-0d0007a53f66')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-ac264b78-d9d1-4a71-87ee-0d0007a53f66 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_calls",
              "summary": "{\n  \"name\": \"df_calls\",\n  \"rows\": 353,\n  \"fields\": [\n    {\n      \"column\": \"symbol\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 9,\n        \"samples\": [\n          \"NVDA\",\n          \"AMZN\",\n          \"JPM\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"fiscal_year\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2,\n        \"min\": 2016,\n        \"max\": 2025,\n        \"num_unique_values\": 10,\n        \"samples\": [\n          2017,\n          2024,\n          2020\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"fiscal_quarter\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1,\n        \"min\": 1,\n        \"max\": 4,\n        \"num_unique_values\": 4,\n        \"samples\": [\n          3,\n          1,\n          4\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"report_date\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2015-05-07\",\n        \"max\": \"2025-10-30\",\n        \"num_unique_values\": 254,\n        \"samples\": [\n          \"2023-11-21\",\n          \"2024-05-02\",\n          \"2021-04-27\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcripts\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcripts_id\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": 44908,\n        \"max\": 631827,\n        \"num_unique_values\": 328,\n        \"samples\": [\n          198100,\n          431759,\n          198046\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"content_full\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 314,\n        \"samples\": [\n          \"Good morning, and welcome to Johnson & Johnson's First Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now like to turn the conference call over to Johnson & Johnson. You may begin. Good morning. This is Joe Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson. Thank you for joining us today to discuss our company's first quarter 2022 financial results and full year 2022 outlook. While many things have changed in the world since our last call, much has stayed the same for Johnson & Johnson. We continue to deliver reliable growth and generate meaningful free cash flow, enabling us to invest and advance our pipeline, increase our dividend for the 60th consecutive year and continued to make a positive impact across the landscape of health care. It is, however, important to take a few moments to recognize the current events that are impacting the world we're living in. Today, while we're all still managing through the global pandemic, as evidenced by the current surge of cases in China, we also acknowledge the increasing hardship brought on by the war in Ukraine. We remain focused on the safety of our employees and their families. Guided by our credo and grounded in our purpose, our hearts are with all those affected by these crises and hope for a rapid resolution to both. Now, I'd like to turn the program over to Jessica Moore, Vice President, Investor Relations, to take you through our Q1 results. Thank you, Joe. A few logistics before we get into the details. This review is being made available via webcast, accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com, where you can also find additional materials, including today's presentation and associated schedules. Please note that today's presentation includes forward-looking statements regarding, among other things, our future operating and financial performance and the anticipated separation of the company's Consumer Health business. We encourage you to review the cautionary statement included in today's presentation, which identifies certain risks and factors that may cause the company's actual results to differ materially from those projected. In particular, there is significant uncertainty about the duration and contemplated impact of the COVID-19 pandemic and other marketplace dynamics. This means that results could change at any time, and the contemplated impact of COVID-19 on the company's business results and outlook is a best estimate based on the information available as of today's date. A further description of these risks, uncertainties and other factors can be found in our SEC filings, including our 2021 Form 10-K, along with reconciliations of the non-GAAP financial measures utilized for today's discussion to the most comparable GAAP measures. These materials are also available at investor.jnj.com. Several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships. Moving to today's agenda, I will review the first quarter sales and P&L results for the corporation and the three segments. Following, Joe will provide additional business and financial commentary before sharing an overview of our cash position, our capital allocation priorities and updated guidance for 2022. The remaining time will be available for your questions. During the Q&A portion of the call, Joe will be joined by, Ashley McEvoy, Executive Vice President and Worldwide Chair, Medtech; Thibaut Mongon, Executive Vice President and Worldwide Chair, Consumer Health; and Jennifer Taubert, Executive Vice President and Worldwide Chair, Pharmaceutical. We have heard your feedback and are implementing a few enhancements this quarter. First, we are now providing select earlier phase clinical trial information on our pharmaceutical pipeline to streamline your data collection efforts from clinicaltrials.gov. Second, rather than sharing detailed business performance commentary on each part of the business, I will summarize the significant business drivers, leaving more time for Q&A. You can find additional detailed segment commentary in our earnings presentation. We anticipate the webcast will last up to 60 minutes. Now, let's move to the first quarter results. Worldwide sales were $23.4 billion for the first quarter of 2022, an increase of 5% versus the first quarter of 2021. Operational sales growth, which excludes the effect of translational currency, increased 7.7% as currency had a negative impact of 2.7 points. In the US, sales increased 2.7%. In regions outside the US, our reported growth was 7.2%. Operational sales growth outside the US was 12.6%, with currency negatively impacting our reported OUS results by 5.4 points. Excluding the net impact of acquisitions and divestitures, adjusted operational sales growth was 7.9% worldwide, 2.8% in the US and 12.9% outside the US. Turning now to earnings. For the quarter, net earnings were $5.1 billion, and diluted earnings per share was $1.93 versus diluted earnings per share of $2.32 a year ago. Excluding after-tax intangible asset amortization expense and special items for both periods, adjusted net earnings for the quarter were $7.1 billion and adjusted diluted earnings per share was $2.67, representing increases of 3% and 3.1%, respectively, compared to the first quarter of 2021. On an operational basis, adjusted diluted earnings per share increased 6.2%. I will now comment on business segment sales performance highlights. Unless otherwise stated, percentages quoted represent the operational sales change in comparison to the first quarter of 2021 and therefore exclude the impact of currency translation. Beginning in 2022, certain over-the-counter products previously reported under the Pharmaceutical segment have been reclassed to Consumer Health. These products represent roughly $100 million of sales per quarter. Please refer to the supplemental sales schedules for prior year restatements. Also, as stated in our 2021 10-K, effective January, our Medical Devices segment is now referred to as MedTech. Beginning with Consumer Health. Worldwide Consumer Health sales of $3.6 billion increased 0.8% with a decline of 3.4% in the US and growth of 4.1% outside the US. Excluding the impact of acquisitions and divestitures, Worldwide growth was 1.6%. Consumer Health was negatively impacted by industry-wide external supply constraints, primarily due to ingredients and packaging availability as well as labor shortages largely reflected in our Skin Health and Beauty business, worth approximately 280 basis points worldwide and 500 basis points in the US. Adjusting for these constraints, Consumer Health delivered solid results, primarily due to above-market growth in OTC driven by increased TYLENOL, MOTRIN and upper respiratory product sales. Moving on to our Pharmaceutical segment. Worldwide Pharmaceutical sales of $12.9 billion increased 9.3% with growth of 2.9% in the US and 16.7% outside of the US. Base Pharmaceutical growth was driven by our broad portfolio of products paired with strong commercial execution, enabling us to deliver above-market adjusted operational sales growth, including six assets with double-digit growth in the quarter. Base business growth was due to strength from DARZALEX, TREMFYA, STELARA, ERLEADA and our paliperidone long-acting portfolio. Growth was partially offset by LOE pressures from both REMICADE and ZYTIGA, along with decrease in IMBRUVICA and XARELTO sales. DARZALEX continues to drive very strong operational growth with sales increases of 40.3%, driven by subcutaneous formulation penetration and meaningful share gains across all lines of therapy and in all regions. IMBRUVICA sales declined 3.9% worldwide due to increased competition from novel oral agents, particularly in US. IMBRUVICA maintains its market leadership position worldwide and continues to drive growth outside of the US despite ongoing competitive pressures. XARELTO sales declined 13.8% in the US, driven largely by a net unfavorable prior period price adjustment and increased cost for patient access, partially offset by continued demand and market growth. The COVID-19 vaccine also contributed approximately $500 million to sales in the quarter. Given these results, we remain confident in our ability to deliver our 11th consecutive year of above-market adjusted operational sales growth in 2022. I'll now turn your attention to the MedTech segment. Worldwide MedTech sales of $7 billion increased 8.5%, with growth of 5.6% in the US and growth of 11.1% outside the US. Excluding the impact of acquisitions and divestitures, worldwide growth was 8.6%. We see strong performance in Q1 driven by market recovery, focused commercial strategies and differentiated new products driving enhanced or sustained market share across most of the 11 priority platforms. We continue to monitor potential impacts on elective procedures driven by COVID-19 resurgences across various markets. Before highlighting the financial performance for the segment, I'd like to share a few notable first quarter MedTech events that demonstrate our stated aspirations of entering higher-growth market segments and continuing to build upon digital technologies across the portfolio. Two acquisitions were closed in the quarter, CrossRoads Extremity with a differentiated portfolio of bunion and hammertoes solutions in the fast-growing elective foot and ankle market; and CUPTIMIZE, which will be a new addition to the VELYS digital surgery platform of connected technologies. The CUPTIMIZE solution is designed to give surgeons an easy-to-use tool to better understand and address the impact of abnormal motion between the spine and pelvis in some patients who require total hip arthroplasty and may help reduce the risk of dislocation related to pelvic tilt. I am also pleased to share that Fast Company selected Johnson & Johnson MedTech as one its top 10 World's Most Innovative Health Companies of 2022, recognizing MedTech's success and commitment to delivering breakthrough scientific innovation and reimagining health in an increasingly digital world. The Interventional Solutions franchise delivered another quarter of worldwide double-digit growth at 17.4%, with double-digit growth in both the US and OUS regions, driven primarily by success of new products in electrophysiology, commercial execution and continued market recovery. Worldwide surgery grew 5%, driven by strong performance in wound closure and biosurgery where we continue to gain market share. MONARCH-enabled procedures now exceed 14,000 since launch, providing continued evidence of the adoption of MONARCH technology in patient treatment regimens. The worldwide Orthopedics franchise grew 5.6%, reflecting COVID-19 recovery, continued penetration in the US ambulatory surgery center channel or ASCs; and penetration of new product launches, such as enhancements to VELYS hip navigation, VELYS robotic-assisted solution and ATTUNE cementless knee system. Partially offsetting this growth was softness in spine procedures in the US. The worldwide Vision franchise continued its double-digit growth, growing 13.9% this quarter. Contact lenses global growth of 10.6% reflects continued positive momentum for our market-leading ACUVUE portfolio, success of commercial initiatives and recently launched products such as ACUVUE OASYS MULTIFOCAL and ACUVUE DEFINE FRESH. Surgical vision delivered global growth of 23.8%, with both the US and OUS posting growth above 20%, fueled by market recovery and share momentum due to the success of recently launched products, including TECNIS Eyhance and TECNIS Synergy. As a reminder, additional sales commentary for all of our segments can be found on the slides. Now turning to our consolidated statement of earnings for the first quarter of 2022. I'd like to highlight a few noteworthy items that have changed compared to the same quarter of last year. Cost of products sold deleveraged by 70 basis points, driven by unfavorable mix in the MedTech business and commodity inflation in the Consumer Health business. Sales, marketing and administrative deleveraged by 110 basis points, driven by higher brand marketing expenses in Consumer Health and timing of brand marketing expenses in the Pharmaceutical segment. We continue to invest strategically in research and development at competitive levels, investing 14.8% of sales this quarter. The $3.5 billion investment was an 8.9% increase versus the prior year, primarily due to portfolio progression in Pharmaceutical and MedTech. In process, research and development reflects an impairment expense of $610 million for certain indications associated with bermekimab, the investigational compound acquired from XBiotech Inc. as disclosed in our previous SEC filings. This impairment was driven by the termination of development of bermekimab for atopic dermatitis based on efficacy data. The other income and expense line was net income of $102 million in the first quarter of 2022 compared to net income of $882 million in the first quarter of 2021. This decrease was the result of lapping prior year gains on the divestiture of Doxil, Calyx and EBRA in 2021, higher unrealized losses on securities and Consumer Health separation costs. This was partially offset by favorable returns associated with our employee benefit plans. Regarding taxes in the quarter, our effective tax rate was 12.2% versus 16.6% in the same period last year. The decreased tax rate was primarily driven by lower US income due to higher unrealized losses on securities and the impairment of bermekimab IP R&D compared to prior year divestiture gains. Excluding special items, the effective tax rate was 13.3% versus 16.5% in the same period last year. I encourage you to review our upcoming first quarter 10-Q filing for additional details on specific tax matters. Lastly, I'll direct your attention to the box section of the slide where we have also provided our income before tax, net earnings and earnings per share, adjusted to exclude the impact of intangible amortization expense and special items. Now let's look at adjusted income before tax by segment. In the first quarter of 2022, our adjusted income before tax for the enterprise as a percentage of sales decreased from 37.1% to 35.1% due to product mix, commodity inflation, increased brand marketing expense, portfolio progression in R&D and comparisons to gains from prior year divestitures. Pharmaceutical margin declined from 45.5% to 44.1%, primarily driven by timing of brand marketing expenses and general portfolio progression in R&D. MedTech margins declined from 30.6% to 27%, driven by unfavorable product mix. Finally, Consumer Health margins declined from 26.8% to 22.1%, due to commodity inflation and higher brand marketing expenses. This concludes the sales and earnings portion of the Johnson & Johnson first quarter results. I am now pleased to turn the call back over to Joe Wolk. As Jess just mentioned, Johnson & Johnson posted solid performance for the quarter, continuing to invest in the business for the long-term success, while overcoming multiple macroeconomic headwinds, including inflationary pressures and higher input costs. These external challenges include limited availability and rising prices of certain commodities; as well as increased costs for labor, energy and transportation. These impacts are pervasive across the enterprise, but most notable in Consumer Health. We expect these pressures will continue to some degree throughout the remainder of 2022. However, mitigation efforts are underway, including cost improvement initiatives, strategic price increases and contract negotiations with external supply partners. We are committed to sustaining supply of the products, medicines and treatments that consumers and patients want and need. Turning to our segments and notable events in the quarter. MedTech led our enterprise performance with nearly 9% adjusted operational sales growth. We continue to drive this business forward and are increasing the value of our pipeline through innovation, internally and externally. We were pleased to see a steady uptick in surgical procedures this quarter with the easing of COVID restrictions in many parts of the world, but we recognize that the situation is fluid, which requires monitoring. Building on more than 20 major new product launches in 2021, MedTech announced the addition of two new innovations to our ATTUNE portfolio, the ATTUNE cementless fixed bearing knee with AFFIXIUM 3DP Technology and the ATTUNE medial stabilized knee system. In our Pharmaceutical business, we continue to deliver above-market growth driven by volume as evidenced by our recently published 2021 Janssen US Transparency Report, which reflects our fifth consecutive year of price decreases across the portfolio despite inflationary pressures. We also continue to advance our Pharmaceutical pipeline. This quarter, we received FDA approval for Carvykti, a CAR-T therapy for the treatment of multiple myeloma developed together with our partner, Legend Biotech. We are partnering with clinics utilizing a phased approach to begin patient dosing, and the feedback to date has been positive. We also filed Teclistamab, our BCMA CD3 bispecific antibody seeking EMA approval, and we also received priority review from the FDA, potentially expanding our multiple myeloma portfolio further. In our Consumer Health business, we remain focused on delivering on our 2022 performance objectives, continuing to achieve above-market growth in our over-the-counter medicines business, while navigating industry-wide supply constraints that have primarily impacted our Skin Health/Beauty business. We continue to be excited about the activity related to the announcement we made in November on the creation of two new industry-leading companies, the new Johnson & Johnson and the new Consumer Health Company. For the new Johnson & Johnson, the portfolio will remain well diversified with 25 brands delivering over $1 billion in sales annually, holding market-leading positions across key therapeutic areas and franchises. The financial hallmarks of Johnson & Johnson will remain the same, including a well-defined capital allocation strategy, a disciplined approach to inorganic growth and a strong balance sheet, while also creating opportunities to sharpen focus on execution and clinically differentiated innovation. The new Consumer Health Company will also have a strong financial profile and be better positioned to drive incremental growth, realizing increased potential in new markets through a more agile operating model. The company will continue to deliver science-backed innovation and enhanced digital consumer-centric solutions. The Consumer Health separation team is making substantial progress related to our efforts in establishing the new independent company. As previously mentioned, we cannot disclose new financial information specific to Consumer Health in order to preserve optionality on the various separation pathways. Our time lines remain unchanged. We anticipate announcing key executive leadership appointments for the new Consumer Health Company in the coming months, with plans to provide the new company name and headquarters location around the middle of this year. In the second half of 2022, we plan to provide the updated path forward and applicable financial information such as refined standup cost estimates and potential short-term dissynergies. Finally, consistent with previous communications, we expect to execute the separation in 2023. You have our ongoing commitment adhering to the regulatory framework to provide transparent updates for material decisions on a timely basis. Turning now to cash and capital allocation. We generated free cash flow for the quarter of nearly $3.4 billion. At the end of the first quarter, we had approximately $30 billion of cash and marketable securities and approximately $33 billion of debt for a net debt position of approximately $3 billion. Our capital allocation priorities remain unchanged. Internal innovation remains critical to our future growth and a top priority. In the first quarter, we increased R&D investment by approximately 9% compared to the first quarter of 2021. We also continue to evaluate opportunities to complement the current portfolio with acquisitions that build upon our capabilities, address portfolio gaps or play in higher-growth markets while yielding solid financial returns. As I mentioned earlier, we were pleased to announce today that our Board of Directors approved an increase in our quarterly dividend for the 60th consecutive year from $1.06 per share to $1.13 per share, an increase of 6.6%. Moving to full year 2022 guidance and key considerations. I'll start with comments on our COVID-19 vaccine and foreign exchange impacts, essentially the only items with updates from our January guidance. As market demand for all COVID-19 vaccines is currently challenged by global supply surplus and vaccine hesitancy in developing markets, we have made the decision to suspend guidance for sales of our COVID-19 vaccine. This will enable investors to focus on the performance of our core businesses, which drive the current and future value for investors. We are maintaining the total adjusted operational earnings per share guidance we provided in January, absorbing, if need be, the modest income impact from the COVID-19 vaccine. Regarding foreign exchange, as you know, we don't offer guidance or predictions on currency movements. But to give you a sense of the impact currency may have on potential full year reported results, utilizing the euro spot rate relative to the US dollar as of last week at 1.08, there is an incremental unfavorable currency impact of $1.1 billion on reported sales and an unfavorable $0.25 for reported adjusted earnings per share versus the calculation related to January's guidance. The full year unfavorable impact is now projected to be $2.5 billion on reported sales and $0.45 on reported adjusted earnings per share. All other line items for which we provide guidance remain the same as communicated in January. To reiterate, we are maintaining our adjusted operational earnings per share guidance. We don't provide quarterly guidance, but do understand that you find value in us providing some qualitative considerations as you update your models. In Consumer Health, we expect supply constraints to continue throughout the year but not to the same extent in the second half. As a result, we anticipate that the back half performance will improve over the first half. For MedTech, while the first quarter demonstrated faster recovery than we anticipated, our full year expectations remain fairly intact. We anticipate continued market recovery and uptake from recently launched products and are monitoring the ever-changing COVID dynamics, particularly the surging cases in China. Similar to Consumer Health, we expect the second half to be stronger than the first half. As a reminder, with respect to growth rates, the second quarter was the strongest quarter for MedTech in 2021. The expectations for the Pharmaceutical base business remain the same. We anticipate delivering another year of above-market adjusted operational sales growth with relatively consistent growth throughout the remainder of the year. In summary, Johnson & Johnson had a solid start to the year despite managing macroeconomic headwinds, and we remain confident in our business. I would like to recognize the continued efforts of our 144,000 global colleagues focused on delivering our innovative healthcare solutions to our credo stakeholders. Their unwavering dedication and support continue to inspire. And on behalf of the executive team, I'd like to extend our gratitude. I am now pleased to welcome to the call, Ashley McEvoy, Thibaut Mongon and Jennifer Taubert, our Worldwide Chairs to address your questions. Kevin, can you please provide instructions and open the line for Q&A? [Operator Instructions] Our first question today is coming from Larry Biegelsen from Wells Fargo. Your line is now live. Good morning. Thanks for taking the question. So many different places to go. But Joe, I'll start with M&A. You know, there were comments on the tape stating that you're eager to deploy cash to M&A, especially for devices. So maybe for you or Ashley, can you add more color to your thinking there and the types of opportunities to consider? You know, you've talked about reaching the top of the peer set in devices. That would seem to require a relatively large deal or a series of small to medium-sized deals to move the needle. Is that a fair way to think about it? Thanks for taking the question. Yes. So Larry, I'll start, and then I'll turn it over to Ashley for some thoughts specific on Medical Devices. But before I answer, Larry, I do want to compliment you and your team for the foreign exchange report that you guys issued back, I think it was on April 13. That was just -- it's a tough topic to really grasp. And you guys did a fantastic job in assessing what it meant for the medical device industry. It was really a fantastic report. So well done. With respect to cash, as you heard us in January, we are reaching our lowest levels of net debt. And we remain very active. You could talk to Thibaut, Jennifer and Ashley, with respect to ideas that they are bringing forth. We continue to have the same principles that we've had historically. We want to make sure there's a strategic fit. And by that, I simply mean we've got capabilities. We've got scientific expertise. Perhaps it's just our scale that adds more value to that asset than where it currently resides. And then we want to make sure that we compensate risk -- compensate shareholders for the risk that we're bearing on their behalf when we do so. I would not get overly locked into size. Johnson & Johnson, quite frankly, have been built through a number of smaller acquisitions, and really the outliers are these larger acquisitions. But we look at really the strategic merit and then the financial value creation and don't get locked in to saying something is too small or too big with respect to adding to our already dynamic internal portfolio and pipeline. Ashley, I don't know if you want to... Yes. No, Larry, maybe before I get to M&A, just kind of some macro thoughts on MedTech in the quarter. I'm pleased with the results of the quarter. We saw positive signs of the market recovery. Clearly, while COVID has not disappeared, health systems around the world are becoming increasingly more resistant with each passing wave. And as we know, the world is -- is a lot more equipped to manage the pandemic, and quite frankly, so is Johnson & Johnson. So encouraged to see in quarter one that we continue to maintain our path to above-market performance. We referenced that this is kind of a growth at scale, if you will, 11, $1 billion platforms, really most of them growing or maintaining share. And we saw robust sales growth across all four of our franchises in all four of our regions. Some standout, encouraging to see both vision surgery and Vision Care, both double-digit performance and growing market share, really fueled by innovation in ACUVUE and TECNIS. We are the world leader in electrophysiology, still a category that has significant under penetration. We've had 11 consecutive years of double-digit performance and really significantly enhanced our share gain. We're the world leader in biosurgery. The business was up almost 10%, really driven by a clinically differentiated portfolio. And then finally, and enthusiastically, I say we had strong performance in joints really by penetrating some new sites of care like ASCs, both with hips and knees. So when I look forward, I'm encouraged by the organic agenda that we see in innovation, like with the likes of the FDA approval on ACUVUE Theravision, the first drug-eluting contact lens. As Joe mentioned earlier, around really shoring up high-growth segments in knees with ATTUNE fixed bearing, and then really with CERENOVUS the launch of EmboGad, the balloon catheter. So continue to advance robotics and digital surgery. You'll hear us talk about MONARCH 14,000 cases with a big pipeline of new indications, and then VELYS completing over 2,000 cases. So when I think about the future of M&A, Larry, we're going to continue to do tuck-ins and to really digitize the patient experience. You heard us talk about CUPTIMIZE as an example around really adding a precise delivery to hit navigation to improve outcomes. You're going to see us continue to penetrate fast-growing segments like what we have in neurovascular, as an example, 90% of our capital deployment has been to $1 billion or more, but we do intend to make sure that we are well positioned to be in the highest growth end state markets. Thank you. Our next question today is coming from Chris Schott from JPMorgan. Your line is now live. Great. Thanks so much. Maybe Ashley, just following up on some of your MedTech comments. Can you specifically comment on China in terms of the impact you're currently seeing to the business and your outlook for that market specifically, given some of the lockdowns that we're seeing there? And then my kind of core question was just on IMBRUVICA. It seems like prescriptions here are really starting to see some erosion. I'm trying to understand the dynamics you're expecting going forward. So is this -- especially maybe in the US market, are you expecting that this erosion continues? Or do you see dynamics in place that we could start to see some of those prescription trends start to stabilize a bit? Thanks so much. Yeah, sure, Chris. So first, we have, I would say, a very strong and healthy business in China. We're the world \\u2013 we are number one in MedTech in China. We have a very diversified portfolio from surgery to orthopedics to interventional as well as vision. We did experience an impact probably in the March time frame due to the recent surge of the viruses happening and the lockdowns, particularly in Shanghai and now other regions. We do anticipate that to continue in April and through the month of May. But like we've seen, I think China might come down a bit faster, but it comes back faster, too. We have very strong leadership there, and there are a lot of patients that need care. I'll turn it to Jennifer maybe to talk about your second question. Great. Thanks a lot. Hi, Chris and hello, everybody. A few comments on the Pharmaceutical business, and then I'll get to the question on IMBRUVICA. First, for our pharm business, I was really proud that we delivered $12.9 billion in worldwide sales. We're definitely above-market adjusted operational growth of 9.3%. And this is our sixth quarter where we achieved worldwide sales exceeding $12 billion. And as I look across the globe, the growth was really broadly based across our portfolio in the regions, with particularly strong growth in EMEA, Asia Pac and Latin America. During the course of the quarter, we really continued to maximize the value of our key brands, so strong double-digit growth across six of them, including DARZALEX, ERLEADA, TREMFYA, INVEGA SUSTENNA, [Privado] (ph) and EDURANT. And we also had a number of important milestones, the first being the FDA approval of Carvykti, which is our first cell therapy for patients with relapsed or refractory multiple myeloma. The teclistamab filing in the EU was mentioned. The FDA approved expanded label indications for CABENUVA to be administered every two months for the treatment of HIV in virologically suppressed adults and adolescents. And we presented great new data on TREMFYA in our approved indications of psoriasis and psoriatic arthritis, as well as from our Phase II studies, where we're evaluating the product in Crohn's Disease and also in UC. So if we take a look at IMBRUVICA more specifically, IMBRUVICA sales did decline for the quarter, 3.9%, and this really was a US story. Outside the US, our sales actually grew 4.5%. In the US, performance was impacted by both competitive factors with a number of new competitors in the market as well as market softness. We haven't seen that market fully rebound to the pre-COVID levels yet. As we take a look at IMBRUVICA, IMBRUVICA has really changed the standard of care for adults with CLL and other B-cell malignancies. And it is the only BTKI that\\u2019s demonstrated overall survival and a high rate of progression-free survival at five years with up to eight years of safety follow-up. So, we remain really confident in the efficacy and safety profile of the product. It's the market share leader and continues to be the most comprehensively studied and prescribed BTKI with over 250,000 patients worldwide. So we continue to work to develop the asset. We do see further growth opportunities through the introduction of new indications and new combination therapies, as we take a look at IMBRUVICA plus venetoclax that we're working to develop and we filed in the EU. We're also taking a look at first line [ph] and CL and really trying to bring that forward. So I think you can anticipate there will continue to be strong competition in that market. We continue to believe in and invest in IMBRUVICA. Thank you. Our next question is coming from Joanne Wuensch from Citi. Your line is now live. Good morning and thank you for taking the question. I'd like to spend a little bit of time talking about the middle of the income statement with all of the multiple headwinds on those factors. How do you think about managing it? What are the levers to pull? And how do you think about raising prices in this environment for each of your key divisions? Yes, good morning, Joanne. Thanks for the question. With respect to operating margins overall, which is really, I think, at the heart of your question, in the front -- the first quarter, I should say, we do tend to adopt a little bit more of an aggressive approach to advertising and promotion and hopes of getting the full year benefit of that promotion to the topline lift throughout the year. And I would say on R&D, it's also a little bit front-end loaded this year, simply from the standpoint of the progression of our pharmaceutical pipeline, as well as digital robotic surgery. So in pharmaceuticals, think about nipocalimab, our RSV vaccine, those had very nice progression. Teclistamab may be moving a little bit faster than we anticipated, as well as being able to launch Carvykti. There was a healthy amount of inflation built into our P&L in the January guidance. What I think our teams have seen in the -- let's say, the first four months of this year is an uptick in that inflationary impact of about 10% or 15%. So still very manageable. Again, as you heard in some of the prepared remarks, we anticipate that that inflationary pressure as well as commodity scarcity will subside a little bit in the second quarter and then hopefully more pronounced in the second half of this year. If it doesn't, it's certainly something that will keep our attention. And we have the resources to adjust accordingly to make sure that we not only meet the needs of long-term value creation, but also meet short-term performance expectations. So we all think it's very manageable at this point in time, but it's something that we're not taking for granted. We're being very active with cost initiative programs. As we look to separate the two companies, we are looking at ways to streamline technology, processes, things that will lead to leverage on the P&L. Thank you. Our next question today is coming from Chris Shibutani from Goldman Sachs. Your line is now live. Thank you. Good morning. Appreciate the opportunity. Perhaps directed at the Pharmaceutical segment for Jennifer. Two products I'd like to focus on, one being STELARA and the other on XARELTO. With STELARA, could you perhaps elaborate a little bit more in terms of some of the underlying dynamics across the various indications, i.e., the derm versus perhaps the IBD in terms of what the growth trends and outlook you're seeing and you expect there? And then for XARELTO, part of your commentary in the prepared segment discussed and mentioned about patient access. Could you just elaborate a little bit further on how that was an impact on the commercial dynamics? Thank you. Sure. Thanks for the question. So let me start off with STELARA. So STELARA sales were $2.29 billion in the first quarter, and that was 9% growth. And we continue to see a lot of strength in STELARA. Ex-US, the product had nearly 18% growth. In the US, what we saw was growth around 3.6%. And what this really was due to, we saw an impact in the US due to the Omicron variant and the impact that it actually had on staffing resources that particularly impacted a number of areas where you had more resource-intensive delivery of care, and GI offices was definitely one. As we take a look at Crohn's Disease and Ulcerative Colitis, our share positions remain strong and with very strong positive momentum. We actually gained over five share points in CD and six share points in ulcerative colitis. So really strong growth and momentum. And with -- in psoriasis, as anticipated with TREMFYA and a very strong growth in psoriasis and psoriatic arthritis, we expected the STELARA sales there to start tailing off, and that's in line with our expectations. So we continue to have a very strong positive outlook for STELARA going through the rest of the year in CD and in Crohn's -- excuse me, Crohn's and ulcerative colitis, where we've really been realizing the growth. And likewise, when you take a look at TREMFYA, we saw 44.5% growth in psoriasis and psoriatic arthritis in the quarter. So together, really, really nice performance there. Question on XARELTO. So XARELTO in the US, we did see sales decline. That was largely driven by a net unfavorable prior period adjustment. And most of this has actually been a positive adjustment that took place in 2021. So when you do the comparable, it was negative. And so that was really due to the vast majority of that. With Xarelto, we continue to see nice share gains and growth at a prescription level across the indications, whether we're talking about CAD and PAD, really the newest indication set, but also across AFib and VTE. And so it really was around the net unfavorable PPA and a little bit of channel mix as well with some of the mix shifting into 340B and Medicaid in some of the lower-priced channels. Thank you. Your next question today is coming from Louise Chen from Cantor Fitzgerald. Your line is now live. Hi. Thanks for taking my question. So I wanted to ask you about CARVYKTI. And what gives you confidence in your ability to meet some of the manufacturing complexity associated with CARVYKTI? And how much capacity do you think you'll be able to bring online this year, both in the US and potentially globally as well? Thank you. Thanks for the question. So we're real proud about our approval and our launch to-date on CARVYKTI. What I can say is that it is going well and it is on track with our expectations. We're real pleased. As you know, this is a customized therapy where the supply chain is literally built around each patient. We've got about a four week to five week period that goes from the collection of the cells, the processing and manufacturing and the return shipment of the final product and then ultimately the infusion back in to the patient at the treatment center. As we have mentioned before we really are taking a thoughtful and a phased approach to scaling this launch, to ensure a predictable and a reliable experience for the patients and for the treatment centers. We really tried to learn from the other launches in the market in this area. And so far, we're off to a really good start there and have been very pleased with the feedback that we're getting back from our customers. So we have activated our initial round of treatment centers. And we did this based on folks who were very well-experienced from our clinical trials and also very broadly dispersed throughout the US and help ensure patient access. We're working through all of the orders and the slots that we have and actually have product now that's been shipped back -- has been manufactured and shipped back to the patients for infusion into the patients. So we're going to continue in a planned and thoughtful responsible approach to this scaling, both in the United States as well as we do -- as we scale outside the US and throughout the world as well. Now we discussed before around lentivirus. Because there is an industry-wide shortage of lentivirus, that is something that we are also working and investing in to scale all of our internal capabilities to be able to meet the demand, both now in our initial launches in the relapsed/refractory setting as well as our ultimate goal to be able to move into first-line setting here. And so we would have an internal control on that as well. So hope this answers your question. Thank you. Your next question is coming from Josh Jennings from Cowen. Your line is now live. Hi. Good morning. Thanks a lot for taking the question. Joe, since Joaquin made some public commentary on his commitment to support Ashley and her team to drive revenue growth acceleration in the Mega Devices unit, your focus has been on M&A opportunities. But how should we think about the level of internal investment to fuel growth of the devices franchise? You don't break out the percentage of R&D spend allocated to devices. But one data point we do have is from the 2019 pharma day when you related $8.4 billion of the $11 billion in R& D expense from 2018 went to pharma initiatives, so that's north of 75%. But just \\u2013 I mean, has that stepped up just the level of investment in the Devices business over the last couple of years? And will that step up even further? And just to be clear, Ashley did not plant this question with our team. I'm going to check the transcript on that, Josh, just to be sure. But listen, I think what you would hear, as Joaquin was sitting here, is that he supports all the businesses with respect to innovation. We realize that our calling card is innovation, and we're going to have growth across all of our franchises when we have products that matter that are differentiated, that are beyond the current standard of care and meeting consumer needs as well. I actually want to credit Ashley and her team for the way they've managed their P&L. They've been conscious about moving more of their investment into R&D. You saw a record number of 20 plus new product launches last year that are considered meaningful. We're going to be very close to probably a very similar number this year. And so that portfolio has taken very much the same approach that I would say Pharmaceuticals did almost a decade ago when the focus is very well understood and where we want to play because we've got a strategic or competitive advantage will be capitalized upon. I don't know, Ashley, if you want to add anything more, but I think that certainly, there is continued support, but a lot of the credit goes to Ashley and her team in terms of managing their levels of investment throughout the P&L. Thanks, Joe. I mean, Josh, I would say that we are investing at a competitive level, and I'm really pleased with the state of execution. We are \\u2013 we have, in our pipeline right now, 27, $100 million-plus eNPV projects. That number three years ago was six. So they continue to focus the pipeline on medium to higher growth segments and really execute and we're off to a good start in 2022. I would maybe underscore too is that gives us the confidence to go out and add in inorganic opportunities when the opportunity presents itself using the criteria of strategic fit as well as financial value creation. So a stronger internal pipeline that gets hopefully success out in the acquisition markets. Just to reference our 10-K, we do provide the breakout of R&D by segment on an annual basis for reference. Thank you. Our next question today is coming from Terence Flynn from Morgan Stanley. Your line is now live. Great. Thanks so much for taking the questions. Jennifer, I was just wondering if you could elaborate a little bit more on the COVID recovery in the Pharma segment. I know you touched on staffing issues on the gas trip [Audio Gap]? Yeah. So I understand Terry's comment really was around the US and what we're seeing in terms of COVID. So as we exited last year, really in the December time frame and entered this year into really January and February, we did see the Omicron variant impact the US business. And what we saw there really, as already mentioned before, we did see staffing shortages because so many people got sick. People weren't able to go into work. And so in a higher \\u2013 more intensive resource settings in some of the markets, we did see slowdown in terms of delayed visits and new patient starts. What we are seeing now is we're looking towards the end of March and in early April, we're seeing nice recovery there. And so this really, hopefully was something really just at the end of last year and the beginning of this year, and it does look to be more specific to the US than to any of the other markets. Thanks. Jennifer. Thibaut, maybe give some insight, too, on the consumer segment and how COVID is impacting. Obviously, it was much more tumultuous I'd say, in 2020 and 2021. But what are you seeing to the early start of this year? Look, clearly, we continue to see the impact of COVID on the life of our consumers. And that has an impact -- the differentiated impact by category. We are looking at China very specifically right now to see how the situation evolves there. What I would say that COVID has really shifted consumer behavior to digital space and digital solutions. And so -- and we see it in the continued growth of our e-commerce channel, representing more and more of our business. So that's what makes all more resilient is ability to count on multiple channels is something that is showing us well in a provident environment. Having said that, we need to continue to monitor how the situation evolves around the world. Thank you. Our next question today is coming from Matt Miksic from Credit Suisse. Your line is now live. Thanks. Thank so much for taking the question. So maybe for Ashley. I was hoping you could provide a little bit more color on med devices in Q1 and the trajectory exiting March. You had pretty impressive growth across the board, so congrats on that. But investors are often trying to think to just figure out the difference between inpatient segments like orthopedics or cardio or advanced surgery and how those are recovering potentially at different rates in the US? And what you might be seeing there? As well as any color you could provide on how, say, Europe and Japan overseas developed markets compared with the recovery trends we've seen in the US? Thanks. Thanks, Matt for the question. And it's April 2022, we're still talking about this, so just huge acknowledgment for our health care workers who are still battling through this. But I would tell you, EMEA really bounced back nicely in quarter one. It was pretty broad-based within EMEA. I would say, Asia with the exception of China recently also bounced back, and then US really gained momentum. I always look at two data points in the US as an example. I look at like, how were diagnostic procedures performing in the US and then how are surgical procedures performing. And probably at our trough when Omicron was hitting in the US in January, we had about flat diagnostic procedures, and we were looking at surgical procedures down near double digit, down 10%. Encouragingly, as we exited March, we started to see diagnostic procedures tick up to high single digit and start to see a flattening of surgical procedures. I expect in the month of April in the US to see it go north of 2019 levels, really driven by cardio cardiac ablation, bariatrics and colorectal surgery. Thank you. Our next question today is coming from Geoff Meacham from Bank of America. Your line is now live. Hey, guys. Good morning. Thanks so much for the question. I just had a couple. Jennifer, in the myeloma market, we'll see REVLIMID generic soon. And I realize that combinations with DARZALEX are standard of care, but what are your expectations for broader market disruption going forward, either from a pricing or share perspective? And then a quick follow-up on the M&A front for Joe. When you think about the P&L or cash flow impact from the consumer separation, to what degree does this inform or impact plans for a larger scale BD or M&A for either a MedTech or Pharma? Thank you. So thanks for the opportunity to talk about our multiple myeloma portfolio in response to your question. So as we take a look at the myeloma market despite the advances to date in therapies, there is still so much unmet need there, given the underlying heterogeneity of the disease. And so it's really important that there are treatment choices. And what we're really trying to do is to have a strong portfolio of highly effected -- highly effective treatments and actually ultimately shoot for a cure. And so as we take a look at the market with DARZALEX -- in DARZALEX FASPRO right now, we're really seeing this as a foundational therapy multiple myeloma. And so irrespective of others and LOE and those types of things, you noted, it's a lot of combination therapy and things like that. That does not fundamentally change the opportunity for DARZALEX and FASPRO. What I'm also really excited about is then you add in CARVYKTI that was recently approved, as we mentioned, for triple refractory multiple myeloma. And we really think that this will ultimately become a preferred treatment for patients with relapsed/refractory multiple myeloma. We also mentioned teclistamab in the filing of teclistamab. And this really is the first-ever BCMA CD3 specific. And we think that this is going to be a great off-the-shelf option and for patients who really are triple-class exposed and who are really not eligible for CARVYKTI or don't have access. And then in the future, we're not stopping there. We're also working on Talquetamab, and this would be the first and potentially best-in-class GPRC5D bispecific that we think could be potentially sequenced combined to help transform outcomes. And so as we take a look at our portfolio, we really think that these assets are additive and complementary versus something where they would be cannibalizing each other. And we really think that these are the important advances that are going to really help transform multiple myeloma in the future and going forward versus any of the older therapies. And Geoff, with respect to cash flow and M&A, I think I'll answer that in two parts. I think short term, we certainly have the credit rating to warrant more firepower should we need it. As you have observed, our cash flow generation over the last couple of years has ticked up to new levels, north of $20 billion or around $20 billion from when we were just maybe $17 billion a few years ago. As the consumer company operates, I think that's going to be actually liberating for both sides. We still have opportunities to improve our cash flow with inventory management and receivables. But as we move to a higher growth segment, we think we'll be able to generate similar cash flow with a higher level of sales growth, managing the P&L appropriately. So I've got every confidence that we'll be able to do small, medium and large scale acquisitions should the right opportunity present itself. I also think it's liberating for the Consumer Health segment because they'll be able to focus their cash flow generation to value-creating opportunities through their particular lens being fit for purpose in a digitized environment that Thibaut spoke to. So whether it's near-term or long-term, I think we're in a very good position to utilize today's cash and hopefully that which should we generate tomorrow. Kevin, maybe we've got time for one more question? Certainly. Our final question today is coming from Danielle Antalffy from SVB Leerink. Your line is now live. Hi. Good morning, everyone. Thanks so much for squeezing me in. This is a question for Ashley. And is the commentary around the ASC penetration. And I'm just curious, Ashley, as that site of care becomes increasingly important, where you guys think you are relative to the market from a penetration perspective? And where you think you can grow meaningful growth driver will your recent success in the ASC be over the next few years? Thanks so much. Well, thank you, Danielle. Appreciate the question and hope you are well. We -- in US, the ASCs, I think, are -- it's still relatively low penetration, I would tell, from a macro US, less than 20%, but I think it's the fastest growing as we know. In a COVID environment, we've seen the model evolve to create a safe, more patient-friendly experience that addresses a patient sentiment of not wanting to go into a hospital setting. Certain procedures have gone there early sooner than later. I'd say hips or migraine and knees, less spine per se, less complicated. Obviously, trauma case is still happening in the hospital setting. We've done a lot of work recently to modify our business model to make it a capital-efficient flow, if you will, in inventory management, on the personalization of care using digital assets to kind of your pre-op and your post-op experience less full of friction. And we're taking a lot of experience in the US ASCs to really what we're doing in China in the Tier 2 and the Tier 3 cities as well as we deliver care. So I'm optimistic that this channel will continue to evolve. I do think that we think we start competitiveness there, and we're making sure that we really have a sustainable business model going forward. Thank you. Thank you, Danielle, and thanks to everyone for your questions and your continued interest in our company. We apologize to those who we couldn't get to because of time, but don't hesitate to reach out to the Investor Relations team as needed. I will now turn the call back to Joe for some brief closing remarks. Great. Thanks, Jess. And as Jess alluded to, we certainly do appreciate your questions and the chance to interact with you. I'd like to remind everybody as we close that we do have the opportunity to engage with shareholders at next week's annual meeting on April 28. Also be on the lookout for an update on our commitments to ESG. On June 8, we will be issuing our Health for Humanity Report, which is an in-depth review on the progress we are making on our 2025 goals. Thank you for your time and your interest in Johnson & Johnson. Have a great day. Thank you. This concludes today's Johnson & Johnson's first quarter 2022 earnings conference call. You may now disconnect.\",\n          \"Nancy Paxton - Apple, Inc. Timothy Donald Cook - Apple, Inc. Luca Maestri - Apple, Inc. Kathryn Lynn Huberty - Morgan Stanley & Co. LLC Shannon S. Cross - Cross Research LLC Steven Milunovich - UBS Securities LLC Kulbinder S. Garcha - Credit Suisse Securities (USA) LLC Antonio M. Sacconaghi - Sanford C. Bernstein & Co. LLC Michael J. Olson - Piper Jaffray & Co. Amit Daryanani - RBC Capital Markets LLC Brian J. White - Drexel Hamilton LLC Good day, everyone, and welcome to this Apple Incorporated Third Quarter Fiscal Year 2017 Earnings Release Conference Call. Today's call is being recorded. At this time for opening remarks and introductions, I would like to turn the call over to Nancy Paxton, Senior Director of Investor Relations. Please go ahead, ma'am. Thank you. Good afternoon and thanks to everyone for joining us. Speaking first today is Apple CEO Tim Cook, and he'll be followed by CFO Luca Maestri. After that, we'll open the call to questions from analysts. Please note that some of the information you'll hear during our discussion today will consist of forward-looking statements, including without limitation those regarding revenue, gross margin, operating expenses, other income and expense, taxes, and future business outlook. Actual results or trends could differ materially from our forecast. For more information, please refer to the risk factors discussed in Apple's Form 10-K for 2016, the Form 10-Q for the first two quarters of 2017, and the Form 8-K filed with the SEC today along with the associated press release. Apple assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates. I'd now like to turn the call over to Tim for introductory remarks. Thank you, Nancy, and good afternoon and thanks, everyone, for joining us. Today we're proud to announce very strong results for our fiscal third quarter, with unit and revenue growth in all of our product categories. We'll review our financial performance in detail, and I'd also like to talk about some of the major announcements we made in June at our Worldwide Developers Conference. It was our biggest and best WWDC ever, and the advances we introduced across hardware, software, and services will help us to delight our customers and extend our competitive lead this fall and well into the future. For the quarter, total revenue was at the high end of our guidance range at $45.4 billion. That's an increase of 7% over last year, so our growth rate has accelerated in three successive quarters this fiscal year. Gross margin was also at the high end of our guidance, and we generated a 17% increase in earnings per share. iPhone results were impressive, with especially strong demand at the high end of our lineup. iPhone 7 was our most popular iPhone, and sales of iPhone 7 Plus were up dramatically compared to iPhone 6s Plus in the June quarter of last year. The combined iPhone 7 and iPhone 7 Plus family was up strong double digits year over year. One decade after the initial iPhone launch, we have now surpassed 1.2 billion cumulative iPhones sold. Services revenue hit an all-time quarterly record of $7.3 billion, representing 22% growth over last year. We continue to see great performance all around the world, with double-digit growth in each of our geographic segments. Over the last 12 months, our Services business has become the size of a Fortune 100 company, a milestone we've reached even sooner than we had expected. We had very positive results for iPad, with broad-based growth in units, revenue, and market share. iPad sales were up 15% year over year and grew across all of our geographic segments. We achieved our highest global market share in over four years based on IDC's latest estimate of tablet market results for the June quarter. And in markets like China and Japan, over half of iPads sold were to people buying their very first iPad. Our iPad product lineup is stronger than ever. The new iPad we launched in March offers great value and performance. And the all-new 10.5-inch iPad Pro, launched in June, features the world's most advanced display with ProMotion technology and is more powerful than most PC desktops. iPad is the perfect tool for teaching in new and compelling ways, and our iPad results were especially strong in the U.S. education market, where sales were up 32% year over year to over 1 million units. We believe that coding is an essential skill that all students should learn. We're thrilled that over 1.2 million students of all ages are now using iPad and Swift Playgrounds to learn the fundamentals of coding. And over 1,000 K-12 schools across the United States plan to use Apple's Everyone Can Code in their curricula this fall. And for high school and community college students who want to pursue careers in the fast-growing app economy, we announced app development with Swift, an innovative full-year curriculum designed by Apple engineers and educators and provided free to schools to teach students to code and design fully functional apps, gaining critical job skills in software development and information technology. I'd like to turn now to Mac, which gained global unit market share and reached new June quarter unit sales records in mainland China and Japan. Mac revenue grew 7% year over year, driven by the strength of the MacBook Pro and iMac despite IDC's latest estimate of a 4% unit contraction in the global PC market. And with the refresh of almost our entire Mac lineup in June, we're off to a great start for the back-to-school season. Sales of Apple Watch were up over 50% in the June quarter, and it's the number one selling smartwatch in the world by a very wide margin. Apple Watch is having a positive impact on people's health and daily lives and motivating them to sit less and move more. With features like built-in GPS and waterproofing, Apple Watch Series 2 is the perfect companion for hiking, running, and swimming. We're also seeing incredible enthusiasm for AirPod, with 98% customer satisfaction based on Creative Strategy's survey. We have increased production capacity for AirPods and are working very hard to get them to customers as quickly as we can, but we are still not able to meet the strong level of demand. We made some big announcements during the June quarter that I'd like to quickly review. We launched a new investment in the future through our Advanced Manufacturing Fund. We've earmarked at least $1 billion for this program, aimed at helping our manufacturing partners develop innovative production capabilities and create high-skill jobs in the United States. We believe this can lay the foundation for a new era of technology-driven manufacturing in the U.S. The first $200 million from the fund has been committed to Corning to support R&D, capital equipment needs, and state-of-the-art glass processing. And as we announced at WWDC, we have a very exciting fall ahead, with stunning advances in iOS 11, macOS High Sierra, and watchOS4. iOS 11 will make iPhones better than ever with Apple Pay peer-to peer payments, an even more intelligent and natural Siri, new expressive messages with full screen effects, richer and more powerful maps, enhanced live photos and memories and portrait mode effects, and much, much more. iOS 11 will also take the iPad experience to a whole new level, with features such as a customizable dock, Multi-Touch drag and drop, powerful new multitasking, more efficient QuickTime, and great new markup and scanning capabilities. One of the most exciting and most promising announcements from WWDC was the introduction of ARKit, a new set of tools for developers to create augmented reality apps. It's still early in the beta period, but it's clear that ARKit has captured the imagination of our developer community. We think ARKit will help the most creative minds in the industry tap into the latest computer vision technologies to build engaging content. We believe AR has broad mainstream applicability across education, entertainment, interactive gaming, enterprise, and categories we probably haven't even thought of. With hundreds of millions of people actively using iPhone and iPad today, iOS will become the world's biggest augmented reality platform as soon as iOS 11 ships. With iOS 11, we're also bringing the power of machine learning to all Apple developers with Core ML, enabling capabilities like face detection, object tracking, and natural language interpretation. Core ML lets developers incorporate machine learning technologies into their apps with all the processing done right on device, so it respects our customers' data and privacy. For Mac, we provided a peek at the immersive gaming, 3D, and virtual reality experiences made possible with the upcoming release of macOS High Sierra and the amazingly powerful new iMac Pro. We're proud to make the best personal computers in the industry and are very excited to deliver even more innovation in the months to come. Apple Watch will become more intelligent than ever this fall with watchOS4, featuring a proactive Siri watch face, personalized activity coaching, and an entirely new music experience. watchOS4 also introduces GymKit, a groundbreaking technology program to connect workouts with cardio equipment. We also previewed HomePod, a breakthrough wireless speaker for the home that delivers amazing audio quality and uses spatial awareness to sense its location in the room and adjust the audio automatically. Visitors to our listening room at WWDC were blown away by the HomePod's incredible sound, which is unlike any other wireless home speaker on the market. With deep knowledge of music, HomePod is designed to work with your Apple Music subscription to help you enjoy the music you already love as well as to discover great new music, based on your personal preferences. As an intelligent home assistant, HomePod is a great way to send messages, set a timer, get updates on news, sports, and weather, or control smart home kit devices by simply asking Siri to turn on the lights, close the shades, or activate a theme. We can't wait to deliver all of these powerful innovations in the months to come. And we might even have some others to share with you later in the year. Now for more details on the June quarter results, I'd like to turn the call over to Luca. Thank you, Tim. Good afternoon, everyone. Revenue for the June quarter was $45.4 billion, up 7% over last year, an acceleration to the growth rate we reported during the first half of our fiscal year. We achieved these results despite a 200 basis point negative impact from foreign exchange on a year-over-year basis, as currency movements, especially in Europe and China, affected our reported results. Our performance was very strong across the board with growth in all our product categories and almost every market around the world. We achieved double-digit revenue growth in many developed markets, including the U.S., Canada, Germany, Spain, Australia, and Korea, and emerging markets outside of Greater China grew 19% over a year ago. Gross margin was 38.5%, at the high end of our guidance range. Operating margin was 23.7% of revenue and net income was $8.7 billion. Diluted earnings per share were $1.67, up 17% over last year, and cash flow from operations was $8.4 billion. During the quarter we sold 41 million iPhones and reduced iPhone channel inventory by 3.3 million units, leaving us with our lowest level of channel inventory in 2.5 years and well within our five-week to seven-week target inventory range. iPhone sales were up year-over-year in most markets we track, with many markets in Asia, Latin America, and the Middle East growing unit sales by more than 25%. We are very pleased with these iPhone results, especially considering the tough comparison to the June quarter last year when we launched iPhone SE. iPhone ASP was $606, up from $595 a year ago, thanks to strong demand for iPhone 7 Plus, which represented a higher percentage of the iPhone mix compared to the Plus model a year ago. The impact of the stronger mix on ASP was partially offset by negative foreign exchange year over year and the reduction in channel inventory, which took place entirely at the high end of the portfolio. Customer interest and satisfaction with iPhone are very strong with both consumers and business uses. In the U.S., the latest data from 451 Research on consumers indicates a 95% customer satisfaction rating for iPhone 7 and 99% for iPhone 7 Plus. Among consumers planning to buy a smartphone, purchase intention for iPhone was nearly three times the rate of our closest competitor. Among corporate smartphone buyers, iOS customer satisfaction was 94%. And of those planning to purchase smartphones in the September quarter, 78% plan to purchase an iPhone. Turning to Services, we set an all-time quarterly record of $7.3 billion, up 22% year over year. The App Store was a major driver of this performance. And according to App Annie's latest report, it continues to be by a wide margin the preferred destination for customer purchases, generating nearly twice the revenue of Google Play. Revenue from our Apple Music streaming service and from iCloud storage also grew very strongly. And across all of our Services offerings, the number of paid subscriptions reached over 185 million, an increase of almost 20 million in the last 90 days alone. The reach, usage, and functionality of Apple Pay continue to grow. We launched Apple Pay in Italy in May. And the UAE, Denmark, Finland, and Sweden are scheduled to go live before the end of this calendar year. Apple Pay is by far the number one NFC payment service on mobile devices, with nearly 90% of all transactions globally. Momentum is strongest in international markets, where the infrastructure for mobile payments has developed faster than in the U.S. In fact, three out of four Apple Pay transactions happen outside the U.S. And with the launch of iOS 11 this fall, our users in the U.S. will be able to make and receive person-to-person payments quickly, easily, and securely. Next, I'd like to talk about the Mac. Thanks to great performance from the new MacBook Pro, we generated 7% revenue growth over last year and gained share in the global PC market based on the latest data from IDC. Customer satisfaction for Mac is very strong at 97% in the most recent survey from 451 Research, and our active installed base of Mac has grown double digits over a year ago. We ended the quarter within our four to five-week target range for Mac channel inventory, and we have a great lineup of Macs for our customers heading into the busy back-to-school season. Turning to iPad, we sold 11.4 million units, up 15% over last year. We were happy to see iPad growth in each of our geographic segments, with strong double-digit increases in key markets such as the U.S., Japan, Germany, France, and Greater China. We exited the quarter within our five to seven-week target range for iPad channel inventory. NPD indicates that iPad had 55% share of the U.S. tablet market in the month of June, including 8 of the 10 best-selling tablets. That's up from 46% share a year ago. And among tablets priced over $200, iPad's share was 89%. In addition, the most recent survey from 451 Research measured business and consumer satisfaction rates ranging from 95% to 99% across iPad models. And among those planning to buy tablets, purchase intent for iPad was over 70%. Our enterprise business continues to expand, and our customers are transforming the way work gets done with iOS and iPad. Walmart will be deploying more than 19,000 iPads for employee training across 50 states, with projections of over 225,000 associates trained on iPad by the end of the year. Initial response from businesses to iOS 11 and the new iPad Pro has been amazing. And companies including Bank of America, Medtronic, and Panera tell us that they will be rolling out the 10.5-inch iPad Pro throughout key areas of their organizations. We're also seeing real traction with our enterprise partners. Just last month, we unveiled the next set of technology announcements in our partnership with Cisco. This new wave adds a whole new category of security features designed to help enterprises and employees defend against growing cyber threats. We believe this investment in our joint security solutions for iOS will make cyber insurance even more attainable for businesses. SAP is making great strides since launching the SAP cloud platform SDK for iOS in March, with a pipeline of hundreds of global opportunities. SAP has also released SuccessFactors Mobile, its first native iOS app for human resources, which will support 47 million iPhone and iPad users worldwide across multiple industries. And our partnership with Deloitte has recently expanded to several more European countries. We're helping clients transform their businesses with iOS. We jointly developed programs such as the Connected Store, a pop-up version of a retail environment, demonstrating iOS tools for sales and demand generation, as well as tailored apps for safe associates, store management, and customers. We also had a tremendous quarter for iPad in education, up 32% year over year. Following the launch of our new iPad in March, an update to our popular Classroom app, and continued enhancements to iOS that make managing iPads in the classroom even easier. The St. Paul Public School District in Minnesota is renewing its One to One program by deploying over 40,000 iPads across every student and teacher in the district. iPad was chosen because of its power and durability, ease of use, multimedia and accessibility features, and the extensive catalog of iOS apps designed specifically for education. The Shawnee Mission School District outside Kansas City recently purchased 19,000 iPads, extending its One to One program started in 2014 thanks to iPad's intuitive interface, superior reliability, and expansive ecosystem of iOS tools for education. It was a very busy quarter for our retail and online stores, which collectively welcomed over 300 million visitors. In addition to our spectacular new store at the Dubai Mall, we opened our first stores in Singapore and in Taiwan during the quarter, expanding our total store footprint to 497 stores. In May, we kicked off Today at Apple, with new in-store programming from music to photography to art and coding. And our stores collectively hosted 87,000 sessions during the quarter. As Tim mentioned last quarter, we have entered a new chapter in retail with unique and rewarding experiences for our customers and some stunning new stores coming in the near future. Let me now turn to our cash position. We ended the quarter with $261.5 billion in cash plus marketable securities, a sequential increase of $4.7 billion. $246 billion of this cash, 94% of the total, was outside the United States. We retired $3.5 billion of debt and issued the equivalent of $10.8 billion in new euro and U.S. dollar-denominated debt during the quarter, including our second green bond, bringing us to $96.4 billion in term debt and $12 billion in commercial paper outstanding. We also returned $11.7 billion to investors during the quarter. We paid $3.4 billion in dividends and equivalents and spent $4.5 billion on repurchases of 30.4 million Apple shares through open market transactions. We launched a new $3 billion ASR program, resulting in initial delivery and retirement of 15.6 million shares, and we retired 3.4 million shares upon the completion of our 10th ASR during the quarter. We have now completed $222.9 billion of our $300 billion capital return program, including $158.5 billion in share repurchases. As we move ahead into the September quarter, I'd like to review our outlook, which includes the types of forward-looking information that Nancy referred to at the beginning of the call. We expect revenue to be between $49 billion and $52 billion. We expect gross margin to be between 37.5% and 38%. We expect OpEx to be between $6.7 billion and $6.8 billion. We expect OI&E to be about $500 million. And we expect the tax rate to be about 25.5%. Also today, our Board of Directors has declared a cash dividend of $0.63 per share of common stock, payable on August 17, 2017 to shareholders of record as of August 14, 2017. With that, I would like to open the call to questions. Thank you, Luca, and we ask that you limit yourself to one one-part question and one follow-up. Rebecca, may we have the first question, please? And that question will come from Katy Huberty with Morgan Stanley. Yes, thanks. Good afternoon. Luca, first question for you, gross margin guidance is strong, but it did tick down from your June quarter guidance, and you also narrowed the range to 50 basis points. I wonder if you can just address. What is the driver of the sequential downtick, and what gives you confidence that you have more visibility than you did three months ago? Katy, sequentially from 38.5% that we just reported, typically we have product transition costs during the September quarter. That's the primary driver. This happens fairly regularly for us. We also have a more difficult memory pricing environment this year than a year ago. And we think that we're going to be able to partially offset this with the positive leverage. As you've seen, we guided up sequentially in revenue. So those are the major puts and takes. In terms of the range that we use for gross margins, we have a fairly good understanding on where we are with our hedging program, and that allows us to mitigate some of the volatility there. So we felt we could guide to a slightly narrower range, which we've done occasionally in the past. Thank you, and maybe a question for both Tim and Luca. As you outlined on this call and at the Developer Conference in June, there is an unprecedented number of products that either ramped volume or launched in the back half of this year. So appreciating you only formally guide a quarter out, I wonder if there's any qualitative commentary you can provide to help us think about the back half of this calendar year and how all those new products that come into the model could impact either revenue seasonality versus past years or could impact just the costs associated with ramping that many products all at once. Thanks. Katy, as Luca mentioned, we did assume some transitional costs in our guidance for the quarter, as is typically the case. And we're looking very much forward to the product rollouts. Thank you, Katy. Could we have the next question, please? We'll go to Shannon Cross with Cross Research. Thank you very much for taking my question. Tim, could you talk a bit about what you're seeing in China? I think obviously, there continues to be strong demand for smartphones. But perhaps mix shift, I think you brought back the iPhone 6 this quarter to be a bit more price aggressive. And then can you just talk a bit about how you see that market developing with the growth of WeChat and some of the other developments that are happening there? Thank you. Yeah. Thanks, Shannon. We were very encouraged by the results this quarter. We improved as we thought we would from the previous quarters a little more than I thought we would. If you look underneath the numbers, mainland China was actually flat year-over-year during Q3. And in constant currency terms, we were actually up 6% in mainland China. And so we're very encouraged about that. iPad grew dramatically more than the market. The Mac grew much more than the market. iPhone was relatively flat year-on-year, similar as the market was. And so we see all of those as very encouraging signs. On top of that, Services grew extremely strongly during the quarter. Hong Kong continued to drag down the total Greater China segment. But on a sequential basis, we're probably at the trough of that, which is nice. With the peg to the dollar there from a currency point of view and tourism being what it is, I don't really know when that market will come back. But what we see on the mainland is definitely much more encouraging. It's interesting to note that upgraders both for the quarter and actually for the full fiscal year to-date was our highest ever, and so that we felt very good about. In terms of WeChat, the way that I look at this is because our share \\u2013 because iOS share is not nearly a majority of the market in China, the fact that a lot of people use that, it makes the switching opportunity even greater. And I think that's more the case than the risk that a lot of folks have pointed out. And so I see Tencent as one of our biggest and best developers. They've done a great job of implementing a lot of iOS features in their apps and we're looking forward to working with them even more to build even greater experiences for our mutual users in China. Great. Thank you. And then can you talk a bit about the composition of the installed base of iPhones at this point, as obviously we're getting close to a refresh? Just you brought in the iPhone SE. You've obviously had strength at the high end. I'm just trying to think about what percent do you think have upgraded in the prior generation, any color you can give us on that? From an absolute quantity point of view, the upgrades for this fiscal year are the highest that we've seen. And so we feel good about that. However, if you look at it from an upgrade rate point of view instead of the absolute number, the rate is similar to what we saw with the previous iPhones, except for iPhone 6, which as we called out in the past had an abnormally high upgrade rate. We do think that based on the amount of rumors and the volume of them that there is some pause in our current numbers. And so where that affects us in the short-term, even though we had great results, it probably bodes well later on. Thank you, Shannon. Could we have the next question, please? Steve Milunovich with UBS. Thank you. I wonder if you wanted to make any comments about switching this quarter. Sure. Switching outside of China was up year-on-year, and so we're happy with that. We continue to see people moving over to iOS and it helped with us making the results that Luca announced earlier, including the channel inventory reduction. Okay, and then a government question. First of all, the President suggested that you may build three big beautiful plants. I wonder if you can comment on if that's a possibility either directly or indirectly. And then in China, I think, we all understand that you have to work within the regulations, but maybe you could comment a bit on how you feel your working relationship is with the government and if there is certain lines that you can't cross. Sure. Starting with the U.S., let me just take this question from what are we doing to increase jobs, which I think is probably where it's rooted. We've created 2 million jobs in the U.S., and we're incredibly proud of that. We do view that we have a responsibility in the U.S. to increase economic activity, including increasing jobs, because Apple could have only been created here. And so as we look at that 2 million, there are three main categories of that, and we have actions going on in each of them to further build on that momentum. The first category is app development. About three-quarters of the 2 million are app developers. And we're doing an enormous amount of things to deliver curriculum to both K-12 with Swift Playgrounds in the K-to-6 area, other curriculum as you proceed beyond grade 6 under the Everyone Can Code area. And just a couple months ago, we announced a new curriculum that's focused on community schools and community colleges, junior colleges, technical colleges, for kids that did not have coding in their elementary and high school years. And so we're excited about that because we think it could increase the diversity of the developer community and the quantity. And I think this area in general and all the things we do for the developer community will be the largest contribution that Apple can make because this is the fastest growing job segment in the country, and I think will be for quite some time. If you look at the second area, we have purchased \\u2013 or we purchased last year about $50 billion worth of goods and services from U.S.-based suppliers. Some significant portion of those are manufacturing-related, and so we've asked ourselves what can we do to increase this. And you may have seen that at the beginning of the quarter, sometime in April I believe, we announced a fund, an Advanced Manufacturing Fund, that we're initially placing $1 billion in. And we've already deployed $200 million of that. And the first recipient is Corning in Kentucky, and they'll be using that money to expand the plant to make very innovative glass. And we purchase that glass and essentially export it to the world with iPhones and iPads. We think there's more of these that we can do. I think there are probably several plants that can benefit from having some investment to grow or expand or even maybe set up shop in the U.S. for the first time, so we're very excited about that. And then the third area is we have about two-thirds or so of our total employee base is in the U.S. despite only a third of our revenues being here, and we'll have some things that we'll say about that later in the year. And so that's what we're doing from a job growth point of view, and we're very, very proud of that. Now turning to China, let me comment on what I assumed is at the root of your question about this VPN issue. Let me just address that head on. The central government in China back in 2015 started tightening the regulations associated with VPN apps, and we have a number of those on our store. Essentially, as a requirement for someone to operate a VPN, they have to have a license from the government there. Earlier this year, they began a renewed effort to enforce that policy, and we were required by the government to remove some of the VPN apps from the App Store that don't meet these new regulations. We understand that those same requirements are on other app stores, and as we checked through that, that is the case. Today there are actually still hundreds of VPN apps on the App Store, including hundreds by developers that are outside China, and so there continues to be VPN apps available. We would obviously rather not remove the apps, but like we do in other countries, we follow the law wherever we do business. And we strongly believe that participating in markets and bringing benefits to customers is in the best interest of the folks there and in other countries as well. And so we believe in engaging with governments even when we disagree. And in this particular case, now back to commenting on this one, we're hopeful that over time the restrictions that we're seeing are loosened because innovation really requires freedom to collaborate and communicate, and I know that that is a major focus there. And so that's what we're seeing from that point of view. Some folks have tried to link it to the U.S. situation last year, and they're very different. In the case of the U.S., the law in the U.S. supported us, which was very clear. In the case of China, the law is also very clear there. And like we would if the U.S. changed the law here, we'd have to abide by them in both cases, that doesn't mean that we don't state our point of view in the appropriate way. We always do that. And so hopefully that's a little bit probably more than you wanted to know, but I wanted to tell you. Thank you. Thank you, Steve. Could we have the next question, please? We'll hear from Kulbinder Garcha with Credit Suisse. Thank you, a question for Tim maybe on the iPhone install base. At various points in the past you've told us the rate at which that was growing. At the end of the first half, what is that up year on year? At what rate is it growing? Can you give us some sense of that? And on upgrade rates over the longer term, there are lots of moving parts, and I get that there's I guess geographic mix shift of your base. There's many new phones that you may or may not bring out. There's how carriers promote your products. But do you think this upgrade rate is sustainable? Do you think it gets faster all the time? How should we think about the major drivers that you want to see for it? Many thanks. I think the upgrade rate is a function of many, many different things, from the size of the installed base, the age of the installed base, the product that is new at the time, the regional distribution, the upgrade plans that are in various markets around the world. And so I think there are many, many factors in that. It's not a simple thing that you can apply a set formula to or one variable or a couple of variable formula in my opinion. But I think in general, because our installed base was up strong double digit once again, there's a lot of factors that are very positive for us. And between the upgraders and the switchers that we see, and the first-time buyer category is still out there too in several countries, including some that you may not think there is, there's still a sizable base in some. Between those three areas, I think we have a lot of opportunity. Thank you. Yes. Thank you, Kulbinder. Could we have the next question, please? Toni Sacconaghi with Bernstein. Yes, thank you. I have one for Luca and one for Tim, please. Luca, typically in the fiscal Q4, Apple builds considerable iPhone channel inventory, like 2 million or 3 million units. You're starting from a very low point at the end of fiscal Q3, as you mentioned on the call, with the drawdown. As we think about what's embedded in your guidance for fiscal Q4 for channel inventory for iPhone, should we be expecting a normal seasonal build, or is it likely to be significantly higher given the very low starting point? As you know, Toni, we do not guide on channel inventory. We've never done that. We are providing a fairly wide range from a revenue standpoint, so obviously that also has an impact on potential channel inventory levels. One thing that I would tell you is that we feel very good about the performance of the business right now. We think that our Services business will continue to grow well. We've got a lot of momentum on iPad and Mac because we refreshed the lineups of those products. Watch and AirPods are doing incredibly well. We're getting a lot of positive customer feedback. And I think in general, even the performance in China, Tim has mentioned it. We think that the performance will continue to improve. So those are the drivers of our guidance range for the quarter. Okay, thanks. Tim, I was wondering if you could maybe talk a little bit about two things that you mentioned in public before. One is television, which you have described as an area of intense interest, but I don't even think there was an update on Apple TV on this call. So perhaps you can talk to us about how you're thinking about content. I know you're doing some original content creation, and how that area is evolving in your thinking. And then recently you talked about how Apple is focusing on autonomous systems for automobiles. And there has been press reports that Apple has been testing autonomous vehicles for potentially up to a year. I was wondering if you could talk a little bit more about Apple's interest in autonomous vehicles and whether self-driving is really likely to be Apple's principal focus in the near to medium-term. On the first part of your question about original content, we have done some original content. It's focused on Apple Music. Currently, we have some more that's launching in a week or so that will be made available on Apple Music. The objective of this is really twofold. One is for our own learning, given that we're new in the video space in terms of creation. And two is to give the Apple Music subscriber some exclusive content and hopefully grow our subscriber base. And we've recently hired two great folks with lots of experience in creating content like Breaking Bad and The Crown and some really top-notch content. And so we'll see how this area goes, but it is still an area of great interest. In terms of autonomous systems, what we've said is that we are very focused on autonomous systems from a core technology point of view. We do have a large project going and are making a big investment in this. From our point of view, autonomy is the mother of all AI projects. And the autonomous systems can be used in a variety of ways and a vehicle is only one. But there are many different areas of it and I don't want to go any further with that. But thank you for the question. Thank you, Toni. Could we have the next question, please? That comes from Mike Olson with Piper Jaffray. Good afternoon. I just have one question for Tim. This may be a hard question to answer in a condensed way, but how would you describe what you expect the most near-term applications will be for developers to target using ARKit? Will it be consumer iPhone and iPad applications, enterprise applications, or I guess some combination of the two? And basically, how does this come to market in the most significant way in the next few quarters as Apple becomes the largest global platform for AR as you've talked about? Thanks. Mike, that is a great question. And I could not be more excited about AR and what we're seeing with ARKit in the early going. And to answer your question about what category it starts in, just take a look at what's already on the web in terms of what people are doing and it is all over the place. From entertainment to gaming, I've seen what I would call more small business solutions. I've seen consumer solutions. I've seen enterprise solutions. I think AR is big and profound and this is one of those huge things that we'll look back at and marvel on the start of it. So I think that customers are going to see it in a variety of ways. Enterprise takes a little longer sometimes to get going. But I can already tell you there's lots of excitement in there. And I think we'll start to see some applications there as well. And it feels great to get this thing going at a level that can get all of the developers behind it, so I couldn't be more excited about it. Thank you. Thanks, Mike. Could we have the next question, please? We'll go to Amit Daryanani. Thanks a lot. Good afternoon, guys. I guess to start off with, on your Services segment, revenues actually I think accelerated by 400 basis points to worse than what you guys had in the first half of this year. Could you just help us understand what's driving this? Is there a way to think about ARPU in a traditional manner within that Services business versus the installed base growing? Amit, Luca. Our Services business is very broad. We've got multiple categories in the Services business, so it's difficult to talk about ARPU in general. It doesn't make a lot of sense. The reason for the acceleration also here is multiple factors. One that is very, very important for us is the fact that the App Store, which is the largest of our Services categories, is seeing an increasingly larger amount of paying accounts. On a year-over-year basis, the number of accounts that are actually transacting and paying on the App Store is growing very, very well. It is happening for a variety of reasons. One of them, for example, is the fact that we are making it easier for customers to pay on the App Store. Outside the United States, in many markets, not every form of payment is accepted. We are making it easier all the time. We launched on Alipay, for example, in China during the December quarter. That has obviously helped a lot with the growth in the number of paid accounts. And we continue to bring more and more forms of payment in the App Store around the world. That's a big reason for that. The other reason why the number of paying accounts is growing is the fact that the quality and the quantity of content continues to improve. And so there's many more ways of experiencing games and entertainment and other apps on the store. We have other businesses like the Apple Music streaming service, which is growing very fast because we just started it a couple of years ago, so we are getting a lot of new subscribers there. Our iCloud storage business continues to grow very, very fast. So it's multiple services. The number of people transacting on our stores continues to grow. In terms of ARPU, maybe I can make a comment on ARPU specifically related to the App Store. What we're seeing and we've seen over a long period of time as we keep track of these cohorts of customers, we see that as customers get on the App Store and start spending on it, we see the spending profile is very similar across generations of customers. People tend to spend more over time. Obviously, you have different spending profiles in different geographies around the world, but in general you see that trend across the board. Got it, that's really helpful. And if I could just follow up, on the iPhone side, there's been a large amount of discussion in blogs and among your component suppliers that the timing this time may be somewhat different and delayed versus past. Your guide almost seems you're more excited about this iPhone launch versus historically because the sequential growth is better. So I guess beyond the fact we probably shouldn't read every blog and believe every blog, what do you think is different with this product launch or product availability through the cycle versus what you've seen historically? We have no comment on anything that's unannounced. Fair enough, I figured it was worth a shot. Thank you. Thank you, Amit. Could we have the next question, please? That will come from Brian White with Drexel. Yes. Tim, growth in the smartphone market is now crawling along at about a low single digit percentage. I know iPhone grew about 2% year over year this quarter, and it looks like you had about a mid-teens market share in units in 2016. So as we look forward maybe three to four years, do you think Apple can expand its unit market share? And if so, what will be the drivers be? And my second question is just about India, general thoughts about India in the quarter. Thank you. The answer to your first question is yes. I do think that we can grow both in units and market share. We don't predict those things, but yes, if you ask me what I think, that's what I think. And so what are the drivers? The installed base is growing. It's still growing very strongly. That will generate more upgrades over time. I feel good about our ability to convince people to switch. And where the developed markets the first-time buyer rates are down other than places like Japan perhaps, the emerging markets, we haven't even gotten started yet, really. From a revenue point of view, we had very strong growth there. Emerging markets ex-China were up 18% year on year. It was a record for us, so we see a lot of opportunity in these markets. We are investing in India. As you mentioned in your second point, we've already launched an app accelerator center. That's on top of working with the channel and looking at expanding our go-to-market in general. And we began to produce the iPhone SE there during the quarter, and we're really happy with how that's going. And so we're bringing all of our energies to bear there. I see a lot of similarities to where China was several years ago. And so I'm very, very bullish and very, very optimistic about India. Great, thank you. Thanks very much, Brian. A replay of today's call will be available for two weeks as a podcast on the iTunes Store, as a webcast on apple.com/investor, and via telephone. And the numbers to the telephone replay are 888-203-1112 or 719-457-0820. Please enter confirmation code 6376964. And these replays will be available by approximately 5:00 PM Pacific Time today. Members of the press with additional questions can contact Kristen Huguet at 408-974-2414. And financial analysts can contact Joan Hoover or me with additional questions. Joan is at 408-974-4570 and I'm at 408-974-5420. Thanks again for joining us. Ladies and gentlemen, that does conclude today's presentation. We do thank everyone for your participation.\",\n          \"Thank you, ladies and gentlemen, for standing by. Welcome to the Q1 2019 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will be given at that time. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our VP of Investor Relations, Kevin Hern. Please go ahead. Thank you. Good morning. Thank you for joining us for Eli Lilly and Company\\u2019s Q1 2019 earnings call. I am Kevin Hern, Vice President of Investor Relations. Joining me on today\\u2019s call are Dave Ricks, Lilly\\u2019s Chairman and CEO; Josh Smiley, our Chief Financial Officer; Dr. Dan Skovronsky, President of Lilly Research Laboratories; Christi Shaw, President of Lilly Bio-Medicines; Anne White, President of Lilly Oncology; and Enrique Conterno, President of Lilly Diabetes and Lilly USA. We are also joined by Kim Macko and Mike Czapar of the Investor Relations team. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on slide three and those outlined in our latest Forms 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions. As we transition to our prepared remarks, a reminder that our commentary will focus on non-GAAP financial measures, which exclude the financial contribution from Elanco during the first quarters of both 2018 and 2019, and present earnings per share as though the full disposition of the exchange offer was complete on January 1, 2018. We believe this view provides insights into the drivers of our underlying business performance as a dedicated pharmaceutical company and provides for cleaner comparisons to future and prior periods. Now, I will turn the call over to Dave for a summary of our progress in Q1. Thanks, Kevin. The Company\\u2019s focus in 2019 is to execute on a broad and exciting range of new products and indication launches, to build and accelerate our pipeline, and continue to improve the focus and competitiveness of our company. We are pleased with the progress on these objectives in Q1 2019. First quarter revenue grew 5% in constant currency, despite a significant decline in U.S. Cialis revenue due to the recent loss of exclusivity. We made significant investments in key commercial and late-stage pipeline products and delivered non-GAAP EPS of 2% putting us on track to meet our full year financial guidance. Our key growth products, which all launched since 2014 contributed meaningfully to our performance and account for 39% of our revenue. While still relatively early in their product life cycles, these products continue to drive growth led by Trulicity, Taltz, Verzenio, and in collaboration with Boehringer Ingelheim, Jardiance and Basaglar. Total volume growth across the entire portfolio was 7% and excluding Cialis was nearly 13%. U.S. diabetes contributed strong volume growth of nearly 17%. Oncology growth accelerated in the U.S., Japan and China. And our international markets grew volume by 9%, as global launches of key brands continue across our major geographies. Excluding the impact of FX on international inventory sold, Q1 non-GAAP operating income as a percent of revenue decreased by nearly 600 basis points versus Q1 2018, reflecting a decrease in gross margin and investment in recent launches and multiple late-stage pipeline opportunities. On the same basis, operating income as a percent of revenue in Q1 increased by nearly 80 basis points versus Q4 2018, reflecting progress toward our 2019 full year margin goal of 28%. We exited Q1 on track with our plans for the full year. We have invested in our future growth, while delivering strong volume growth across the business. Importantly, several pipeline assets achieved milestones this quarter, including the regulatory submission for the Trulicity REWIND study for CV outcomes label in the U.S. and in Europe. The FDA granted priority review for Emgality for cluster headache in the U.S. The submission of Ultra Rapid Lispro for Type 1 and Type 2 diabetes in both Europe and Japan. The U.S. submission of our first connected device, our connected care prefilled insulin pen. And we had several Phase 3 data readouts. We also announced an updated timeline for expected regulatory action timing for nasal glucagon. We received notification. The FDA has extended the review timeline by up to three months to analyze information requested late in that review cycle. We remain confident in nasal glucagon submission package and look forward to FDA action in the coming months. In terms of capital deployment, we continue to utilize our strong operating cash flow to access value creating external innovation, which will enhance our future growth prospects. We completed the acquisition of Loxo Oncology and in key pipeline assets and expanding our presence into precision medicine. We completed the full separation of Elanco Animal Health via an exchange offer, retiring 65 million Lilly shares with approximately $8.2 billion. We entered into a global licensing and research collaboration with ImmuNext, focused on new medicines for autoimmune disease. We announced a global licensing and research collaboration with Avidity, focused on potential new medicines in immunology and select other indications. We announced an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, as well as a manufacturing facility to Eddingpharm, a Chinese-based specialty pharmaceutical company. And we returned an additional $3.5 billion to shareholders via a previously announced accelerated share repurchase program and $600 million in dividends, representing a 15% increase per share versus 2018. Moving on to slides five and six, you will see more details on key events since our February earnings call, including our announcement to introduce Insulin Lispro a low priced version of Humalog in the U.S. Now, I will turn the call over to Josh to review our Q1 results and to provide an update on our post Elanco financial guidance. Thanks Dave. Slide seven summarizes our presentation of GAAP results and non-GAAP measures and slide eight provides a summary of our GAAP results. Looking at the non-GAAP measures on slide nine, you will see revenue increased 30%. Excluding the impact of FX on international inventories sold, gross margin as a percent of revenue was 80.2%, in line with our long-term goals for manufacturing efficiency and profitability. On the same basis, gross margin declined 130 basis points compared to Q1 2018, driven by production timing and lower volumes from post patent products. Total operating expense increased 12%, with marketing selling and administrative expense, increasing 13%, driven primarily by increased investment to support our recent launches, including DTC campaign campaigns to drive awareness from Emgality, Verzenio and Taltz. R&D expense increased 11%, reflecting the ramp up of multiple late-stage pipeline assets, the addition of the Loxo Oncology portfolio and the insight communicating to us that they would no longer co-fund the development of baricitinib, which reduces the royalty we will pay them moving forward. As a result of the investments described above, operating income decreased 8% compared to Q1 2018, which put our operating income as a percent of sales at 26.2% for the quarter. As our recent launches continue to drive revenue and operating leverage, we expect income growth and improvements in operating margin during the remainder of 2019. Other income and expense was income of $86 million this quarter compared to income of $70 million in Q1 2018, driven by over $100 million in gains of mark-to-market of public equities held through venture capital investments and strategic partnerships, partially offset by higher net interest expense. Our tax rate for the quarter was 12.9%, a decrease of 260 basis points compared with the same quarter last year, driven primarily by timing associated with the impact of U.S. Tax Reform. At the bottomline, net income declined 4%, while earnings per share increased 2%, due to a reduction in shares outstanding from share repurchases. Recall that our non-GAAP comparisons remove the 65 million shares retired through the Elanco exchange for both 2018 and 2019. While income declined this quarter versus Q1 2018 we made important progress on several fronts that will drive future growth, as demonstrated by growing revenue despite significant headwinds from the loss of exclusivity of Cialis in the U.S., investing behind key growth brands, such as Emgality, Verzenio, Taltz, Jardiance and Trulicity, and advancing several pipeline assets to the next phase of development, including multiple regulatory submissions. Slide 10 provides a reconciliation between reported and non-GAAP EPS and you will find additional details on these adjustments on slide 23. Moving to slide 11, let\\u2019s take a look at the effective price rate and volume on revenue growth. This quarter, foreign exchange reduced revenue growth by 2 percentage points. As Dave mentioned earlier, worldwide revenue grew 5% on a performance basis, driven by a 7% increase in volume, partially offset by price, Q1 is the ninth straight quarter our business grew volume in each major geography. U.S. revenue increased 3%. Like last quarter Trulicity, Taltz, Verzenio and Basaglar were the key drivers of 6% volume growth, partially offset by price. Excluding Cialis, volume grew nearly 15% in the U.S., highlighted by diabetes products delivering nearly 17% volume growth. Consistent with our 2019 financial guidance U.S. price declined 3%, driven by increased utilization of patient affordability programs, mainly for insulins and Taltaz, adjustments through estimates for rebates and discounts at higher contracted rates, primarily related to Trulicity, which were partially offset by favorable segment mix across the portfolio. Moving to Europe, strong volume growth of 9% was largely offset by the negative effect of foreign exchange and to a lesser extent price. Volume growth was led by Trulicity, Olumiant and Taltz. In Japan, strong volume growth of 7%, driven by Cymbalta, Verzenio and Trulicity, was largely offset by a drag of 6% from price, as a result of the government mandated price decreases that went into effect in 2018. Revenue in the rest of the world increased 9% on a performance basis this quarter, led by volume growth from Humalog, Trulicity, Cialis, Jardiance and the recently launched Tyvyt, a China-only anti-PD1 immunotherapy agent in collaboration with Innovent Biologics. As shown on slide 12, our key growth drivers were once again the engine of our worldwide volume growth. These products drove 14.8 percentage points of volume growth this quarter, an increase of over 100 basis points versus their contribution to growth in Q4 2018. Brands that have experience loss of exclusivity provided a drag of 530 basis points, driven primarily by Cialis. You may recall, the generic versions of the Cialis entered the U.S. market at the end of September last year, and as expected, we have seen a rapid erosion of sales. When excluding LOE, the rest of our products posted robust Q1 volume growth of nearly 16%. Slide 13 provides a view of our key growth products. In total, these brands generated nearly $2 billion in revenue this quarter, representing 39% of revenue. Trulicity continues to post robust growth, having achieved over 45% total share of the U.S. market, in a rapidly expanding class, that grew nearly 30% this quarter. Similarly, Jardiance posted impressive U.S. share gains in volume growth, now capturing 50% and 64% share of market in total and new prescriptions respective. Both products continue to be the market leaders in their classes. Emgality launch trajectory continues to be strong, with nearly 33% share of market for new prescriptions in the U.S., an increase of almost 13 share points from where we finished 2018. We expect increasingly strong performance in the U.S., combined with best-in-class access to drive meaningful sales contribution in the second half of 2019. Continuing with our non-GAAP explanations on Slide 14, foreign exchange rates had a modest impact on our revenue, but a more meaningful impact on cost of sales, due to the effect in last year\\u2019s quarter, resulting in the mid-single digit impact of operating income and EPS. Turning to our 2019 financial guidance on Slide 15, you will see that we maintained non-GAAP-pharma-only expectations we shared in February. And with the Elanco exchange offer complete, are now providing EPS on the same basis. Our non-GAAP earnings per share range is $5.60 to $5.70, an increase of $0.05 versus our previously issued guidance range, which included Elanco. While the line items remain unchanged from the previously communicated pharma-only expectations, I\\u2019d highlight two items that impact our outlook for the remainder of 2019. First, we will manage expenses to deliver within our SG&A range, while investing thoughtfully to drive continued revenue growth. And second in Q1, OID benefited from mark-to-market equity gains and our tax rate benefited from a net discrete item. We are maintaining our full year outlook for these items, however, as these items are highly variable and it is early in the year. Touching briefly on our updated GAAP guidance, we expect earnings per share to be in the range of $8.57 to $8.67, which includes a $3.7 billion gain on the disposition of Elanco recorded in discontinued operations. On Slide 16, we provide an update on our recent activity regarding capital allocation. Consistent with our strategic priorities, we spent over $8 billion on initiatives to drive future growth. In addition to investing in internal R&D, we closed the Loxo Oncology acquisition which augmented our pipeline, and returned over $4 billion of cash to shareholders. As Dave mentioned earlier, we completed the successful divestiture of Elanco this quarter via an exchange offer. We exited Elanco at an attractive price and recognized a $3.7 billion gain on the disposition. In addition, the exchange offer was substantially oversubscribed, and resulted in earnings accretion in 2019, from retiring Lilly shares. As we have returned to growth, our confidence in our business outlook has been reflected in meaningful dividend increases in 2018 and 2019. As we move ahead, our ability to continue to generate strong operating cash flow supports our pursuit of external innovation to enhance our long-term growth and create shareholder value. Now I will turn the call over to Dan to highlight our progress on R&D. Thanks Josh. Slide 17 shows select pipeline opportunities as of April 24. Movement since our last earnings call includes, the regulatory submission of Trulicity rewind data for CV outcomes label in the U.S. and Europe, submission of our Connected Care prefilled insulin pen for Type 1 and Type 2 diabetes in the U.S., submission of a fixed-dose combination of empagliflozin. linagliptin and metformin XR, for type-2 diabetes in the U.S. and submission of Ultra Rapid Lispro from type-1 and type-2 diabetes in Europe and Japan. We also highlight the initiation of Phase 2 testing for our IL-33 monoclonal antibody and immunology. The initiation of Phase 1 testing for three new molecular entities, including our GIP, GLP glucagon tri-agonist, and the attrition of two Phase 2 molecules. With the submission of Ultra Rapid Lispro, we are now on track to deliver 12 NME approvals since 2014. Therefore, a common question I get is, what\\u2019s next? As we replenish our late-stage pipeline, in the past 12 months we have made four big innovation bets with mirikizumab, pegilodecakin, our recently acquired RET inhibitor and tirzepatide. Moving to Slide 18, mirikizumab is our IL-23 in Phase 3 for psoriasis and ulcerative colitis, with expected data readouts in 2020 and 2021 respectively. We see first-in-class potential for ulcerative colitis, a disease with high unmet need in growing incidence, where we saw strong Phase 2 efficacy and clinical response and endoscopic healing. Based on positive Phase 2 data in Crohn\\u2019s disease, which we will be presenting in a few weeks at DDW, we are now moving quickly into Phase 3 for Crohn\\u2019s disease yet this year. Pegilodecakin is our first-in-class PEGylated IL-10 from ARMO Biosciences. We see strong biological rationale and single agent activity in renal cancer. There\\u2019s also an intriguing signal in combination with both chemotherapy and checkpoint inhibitors in several tumor types. We are looking forward to data readouts from the Cypress-1 and Cypress-2 non-small cell lung cancer studies by the end of this year, as well as the Phase 3 pancreatic cancer trial in 2020. We will also be starting a clinical program in renal cell carcinoma this year. Our most recent late stage entry is our potential first-in-class and best-in-class RET inhibitor from Loxo Oncology. Currently in the Phase 2 portion of the LIBRETTO-001 study, we look forward to having both additional data readout and a regulatory submission by the end of this year. This molecule has received breakthrough designation from the FDA for three indications, RET fusion positive non-small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion positive thyroid cancer. We are excited about the data we have seen to-date, which has shown robust response rates and encouraging response durations. We look forward to presenting new data at a medical meeting in the second half of this year. Finally, tirzepatide, our novel first-in-class and best-in-class GIP, GLP dual agonist twincretin, which started its Phase 3 SURPASS program in late 2018, on the heels of presenting impressive Phase 2 results in October at EASD. We believe tirzepatide could provide levels of efficacy not seen with existing products. All SURPASS studies for the global submission should start by the end of the year, with data expected in 2021. We also expect to initiate Phase 3 studies in obesity and a Phase 2 study in NASH later this year. We look forward to presenting new data at ADA in June on tirzepatide, including the additional dose escalation data from a Phase 2 trial in diabetes, data from a Japan clinical trial and new biomarker data from our Phase 2 trial supporting potential efficacy for NASH. We are excited about this cohort of innovative first-in-class, late-stage assets each with the potential to improve the standard of care across immunology, oncology and diabetes. We look forward to what\\u2019s next from these assets as they achieve important milestones and readouts over the next 12 months. Slide 19 shows a tally of a significant progress we have made since our last earnings call on key events we are monitoring for 2019 including submissions across four key line extensions or NMEs that I described earlier, the regulatory submission of Emgality for episodic cluster headache in Europe, positive results from CAROLINA CV outcome study of Trajenta, positive results for a Phase 3 study of Taltz for non-radiographic axial spondyloarthritis. Results from two Phase 3 studies of Tanezumab, the first in patients with chronic lower back pain and the second a long-term safety study in patients with osteoarthritis pain. Positive results from a Phase 3 study of Cyramza for first line EGFR non-small cell lung cancer. We also note that we received notification that for technical reasons the FDA has refused to file the supplemental NDA for Empagliflozin in type 1 diabetes and that we have made a decision to not pursue the development of Olumiant for psoriatic arthritis. In addition to the late-stage highlights I shared with you today, we are growing our early stage pipeline through both enhanced internal productivity and external innovation. We will highlight several examples in upcoming earnings calls. Now I will turn the call back over to Dave for some closing remarks. Thanks, Dan. In the first quarter, we delivered strong volume based revenue growth of 5% on a constant currency basis, driven entirely by our key growth products. We made strategic investments in commercial and late-stage products, which will enhance our future growth prospects. We have seen good pipeline progress this quarter, including a number of regulatory submissions. In addition, we bolstered our early phase pipeline by advancing multiple assets into the clinic and signing research agreements. We also completed two significant transactions that will allow us to simultaneously focus the business and accelerate our pipeline of innovative medicines, the disposition of Elanco and the acquisition of Loxo Oncology. Finally, we returned over $4 billion to shareholders via the dividend and share repurchases. Speaking for the entire team at Lilly, we remain incredibly excited about the prospects in front of us to reach millions of people, who need better medicines for difficult diseases. And we are eager to continue to execute on the growth opportunity in front of the company. This concludes our prepared remarks and now I will turn the call over to Kevin to moderate our Q&A. Thanks, Dave. We would like to take questions from as many callers as possible. So we ask that you limit your questions to two or to a single question with two parts. Karen [ph], please provide the instructions for the Q&A session. And then we are ready for the first caller. [Operator Instructions] We will go to the line of Chris Schott from JPMorgan. Please go ahead. The first one from me was just elaborating a little bit more on Trulicity dynamics this quarter, particularly as you think about price as well as to make sure I heard the comments in the prepared remarks properly. But how should we be thinking about net pricing and the overall pricing environment for Trulicity in 2019? And were there any one-time impacts or true-ups of rebates for Trulicity this quarter? My second question is really quick one on Emgality, and just how we should we be thinking about where net pricing is going to shake out for this one. And should we think about second quarter results reflecting maybe more normalized gross to net then we saw with the Q1 result? Thanks very much. Thanks, Chris we will go to Enrique for Trulicity and then Christi for Emgality. Chris, thank you for your question allow me to provide some color on Trulicity\\u2019s overall performance. We continue to be very excited about the underlying business fundamentals of the product. When we look at volume growth, we are basically the beneficiary of very strong share growth. We are now sitting at 46%, which is an all time high for Trulicity and with the tailwind of very significant class growth now sitting at 30%. Something to note is that when we look at sequentially volume while scripts basically increased for Trulicity from Q4 of 2018 to Q1 of 2019 by about 5%/6%, our actual shipments declined by 7%. So I want to make sure that we are looking at the underlying business fundamentals and not necessarily just some shift in retail or wholesale inventory dynamics. When it comes to pricing, there hasn\\u2019t been a step change, when it comes to pricing. I think of course, we see pricing pressures across all diabetes categories. But it\\u2019s important to note that our price this quarter was comparable to our price in Q4 of 2018. Now what we basically see in terms of pricing is relative to Q1 of 2018 is higher rates, when it comes to managed care and rebates. Growth in highly rebated segments, whether it\\u2019s the Department of Defense,VA and so forth. And then we also had a negative impact due to changes in the estimates for rebates and discounts. And Chris on Emgality, your question on net pricing and will be more normalized on Q2, what we saw in Q1, first of all, on-demand, very excited about the fact that we are now the number two CGRP passing a JV in both new prescriptions and total prescriptions. And we are on track in Q2 to pass Aimovig in new prescriptions. As we look at the net, we saw a higher than typical free goods as reimbursement was coming on. To give you a little bit of flavor the first quarter had a 57% of commercial claims were reimbursed. We exited Q1 at 67 or two out of every three prescriptions are claims -- commercial claims being reimbursed. So as the reimbursement comes on in Q2, we should see an improvement in that. Next we will go to the line of Jason Gerberry, Bank of America. Please go ahead. Christi, just to follow up on the Emgality comment I know that a lot of companies in the space of kind of frame second half payer environment is a little bit fluid. So is your comment that where you exited 1Q, should we be thinking about that as a linear trend. Are there any puts and takes going on changes in the reimbursement of CGRP biologics just wanted to get a better sense there. And I guess my follow up probably staying with you AbbVie\\u2019s SKYRIZI got pretty good early access. And so I am just sort of curious, your thoughts winners and losers there either be the established novel interleukins or do you see this as more cannibalization of AbbVie\\u2019s own Humira franchise. Thanks. Sure so, continuing on Emgality in terms of access. First of all, we saw very good receptivity by the payers for this class really given doctors and patients choice. And also not having many if any real restrictions for primary care prescribing. So on the reimbursement side we see the payers coming on board and more and more are coming on board right now our access ending Q1 is 82%. So we do expect that to get better and better over the course of the year. So I hope that answers your question there. On SKYRIZI, the data on SKYRIZI is as expected and as we look at tolerability to compete, the competitive landscape that we environment that we are in really doesn\\u2019t change access is very similar SKYRIZI and Taltz all of the newer agents really coming to market and helped increase the expectations of patients and doctors should have on really skin clearance. And so it\\u2019s a competitive marketplace, but we like our chances because with Taltz in the dermatology office we know clear skin, very fast and it lasts up to five years, we have seen data that sustained and no new safety signals. And we also have the head to head versus an IL-23 that will be coming out this year which will demonstrate that speed and clearance at 12 weeks and 24 weeks for the IL-23 really show their peak efficacy. So we are looking forward to that and in rheumatology we will continue to compete there as we just released our head-to-head data versus Humira showing superiority and then later this year, being able to look at the regulatory approval of AxSpA. So the competition is fierce, but our chances and our add with Taltz are extremely good. And we don\\u2019t care huge difference in the landscape because of really coming in. Seamus Fernandez from Guggenheim. Please go ahead. I am sorry. One moment. Yes go ahead please. So just a couple of quick questions. As we think about the evolving competitive landscape in the insulin space. We have seen Humalogtake up quite a bit of share in a short period of time. And then there\\u2019s also the threat of potential biosimilars reaching the market in the next couple of years. The evolving landscape and how that potentially impacts your portfolio as it relates to Humalog or also for the long-acting insulins going forward. And then just a second quick question for Dan. You guys have some data on your ERK inhibitor at ASCO, just hoping that you could give us your thoughts on data coming at ASCO for that product and perhaps any other datasets, that you think we should be watching for. Thanks. Thank you, Enrique, if you want to answer the insulin question we will go to Dan. Sure. Clearly, there\\u2019s -- there are new competitors in the insulin space, I think, in the case of EADVI think it\\u2019s important to reflect that their most of their share gains really have been driven and managed Medicaid outside more look and Humalog of management are -- our overall script are basically flat, clearly there is an evolving landscape, when . it comes to insulin with the potential entry of other insulins follow-ons. As you know the insulin categories are going to be transitioning to BLAs in the 2020 timeframe. Clearly, there\\u2019s questions about interchangeability and when is that going to play out as we said in the past, we don\\u2019t view interchangeability or something imminent. We eventually think, this is going to happen, but it needs to be more clarity. So this is likely something that won\\u2019t happen before 2021. Now, it\\u2019s difficult for us to predict when insulin follows up will come into the market in particular in the U.S., given that some of these products have expressed certain expectation when it come to launch timelines, but have been delayed. Importantly, to note as well is that we continue to evolve our overall instrument strategy and we like to say that we are reimagining insulin systems and an insulin delivery with by basically bringing in a connected care platforms to be able to improve patient outcomes in a much more meaningful way. So we are excited about our overall innovations with systems connected care, but also bringing new insulin like our Ultra Rapid Insulin Lispro that we are developing. Yes, thanks for the question on our ERK inhibitor. This is a Phase 1 program, but it\\u2019s still very early, but we are pretty excited about it. The reason that we are excited about this pathway is because the MAP Kinase pathway is implicated in driving about 30% of solid tumors. So it\\u2019s a great opportunity to drive that pathway. At ASCO, we have a couple of presentations on the ERK inhibitor, including some of the early Phase 1 data in a variety of patients and some data in lung cancer patients as well. So we look forward to being able to share that, but again it\\u2019s a early program. I think we have a few other disclosures ASCO, but we are excited about, turn it over to Anne to comment on late-phase disclosure. Yes. So one of the disclosure that we are very excited about at ASCO is the results of our EGFR mutation positive first-line lung cancer study in CYRAMZA. So this is the RELAY Study and we shares top line data in March that the study was positive and met the primary endpoint of progression-free survival. So we will be submitting to regulators globally midyear and approval on this would make the six indication that we have achieved for Cyramza. Importantly, we are excited about the data and we look forward to this oral presentation at ASCO. Also there\\u2019s currently the standard of care in this setting and we know that our magnitude of benefit must be competitive with that. We look forward to providing more answers for patients in the setting and also providing more options for physicians as they look to sequence therapy for the best outcomes for their patients. So we look forward to sharing more with you at ASCO. And next we will go to Tim Anderson with Wolfe. Please go ahead. On the rewind data for Trulicity coming up at ADA without running the data. Can you just talk about your level of excitement and if this is the data where once just presented you think the prescriber community is going to say well, that\\u2019s really a game changer? And then second question on Tanezumab, I think a lot of investors see this program is probably dead based on the latest data disclosure from you and Pfizer. Can you just share your perspective? So we will go to Enrique on rewind, and then Dan, you want to talk about the tanezumab results. Yes. We continue to be excited about the rewind results for Trulicity. I am going to -- I have a plug here for my Investor Relations colleagues that we have an investor, we are planning on in new investor call at the ADA post disclosure of rewind we saw. Also, we hope to either see you there. Hope there you can either connector be there in person. Yes. Great, thanks for the question on tanezumab. Before I address your question on the future tanezumab, I think it\\u2019s important to comment on why we entered into this partnership with Pfizer and why we have pursued this program. It\\u2019s obviously because of the dramatic unmet medical need here. There are nearly 60 million Americans suffering with chronic pain from osteoarthritis and chronic lower back pain, many of whom have moderate to severe disease and aren\\u2019t getting relief from currently available therapies. When you put that in the context of the drawbacks of the therapies that are currently available, including in many cases opioids, you can just understand how important it is to have new non-opioid mechanisms to address pain. So that\\u2019s why we entered into this program and as we said before, we entered in, with a high level of confidence on the efficacy of this mechanism. But what we saw to discharge was the safety risk through this program. And so that brings us to the final study, which of course was designed to fully understand the safety risk of this mechanism that reason in the study enrolled a different population of patients and we enrolled in the others, we wanted to compare to NSAIDs and therefore we had to enroll patients, who were getting some measure of relief and it is tolerate chronic NSAIDs. So we are continuing to analyze the results from that study from 10.58, we are looking at that so in the context of all of the available data on tanezumab. Our plan then is to discuss the totality of the data with regulators in the coming months and that will help us decide on what the next steps are, and then we will be able to share an update with you when that\\u2019s globally. Next we will go to the line of Geoff Meacham from Barclays. Please go ahead. For Dan on the Olumiant and atopic derm, what do you guys see as differentiation in the data so far among the JAKs. I know you still have some data coming up. And in this indication is your view from the field how attractive oral options are versus injectables. And then just a real quick one for Enrique on Trulicity, just wanted to ask your view of the class growth differences in the U.S. versus O-US and how durable says, I know this has been a big driver in independent of the share gains that Trulicity has gotten over the years. Thank you. Thanks, Geoff. So Dan and then we will go to Christi. Okay, maybe I will start with the comment on differentiation and toss it to Christi for the commercial insights on patient interest and in an oral here. Although I should just say it\\u2019s premature to speculate differentiation versus other molecules where we haven\\u2019t seen the full data from theirs or even ours. But we are excited about the opportunity to be first year in atopic derm. Christi? Yes, exactly, right now DUPIXENT is available, but it\\u2019s an injectable for the more severe type of atopic derm and there\\u2019s so many more patients out there suffering millions of patients. In fact, our dermatologist tell us atopic derm space reminds them of the psoriasis space about 15, 20 years ago. So we do think it\\u2019s a large opportunity and we do plan to be the first JAKs to market. We have released on the fact that our first two studies were positive. You probably saw that we have three more studies to read out this year and then based on the totality of that data, if they continue to be positive. We will be submitting next year. So when it comes to Trulicity class or GLP-1class growth, I think we see the same dynamics in most markets, the drivers are similar, which is the updated guidelines that having recently released. So when we look outside of the U.S., we are GLP-1class growth is in the mid \\u201820s, given the maturity of the class in the U.S., it is impressive that the growth in the U.S. is even higher than that, but it\\u2019s very exciting to see and as a corollary to that, I think the Trulicity\\u2019s performance is very consistent across many markets. Next we will go to the line of Andrew Baum from Citi. Please go ahead. Just going back to SKYRIZI for the first question. What\\u2019s your first-line market share for Taltzin psoriasis and do you expect to be able to grow it now that\\u2019s SKYRIZI has been introduced into the market. I am obviously referencing Avi\\u2019s enormous rebates influence as well as the profile of that drug and what it may mean for the contraction of the more refractory lines of therapy? And then second, perhaps Dave could comment on the timing and the impact of the proposed rebate reform on your diabetes business expressly on the near-term impact for realized pricing because of the Medicare math, assuming it does get implemented at the beginning of next year. Many thanks. Thanks, Andrew, so we will go to Christi for the comment on SKYRIZI and then, Enrique, if you want to talk about the impact on diabetes so then proposed rebate Safe Harbor world. Yes, so in dermatology specifically, our total prescriptions are a little over 15% and we do see growth continuing absolutely, we see actually with the new therapies that have come to market. It actually has increased the market growth, so right now the market is growing at 13%. And the more of the newer agents coming to market, I think the more, you will see the older TNFs be used for short periods of time or potentially not used first line in the future. And so we do see our growth coming from the fact also our ability to compete in dermatology. So the SKYRIZI versus Taltztop to head will be another place for us to go five year data sustained efficacy and we really are the only one that\\u2019s had been able to show not only clear positive 100, but the ability to do it fast and one to two weeks and that sustainability. So our growth continues and we continue to see have very high confidence that growth will continue. The biggest impact from the proposed rule is really at the patient level, because patients will have access to medicine side to more affordable prices. And if you take that threat forward, I think what you will basically see is better appearance, and I think that\\u2019s something that we all want when it comes to healthcare, which is better appearance to medicine. So the impact that is not often talked about is really, when it comes to maybe an impact on volume. When it comes to some of the mechanics and so forth honestly, I view pretty neutral overall. Let me just jump in Andrew, on both of those points. I think it\\u2019s important to note in psoriasis two things, one that there\\u2019s four stepping through TNFs for almost every patient, if that were to change, I think that\\u2019s a big positive for the newer innovation, so the doctors can select appropriate therapy for patients with psoriasis noting that TNFs don\\u2019t work nearly as well as in the new classes and amongst those we think tells us the best profile. Also within derm, there\\u2019s a lot of switching anyway, so the front-line market is versus the total is much smaller than other immunology indications. That\\u2019s an important thing to keep in mind. On the rebate rule we do, we are planning for implementation January 1, I think Enrique rightly notes that the volume upside, the thing I would worry about is rate compression because presumably you would have more facial transparent pricing. But I think across our portfolios, because of the hike consolidation on the payer side, the rates are pretty compressed already. There aren\\u2019t big differences between what the payers are paying. So that\\u2019s why we lean into this one, we think it\\u2019s the right policy answer to help seniors with medication costs and to shift the debate from list pricing to net pricing, which we see as our long-term interests. Thanks for your questions, Andrew, next caller please. I will go to Vamil Divan from Credit Suisse. Please go ahead. Hi. Great. Thanks for taking the questions. So just first on Olumiant, I think, I asked this question before, but just the U.S. opportunity there against our limited sales this quarter. I think you said in your prepared remarks, you are not going to be filing for psoriatic arthritis, just correct me if I miss heard that? And I am just, I guess, on how you think about getting the 4-milligram to the market and so the opportunity in the U.S. for that product and also the implications from the data of Pfizer recently released from their long-term trial showing some additional question on thrombosis? And then the second one, just following up on the psoriasis questions, you mentioned mirikizumab and the data there in psoriasis, I know you said you will be first in GI, I am just curious what the differentiation of any would be in psoriasis for that product or is it really more just a GI focus we should think about? Thanks. Thanks, Vamil. We will go to Christi for Olumiant Americas questions. Okay. So for Olumiant, yeah, I think, what we see in the U.S. is it will be slow and steady in Olumiant 2 milligrams RA. Your question about psoriatic arthritis, you did hear correctly, as we look at the opportunities for us to be best-in-class, first-in-class and really enter market with unmet need. In psoriatic arthritis in the ankylosing spondylitis non-radiographic expire as well. We already have Taltz and Taltz has shown very remarkable results and so we feel very good with that play as we look to study Olumiant and other indications like atopic dermatitis. Remember Lupus got Fast Track designation in December. We are studying both 2 milligrams and 4 milligrams in that indication, as well as atopic dermatitis and we have our alopecia areata study where Phase 2 will readout later this year and if positive we will move to Phase 3. So we are still very big on the opportunity of baricitinib as a whole, the RA 2 milligrams will be slow and steady growth and 4-milligram is being studied and we looked at CD efficacy results there and bring it to market if they are positive. In regards to the Pfizer question about what readout in their Jack high dose. So we -- as we look at the data that we have and 55 countries that have approved Olumiant, we haven\\u2019t seen unusual safety signals in DTEs and we continue to study, obviously, post marketing research that we are doing in collaboration with agreement with FDA both on real world evidence and in randomized clinical trials, those will continue as well. So no news on -- no unusual news on our Taltz and Olumiant like the Pfizer announcement. And then lastly on mirikizumab, so, yes, we are in Phase 3 studies with both psoriasis and ulcerative colitis, we are very excited about the GI space because mirikizumab should be the first IL-23 to ulcerative colitis. We also finished our Phase 2 data on Crohn\\u2019s disease that data will be released at DDW in just a few weeks here in May. So look for that. And then, yes, in psoriasis we are doing a Phase 3 clinical trial with some competitive endpoints in head-to-head data. So when that study reads out we will be looking to see if we can have stronger and more sustained results then current IL-23 in the market. Vamil, thanks for your questions. Next caller please. And next we will go to Umer Raffat from Evercore. Please go ahead. Hi. Thanks so much for taking my questions. First, can you quantify for us what percentage of TRx are paid versus free on Taltz, as well as Emgality? And secondly, I noticed one of the trials reading out for you this fall, the IL-10 plus Opdivo trial in second-line lung has been shrunk from 100 down to 50 patients. Is that simply a function of increasing Keytruda use in first-line or is there another dynamic here as well? Thank you very much. Okay. Thank you. We will go to Christi for the questions around Taltz and Emgality and then Enrique will talk about pegilodecakin. Sure. First of all, Lilly believes in really open access and giving choice to patients and physicians. So we continue to work with payers on access with Taltz. In spite of that, we -- the barriers that we have had -- we had very good uptake with Taltz and as we look at our programs, patient specific, copay cards, et cetera, being able to allow patients on drug and then transition to insurance coverage, we see that two-thirds of patients in the market on Taltz are paid for. On Emgality, as I said before, the commercial claims that have been submitted, we see in Q1 that 57% of those have been reimbursed. And as we exited Q1, we saw that in the mid \\u201860s, two out of every three patients that submitted a claim we had reimburse coverage for. Thanks, Christi. Yes. On the question on pegilodecakin, this is the Cyprus 2 study referring to. So this is a second-line lung study, its Phase II study IO-naive patients. So following first-line treatment, but not in immunotherapy and then it\\u2019s in combination with Opdivo in low expressers. And what we are finding, as you know, well, is that IO-naive patients in the second-line are becoming increasingly rare. So what we decided to do was analyze that data and have that inform the next steps for the program. But not continued to further enrolled patients in this somewhat diminishing population. We have remain confident that the greatest opportunities for pegilodecakin remain in lung cancer, both in the first-line setting and in later lines, and also in renal cell cancer. So as Dan mentioned, we will be starting a renal cell study later this year. But we look forward to readouts in lung at the end of this year and then also in pancreatic cancer early next year and remain confident in the opportunities for pegilodecakin across those tumor types. So I look forward to hearing more towards the end of the year, both on Cyprus 2 and on the Cyprus 1 study, which is in the first-line setting. Thanks, for the questions Umer. Next caller, please. And we will go to David Risinger, Morgan Stanley. Please go ahead. Yes. Thanks very much. I have two questions. The first is for Dave. I am hoping that you can help us understand a little bit better, how you are thinking about the forthcoming HHS action on the elimination of rebates and how that will negatively impact companies that use volume based discounts such that a product like Taltz will be able to step up on the formulary and maybe move into a formulary position that another larger player held in psoriasis? And then second, Enrique, with respect to Trulicity, just hoping that you can help us with a little bit more of a bridge. So you said that, Rx increased sequentially by 5% to 6%, actual shipments declined by 7%. So does that mean there was an inventory work down of 12% to 13% and could you also quantify the negative dollar change in reserves? Thank you. Thank you, Dave, and then Enrique. Yes. Thanks, Dave. So on the rebate rule, again, we are planning for this January 1, of course, it\\u2019s Part D, there are some legislative efforts to look at regulating commercial market. I guess, at this point, my speculation would be that looks more challenging either for political or practical reasons. But I do think once Part D changes and I think we are, as I said, planning toward that, you will start to see increased interest from payers that are not in the government systems or commercial payers to have similar benefits provided to their beneficiaries, particularly in chronic disease where list price effects have a lot of distortion and increased out-of-pocket costs and we have all heard the upgrade around that really centered on insulin, frankly. So I think your logic is the right one in the sense that today with rebates which are not share with patients and confidential payers have a strong incentive to keep those confidential and use those to compete on premiums, that\\u2019s the way it works. I think in the future world where that can\\u2019t be the way they use those rebates, they will need compete for premiums in other ways, efficiency, presumably, and patients will have a choice at the counter based on net pricing. I would assume the doctors are informed about those net prices and that also becomes an influence on prescribing. So for new innovative therapies hypothetically one in specialty market or in a general practitioner market like Emgality, I think that will be an important part of any company\\u2019s strategy to understand the net price that will officially be there for the consumer. The final comment is, of course, Part D is senior program. So the demographics will affect us mostly in our diabetes franchise initially and that\\u2019s where a lot of our planning is focused right now. Thanks, Dave. Enrique? Whenever we look at sequential growth you -- there\\u2019s a lot -- what I call the colloquially a double whammy effect. So we could be double counting here is not to simply add up. One good way to think about it is just if we were to shift 5% of the units from Q4 to Q1 that that explains 10 percentage points of difference, but in reality we are only shipping 5% of units from one quarter to another. That\\u2019s a long way of saying that, I will have your estimate likely the -- we don\\u2019t have full visibility into the retail inventories, but my assessment is about 6 points. Thank you. Dave, thanks for the questions. Next caller please. And next we will go to Steve Scala from Cowen. Please go ahead. Thank you. I have a couple of questions. We were expecting Verzenio data in 2019 from MONARC Her and MONARCH plus. I am wondering if there still on track. And then, secondly, Enrique, one of the concerns with the upcoming rewind readout is that the benefit might be driven by the 30% or so of patients in the trial with pre-existing cardiovascular disease and that the remaining patients add little to the overall outcome. So, overall, the benefit might be a solid but unspectacular 20% or so reduction in risk, which won\\u2019t offer opportunity for differentiation. I am just wondering, can you tell us not to be concerned about this point? Thank you. All right. We will go to Anne for the question on Verzenio and then Enrique on rewind. Yeah. So you are correct. So we are looking to deliver our new data to drive additional growth in one of them the HER-2 positive study, which we will report results on towards the end of the year at a medical meeting. The MONARCH 2 overall survival data will readout as we had communicated in the past in 2020. And then we also have importantly the adjuvant study reading out in 2021. And I appreciate asking about Verzenio because there has been an encouraging start to the year. The revenue grew 30% over Q4 and we also are seeing nice uptake across Japan and European markets. So we look forward to these additional data readouts helping contribute to that message. But look forward to those readouts coming as we had communicated in the past. Thanks, Anne. Enrique? We are unable to provide additional comments on rewind, but look -- we look forward to seeing you at the conference call. Thanks, Steve. Next caller, please. Thank you. Next we will go to the line of Alex Arfaei, BMO. Please go ahead. Okay. Thank you and good morning. On tirzepatide, your -- good to see the program formally, I guess, extended in obesity and NASH. Regarding your Phase 3 obesity trial, could you give us a little bit more color in terms of the outcomes you are looking forward the competitor are you using and the potential readout? And you mentioned you have dose titration data at ADA, can you comment on the extent to which that data shift you dosing for the Phase 3 trials, particularly the high dose? Thank you. Enrique? Yeah. So we are very excited about the tirzepatide and being able to start our Phase 3 Type 2 diabetes study and basically pursuing both obesity in Phase 3 and NASH in Phase 2. We are not providing additional color on the specific obesity trials that we are conducting -- that we plan to conduct. Clearly we need to have the appropriate discussions with the FDA as we engage in this Phase 3 trial, but we plan to do sometime -- that sometime in the future. And as far as the titration question, yes, we do plan to have presentation at ADA, looking at some of the additional titration data for separate thing. Thanks for the questions, Alex. Next caller, please. Thank you. Next we will go to Louise Chen, Cantor. Please go ahead. Hi. Thanks for taking my questions. So my first question is on mirikizumab, you had mentioned that you will likely be the first to IL-23 to marketing you see in Crohn. I am just curious in addition to that, what are the competitive advantages do you see as it relates to other ILs and about and also Jack? And then the second question I had was on LOXO-292, you showed very good ORR median duration percentage of patients on therapy. How do you think that will hold up into the Phase 2 readout and how do you think you might compare with other RET inhibitors in development? Thank you. Thanks. We will go to Christi for mirikizumab and then Anne on RET inhibitor. Thanks Louise for the question on miri. So, to be clear, we expect to be first in to the market on ulcerative colitis and first of a couple to market on Crohn\\u2019s disease. So, you never know, we have been speeding up the Phase 2 trial and look forward to entering the next, but that\\u2019s where we are on GI. We are very excited, because our studies are set up to be best-in-class and so if they read out positively, we expect to not only be first-in-class or best-in-class in ulcerative colitis and Crohn\\u2019s disease. Thanks, Christi. Anne? Yes. When we have thoughts on the Loxo question, when we start to move into precision medicine and to obtain a RET inhibitor, we really thoroughly survey the landscape and selected the molecule in the portfolio that we believe to be first and best-in-class, and we continue to believe that today. We intend to submit in the U.S. by the end of the year end in Europe shortly thereafter. So to answer your question, we remain very confident in the efficacy, safety profile and the duration of our RET inhibitor. And we will continue to expect that will deliver first in both lung and thyroid cancer. So we are actually be having -- we are presenting an update on the registrational data in the second half of 2019 at a major -- a couple of major medical meetings in advance of that potential regulatory filing. And importantly, as you look at this data set, we now have over 400 patients enrolled across tumor types with RET fusion or mutations. And so we fully expect the data to continue to bear out what we saw last year, which is in response rates, as you said, from 60% to 80%, with well over 90% of patients remaining on study. This is the data reported last year and then we will provide an update later this year. Thanks, Anne. Louise, thanks for your questions. Next caller, please. Certainly. [Operator Instructions] Next we will go to Navin Jacob from UBS. Please go ahead. Hi. Thanks for taking my questions. So, number one, I just wanted to -- I am sorry to beat a dead horse on GLP-1 pricing. But Enrique, if you could just dig in a little bit further, just wanted to understand in Q1 of this year, how much of the lower price was related to Medicare Part D on whole changes versus other rebate related changes, because you mentioned that there was rebate estimate adjustments, I want to understand is that a one-time impact for accrual accounting related issues or is it something that we should be thinking about as continuing on going forward. And so, overall, just wanted to understand, where is the GLP class going in terms of pricing, is there going to be continued pricing pressure over the next couple of years? And then, secondly, just on op margins, if you could help us understand longer term where the op margin profile for the human health business will look like. Can we expect margins to reach mid-to-high \\u201830s in line with some of your other peers? Appreciate the help. Thanks, Navin. We will go to Enrique for Trulicity. Then Josh on the op margin question. Yeah. So I just first to address the question about the doughnut hole. The doughnut hole becomes a little more important in Q2, I don\\u2019t have the numbers in front of me, but in the case of diabetes medicines maybe Q1 is maybe only about 10% of the overall doughnut hole from an accounting perspective, what we are going to see throughout the year. So when we think about Trulicity, while there was some impact of the doughnut hole. It was not material to the pricing results. As we -- as I mentioned, when we look at Trulicity, we do have high rebates in managed care and so forth relative to Q1 of last year, the change is due to estimates -- change in estimates for rebates and discounts. That -- yes, that is basically changing because of how we had accrued them based on a full review of the claim that we received later basically changes the information that we have on hand and we need to account for that as soon as we know that information. So, yes, that is a particular impact that was from other quarters that basically is impacting this particular quarter. So that\\u2019s probably as much detail as I can provide. Thanks, Enrique. Josh? I mean on operating margins for the quarter, we were slightly above 26%, our guidance for the year is to be at 28% we are confident we will get there. I think you will see through the remainder of the year that we will see if power guidance topline growth netting out currency effects similar to what we are seeing this quarter and we will see sort of the operating expenses at a more constant absolute level than what we are seeing in Q1. So we are confident in our 28% for the year. And then for 2020 our goal is 31% and we are confident as well in achieving that. That\\u2019s for pharma only, so that\\u2019s on our new basis excluding Elanco. We see good opportunity to get to the 31%. So we are no change there. I think if you look past 2020, we would expect margin expansion to continue. We have a limited patent expirations in the first half of the next decade and we still have the new products that we are launching now will still be in their growth phase. So we definitely see margin expansion opportunities post 2020. But we haven\\u2019t given a specific goal. Thanks, Josh. Next caller, please. There are no further questions in queue at this time. Dave Ricks, please go ahead. All right. Thank you. Thank you all for joining us and we appreciate your participation in today\\u2019s earnings call and your interest in the Eli Lilly and Company. We began 2018 with a lot of momentum and we made meaningful progress in our first quarter. Although, Q1 was a period of investment, we remain committed to our revenue and profitability goals for 2019 and 2020. We continue to advance our innovation-based strategy to progressing internally discovered medicines, augmented with external innovation. We completed two transformative transactions this quarter as well, with the full separation of Elanco and the addition of Loxo Oncology. With a robust pipeline and volume driven revenue growth Lilly continues to be a compelling investment. Thanks again for dialing in. Please follow up with our IR team if you have additional questions that were not addressed on today\\u2019s call. Have a great day. Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 13
        }
      ],
      "source": [
        "#Fetch full transcript text\n",
        "rows = []\n",
        "\n",
        "for sym, sub in meta_10y.groupby(\"symbol\"):\n",
        "    tr = Ticker(sym).earning_call_transcripts()\n",
        "\n",
        "    for _, r in sub.iterrows():\n",
        "        try:\n",
        "            tdf = tr.get_transcript(int(r.fiscal_year), int(r.fiscal_quarter))\n",
        "            content_full = (\n",
        "                \" \".join(tdf[\"content\"].astype(str))\n",
        "                if tdf is not None and not tdf.empty\n",
        "                else \"\"\n",
        "            )\n",
        "        except Exception:\n",
        "            content_full = \"\"\n",
        "\n",
        "        rows.append({\n",
        "            \"symbol\": sym,\n",
        "            \"fiscal_year\": r.fiscal_year,\n",
        "            \"fiscal_quarter\": r.fiscal_quarter,\n",
        "            \"report_date\": r.report_date,\n",
        "            \"transcripts\": r.get(\"transcripts\"),\n",
        "            \"transcripts_id\": r.get(\"transcripts_id\"),\n",
        "            \"content_full\": content_full\n",
        "        })\n",
        "\n",
        "df_calls = pd.DataFrame(rows)\n",
        "df_calls.head()\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "tJKGx2GX80LZ",
        "outputId": "209fe81e-f6f5-413a-ff74-1beec53b0d9d"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "[nltk_data] Downloading package vader_lexicon to /root/nltk_data...\n",
            "[nltk_data]   Package vader_lexicon is already up-to-date!\n"
          ]
        }
      ],
      "source": [
        "#Vader for Sentimental Analysis\n",
        "import nltk\n",
        "from nltk.sentiment import SentimentIntensityAnalyzer\n",
        "nltk.download('vader_lexicon')\n",
        "sia = SentimentIntensityAnalyzer()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "MuCfHK_z82xL"
      },
      "outputs": [],
      "source": [
        "def compute_key_features(text):\n",
        "    #Handle missing or empty text\n",
        "    if not isinstance(text, str) or not text.strip():\n",
        "        return {\n",
        "            'vader_mean': np.nan,\n",
        "            'vader_pos_share': np.nan,\n",
        "            'vader_neg_share': np.nan,\n",
        "            'vader_neu_share': np.nan,\n",
        "            'avg_sentence_length': np.nan\n",
        "        }\n",
        "\n",
        "    #Split into sentences\n",
        "    sentences = re.split(r'[.!?]+\\s+', text.strip())\n",
        "    sentences = [s for s in sentences if len(s.split()) >= 3]\n",
        "\n",
        "    #If no usable sentences, fall back to full text\n",
        "    if not sentences:\n",
        "        score = sia.polarity_scores(text)['compound']\n",
        "        return {\n",
        "            'vader_mean': score,\n",
        "            'vader_pos_share': np.nan,\n",
        "            'vader_neg_share': np.nan,\n",
        "            'vader_neu_share': np.nan,\n",
        "            'avg_sentence_length': np.nan\n",
        "        }\n",
        "\n",
        "    #Sentence-level VADER scores\n",
        "    scores = np.array(\n",
        "        [sia.polarity_scores(s)['compound'] for s in sentences],\n",
        "        dtype=float\n",
        "    )\n",
        "\n",
        "    return {\n",
        "        'vader_mean': scores.mean(),\n",
        "        'vader_pos_share': (scores > 0.05).mean(),\n",
        "        'vader_neg_share': (scores < -0.05).mean(),\n",
        "        'vader_neu_share': ((scores >= -0.05) & (scores <= 0.05)).mean(),\n",
        "        'avg_sentence_length': np.mean([len(s.split()) for s in sentences])\n",
        "    }"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 479
        },
        "id": "6OQgJ40tAjEA",
        "outputId": "2cc1cab9-6c1b-461c-83f6-53c2bf70a928"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "  symbol  fiscal_year  fiscal_quarter report_date  \\\n",
              "0   AAPL         2025               4  2025-10-30   \n",
              "1   AAPL         2025               3  2025-07-31   \n",
              "2   AAPL         2025               2  2025-05-01   \n",
              "3   AAPL         2025               1  2025-01-30   \n",
              "4   AAPL         2024               4  2024-10-31   \n",
              "\n",
              "                                         transcripts transcripts_id  \\\n",
              "0  [{'paragraph_number': 1, 'speaker': 'Suhasini ...           <NA>   \n",
              "1  [{'paragraph_number': 1, 'speaker': 'Suhasini ...           <NA>   \n",
              "2  [{'paragraph_number': 1, 'speaker': 'AI Insigh...           <NA>   \n",
              "3  [{'paragraph_number': 1, 'speaker': 'Suhasini ...         506955   \n",
              "4  [{'paragraph_number': 1, 'speaker': 'Suhasini ...         455679   \n",
              "\n",
              "                                        content_full  vader_mean  \\\n",
              "0  Good afternoon, and welcome to the Apple Q4 Fi...    0.245773   \n",
              "1  Good afternoon, and welcome to the Apple Q3 Fi...    0.251060   \n",
              "2   Good afternoon, and welcome to the Apple Q2 F...    0.216898   \n",
              "3  Good afternoon, and welcome to the Apple Q1 Fi...    0.276358   \n",
              "4  Good afternoon, and welcome to the Apple Q4 Fi...    0.294967   \n",
              "\n",
              "   vader_pos_share  vader_neg_share  vader_neu_share  avg_sentence_length  \n",
              "0         0.524027         0.059497         0.416476            17.558352  \n",
              "1         0.543779         0.062212         0.394009            18.069124  \n",
              "2         0.529284         0.088937         0.381779            16.869848  \n",
              "3         0.609700         0.071594         0.318707            17.618938  \n",
              "4         0.640553         0.076037         0.283410            17.709677  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-8d993113-286a-4787-90ea-73f631743af9\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>symbol</th>\n",
              "      <th>fiscal_year</th>\n",
              "      <th>fiscal_quarter</th>\n",
              "      <th>report_date</th>\n",
              "      <th>transcripts</th>\n",
              "      <th>transcripts_id</th>\n",
              "      <th>content_full</th>\n",
              "      <th>vader_mean</th>\n",
              "      <th>vader_pos_share</th>\n",
              "      <th>vader_neg_share</th>\n",
              "      <th>vader_neu_share</th>\n",
              "      <th>avg_sentence_length</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>2025</td>\n",
              "      <td>4</td>\n",
              "      <td>2025-10-30</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'Suhasini ...</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>Good afternoon, and welcome to the Apple Q4 Fi...</td>\n",
              "      <td>0.245773</td>\n",
              "      <td>0.524027</td>\n",
              "      <td>0.059497</td>\n",
              "      <td>0.416476</td>\n",
              "      <td>17.558352</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>2025</td>\n",
              "      <td>3</td>\n",
              "      <td>2025-07-31</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'Suhasini ...</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>Good afternoon, and welcome to the Apple Q3 Fi...</td>\n",
              "      <td>0.251060</td>\n",
              "      <td>0.543779</td>\n",
              "      <td>0.062212</td>\n",
              "      <td>0.394009</td>\n",
              "      <td>18.069124</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>2025</td>\n",
              "      <td>2</td>\n",
              "      <td>2025-05-01</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'AI Insigh...</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>Good afternoon, and welcome to the Apple Q2 F...</td>\n",
              "      <td>0.216898</td>\n",
              "      <td>0.529284</td>\n",
              "      <td>0.088937</td>\n",
              "      <td>0.381779</td>\n",
              "      <td>16.869848</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>2025</td>\n",
              "      <td>1</td>\n",
              "      <td>2025-01-30</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'Suhasini ...</td>\n",
              "      <td>506955</td>\n",
              "      <td>Good afternoon, and welcome to the Apple Q1 Fi...</td>\n",
              "      <td>0.276358</td>\n",
              "      <td>0.609700</td>\n",
              "      <td>0.071594</td>\n",
              "      <td>0.318707</td>\n",
              "      <td>17.618938</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>2024</td>\n",
              "      <td>4</td>\n",
              "      <td>2024-10-31</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'Suhasini ...</td>\n",
              "      <td>455679</td>\n",
              "      <td>Good afternoon, and welcome to the Apple Q4 Fi...</td>\n",
              "      <td>0.294967</td>\n",
              "      <td>0.640553</td>\n",
              "      <td>0.076037</td>\n",
              "      <td>0.283410</td>\n",
              "      <td>17.709677</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-8d993113-286a-4787-90ea-73f631743af9')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-8d993113-286a-4787-90ea-73f631743af9 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-8d993113-286a-4787-90ea-73f631743af9');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-b92ffb98-cc82-4ffa-aad1-2ed37c7fb537\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-b92ffb98-cc82-4ffa-aad1-2ed37c7fb537')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-b92ffb98-cc82-4ffa-aad1-2ed37c7fb537 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_final",
              "summary": "{\n  \"name\": \"df_final\",\n  \"rows\": 353,\n  \"fields\": [\n    {\n      \"column\": \"symbol\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 9,\n        \"samples\": [\n          \"NVDA\",\n          \"AMZN\",\n          \"JPM\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"fiscal_year\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2,\n        \"min\": 2016,\n        \"max\": 2025,\n        \"num_unique_values\": 10,\n        \"samples\": [\n          2017,\n          2024,\n          2020\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"fiscal_quarter\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1,\n        \"min\": 1,\n        \"max\": 4,\n        \"num_unique_values\": 4,\n        \"samples\": [\n          3,\n          1,\n          4\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"report_date\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2015-05-07\",\n        \"max\": \"2025-10-30\",\n        \"num_unique_values\": 254,\n        \"samples\": [\n          \"2023-11-21\",\n          \"2024-05-02\",\n          \"2021-04-27\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcripts\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcripts_id\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": 44908,\n        \"max\": 631827,\n        \"num_unique_values\": 328,\n        \"samples\": [\n          198100,\n          431759,\n          198046\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"content_full\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 314,\n        \"samples\": [\n          \"Good morning, and welcome to Johnson & Johnson's First Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now like to turn the conference call over to Johnson & Johnson. You may begin. Good morning. This is Joe Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson. Thank you for joining us today to discuss our company's first quarter 2022 financial results and full year 2022 outlook. While many things have changed in the world since our last call, much has stayed the same for Johnson & Johnson. We continue to deliver reliable growth and generate meaningful free cash flow, enabling us to invest and advance our pipeline, increase our dividend for the 60th consecutive year and continued to make a positive impact across the landscape of health care. It is, however, important to take a few moments to recognize the current events that are impacting the world we're living in. Today, while we're all still managing through the global pandemic, as evidenced by the current surge of cases in China, we also acknowledge the increasing hardship brought on by the war in Ukraine. We remain focused on the safety of our employees and their families. Guided by our credo and grounded in our purpose, our hearts are with all those affected by these crises and hope for a rapid resolution to both. Now, I'd like to turn the program over to Jessica Moore, Vice President, Investor Relations, to take you through our Q1 results. Thank you, Joe. A few logistics before we get into the details. This review is being made available via webcast, accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com, where you can also find additional materials, including today's presentation and associated schedules. Please note that today's presentation includes forward-looking statements regarding, among other things, our future operating and financial performance and the anticipated separation of the company's Consumer Health business. We encourage you to review the cautionary statement included in today's presentation, which identifies certain risks and factors that may cause the company's actual results to differ materially from those projected. In particular, there is significant uncertainty about the duration and contemplated impact of the COVID-19 pandemic and other marketplace dynamics. This means that results could change at any time, and the contemplated impact of COVID-19 on the company's business results and outlook is a best estimate based on the information available as of today's date. A further description of these risks, uncertainties and other factors can be found in our SEC filings, including our 2021 Form 10-K, along with reconciliations of the non-GAAP financial measures utilized for today's discussion to the most comparable GAAP measures. These materials are also available at investor.jnj.com. Several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships. Moving to today's agenda, I will review the first quarter sales and P&L results for the corporation and the three segments. Following, Joe will provide additional business and financial commentary before sharing an overview of our cash position, our capital allocation priorities and updated guidance for 2022. The remaining time will be available for your questions. During the Q&A portion of the call, Joe will be joined by, Ashley McEvoy, Executive Vice President and Worldwide Chair, Medtech; Thibaut Mongon, Executive Vice President and Worldwide Chair, Consumer Health; and Jennifer Taubert, Executive Vice President and Worldwide Chair, Pharmaceutical. We have heard your feedback and are implementing a few enhancements this quarter. First, we are now providing select earlier phase clinical trial information on our pharmaceutical pipeline to streamline your data collection efforts from clinicaltrials.gov. Second, rather than sharing detailed business performance commentary on each part of the business, I will summarize the significant business drivers, leaving more time for Q&A. You can find additional detailed segment commentary in our earnings presentation. We anticipate the webcast will last up to 60 minutes. Now, let's move to the first quarter results. Worldwide sales were $23.4 billion for the first quarter of 2022, an increase of 5% versus the first quarter of 2021. Operational sales growth, which excludes the effect of translational currency, increased 7.7% as currency had a negative impact of 2.7 points. In the US, sales increased 2.7%. In regions outside the US, our reported growth was 7.2%. Operational sales growth outside the US was 12.6%, with currency negatively impacting our reported OUS results by 5.4 points. Excluding the net impact of acquisitions and divestitures, adjusted operational sales growth was 7.9% worldwide, 2.8% in the US and 12.9% outside the US. Turning now to earnings. For the quarter, net earnings were $5.1 billion, and diluted earnings per share was $1.93 versus diluted earnings per share of $2.32 a year ago. Excluding after-tax intangible asset amortization expense and special items for both periods, adjusted net earnings for the quarter were $7.1 billion and adjusted diluted earnings per share was $2.67, representing increases of 3% and 3.1%, respectively, compared to the first quarter of 2021. On an operational basis, adjusted diluted earnings per share increased 6.2%. I will now comment on business segment sales performance highlights. Unless otherwise stated, percentages quoted represent the operational sales change in comparison to the first quarter of 2021 and therefore exclude the impact of currency translation. Beginning in 2022, certain over-the-counter products previously reported under the Pharmaceutical segment have been reclassed to Consumer Health. These products represent roughly $100 million of sales per quarter. Please refer to the supplemental sales schedules for prior year restatements. Also, as stated in our 2021 10-K, effective January, our Medical Devices segment is now referred to as MedTech. Beginning with Consumer Health. Worldwide Consumer Health sales of $3.6 billion increased 0.8% with a decline of 3.4% in the US and growth of 4.1% outside the US. Excluding the impact of acquisitions and divestitures, Worldwide growth was 1.6%. Consumer Health was negatively impacted by industry-wide external supply constraints, primarily due to ingredients and packaging availability as well as labor shortages largely reflected in our Skin Health and Beauty business, worth approximately 280 basis points worldwide and 500 basis points in the US. Adjusting for these constraints, Consumer Health delivered solid results, primarily due to above-market growth in OTC driven by increased TYLENOL, MOTRIN and upper respiratory product sales. Moving on to our Pharmaceutical segment. Worldwide Pharmaceutical sales of $12.9 billion increased 9.3% with growth of 2.9% in the US and 16.7% outside of the US. Base Pharmaceutical growth was driven by our broad portfolio of products paired with strong commercial execution, enabling us to deliver above-market adjusted operational sales growth, including six assets with double-digit growth in the quarter. Base business growth was due to strength from DARZALEX, TREMFYA, STELARA, ERLEADA and our paliperidone long-acting portfolio. Growth was partially offset by LOE pressures from both REMICADE and ZYTIGA, along with decrease in IMBRUVICA and XARELTO sales. DARZALEX continues to drive very strong operational growth with sales increases of 40.3%, driven by subcutaneous formulation penetration and meaningful share gains across all lines of therapy and in all regions. IMBRUVICA sales declined 3.9% worldwide due to increased competition from novel oral agents, particularly in US. IMBRUVICA maintains its market leadership position worldwide and continues to drive growth outside of the US despite ongoing competitive pressures. XARELTO sales declined 13.8% in the US, driven largely by a net unfavorable prior period price adjustment and increased cost for patient access, partially offset by continued demand and market growth. The COVID-19 vaccine also contributed approximately $500 million to sales in the quarter. Given these results, we remain confident in our ability to deliver our 11th consecutive year of above-market adjusted operational sales growth in 2022. I'll now turn your attention to the MedTech segment. Worldwide MedTech sales of $7 billion increased 8.5%, with growth of 5.6% in the US and growth of 11.1% outside the US. Excluding the impact of acquisitions and divestitures, worldwide growth was 8.6%. We see strong performance in Q1 driven by market recovery, focused commercial strategies and differentiated new products driving enhanced or sustained market share across most of the 11 priority platforms. We continue to monitor potential impacts on elective procedures driven by COVID-19 resurgences across various markets. Before highlighting the financial performance for the segment, I'd like to share a few notable first quarter MedTech events that demonstrate our stated aspirations of entering higher-growth market segments and continuing to build upon digital technologies across the portfolio. Two acquisitions were closed in the quarter, CrossRoads Extremity with a differentiated portfolio of bunion and hammertoes solutions in the fast-growing elective foot and ankle market; and CUPTIMIZE, which will be a new addition to the VELYS digital surgery platform of connected technologies. The CUPTIMIZE solution is designed to give surgeons an easy-to-use tool to better understand and address the impact of abnormal motion between the spine and pelvis in some patients who require total hip arthroplasty and may help reduce the risk of dislocation related to pelvic tilt. I am also pleased to share that Fast Company selected Johnson & Johnson MedTech as one its top 10 World's Most Innovative Health Companies of 2022, recognizing MedTech's success and commitment to delivering breakthrough scientific innovation and reimagining health in an increasingly digital world. The Interventional Solutions franchise delivered another quarter of worldwide double-digit growth at 17.4%, with double-digit growth in both the US and OUS regions, driven primarily by success of new products in electrophysiology, commercial execution and continued market recovery. Worldwide surgery grew 5%, driven by strong performance in wound closure and biosurgery where we continue to gain market share. MONARCH-enabled procedures now exceed 14,000 since launch, providing continued evidence of the adoption of MONARCH technology in patient treatment regimens. The worldwide Orthopedics franchise grew 5.6%, reflecting COVID-19 recovery, continued penetration in the US ambulatory surgery center channel or ASCs; and penetration of new product launches, such as enhancements to VELYS hip navigation, VELYS robotic-assisted solution and ATTUNE cementless knee system. Partially offsetting this growth was softness in spine procedures in the US. The worldwide Vision franchise continued its double-digit growth, growing 13.9% this quarter. Contact lenses global growth of 10.6% reflects continued positive momentum for our market-leading ACUVUE portfolio, success of commercial initiatives and recently launched products such as ACUVUE OASYS MULTIFOCAL and ACUVUE DEFINE FRESH. Surgical vision delivered global growth of 23.8%, with both the US and OUS posting growth above 20%, fueled by market recovery and share momentum due to the success of recently launched products, including TECNIS Eyhance and TECNIS Synergy. As a reminder, additional sales commentary for all of our segments can be found on the slides. Now turning to our consolidated statement of earnings for the first quarter of 2022. I'd like to highlight a few noteworthy items that have changed compared to the same quarter of last year. Cost of products sold deleveraged by 70 basis points, driven by unfavorable mix in the MedTech business and commodity inflation in the Consumer Health business. Sales, marketing and administrative deleveraged by 110 basis points, driven by higher brand marketing expenses in Consumer Health and timing of brand marketing expenses in the Pharmaceutical segment. We continue to invest strategically in research and development at competitive levels, investing 14.8% of sales this quarter. The $3.5 billion investment was an 8.9% increase versus the prior year, primarily due to portfolio progression in Pharmaceutical and MedTech. In process, research and development reflects an impairment expense of $610 million for certain indications associated with bermekimab, the investigational compound acquired from XBiotech Inc. as disclosed in our previous SEC filings. This impairment was driven by the termination of development of bermekimab for atopic dermatitis based on efficacy data. The other income and expense line was net income of $102 million in the first quarter of 2022 compared to net income of $882 million in the first quarter of 2021. This decrease was the result of lapping prior year gains on the divestiture of Doxil, Calyx and EBRA in 2021, higher unrealized losses on securities and Consumer Health separation costs. This was partially offset by favorable returns associated with our employee benefit plans. Regarding taxes in the quarter, our effective tax rate was 12.2% versus 16.6% in the same period last year. The decreased tax rate was primarily driven by lower US income due to higher unrealized losses on securities and the impairment of bermekimab IP R&D compared to prior year divestiture gains. Excluding special items, the effective tax rate was 13.3% versus 16.5% in the same period last year. I encourage you to review our upcoming first quarter 10-Q filing for additional details on specific tax matters. Lastly, I'll direct your attention to the box section of the slide where we have also provided our income before tax, net earnings and earnings per share, adjusted to exclude the impact of intangible amortization expense and special items. Now let's look at adjusted income before tax by segment. In the first quarter of 2022, our adjusted income before tax for the enterprise as a percentage of sales decreased from 37.1% to 35.1% due to product mix, commodity inflation, increased brand marketing expense, portfolio progression in R&D and comparisons to gains from prior year divestitures. Pharmaceutical margin declined from 45.5% to 44.1%, primarily driven by timing of brand marketing expenses and general portfolio progression in R&D. MedTech margins declined from 30.6% to 27%, driven by unfavorable product mix. Finally, Consumer Health margins declined from 26.8% to 22.1%, due to commodity inflation and higher brand marketing expenses. This concludes the sales and earnings portion of the Johnson & Johnson first quarter results. I am now pleased to turn the call back over to Joe Wolk. As Jess just mentioned, Johnson & Johnson posted solid performance for the quarter, continuing to invest in the business for the long-term success, while overcoming multiple macroeconomic headwinds, including inflationary pressures and higher input costs. These external challenges include limited availability and rising prices of certain commodities; as well as increased costs for labor, energy and transportation. These impacts are pervasive across the enterprise, but most notable in Consumer Health. We expect these pressures will continue to some degree throughout the remainder of 2022. However, mitigation efforts are underway, including cost improvement initiatives, strategic price increases and contract negotiations with external supply partners. We are committed to sustaining supply of the products, medicines and treatments that consumers and patients want and need. Turning to our segments and notable events in the quarter. MedTech led our enterprise performance with nearly 9% adjusted operational sales growth. We continue to drive this business forward and are increasing the value of our pipeline through innovation, internally and externally. We were pleased to see a steady uptick in surgical procedures this quarter with the easing of COVID restrictions in many parts of the world, but we recognize that the situation is fluid, which requires monitoring. Building on more than 20 major new product launches in 2021, MedTech announced the addition of two new innovations to our ATTUNE portfolio, the ATTUNE cementless fixed bearing knee with AFFIXIUM 3DP Technology and the ATTUNE medial stabilized knee system. In our Pharmaceutical business, we continue to deliver above-market growth driven by volume as evidenced by our recently published 2021 Janssen US Transparency Report, which reflects our fifth consecutive year of price decreases across the portfolio despite inflationary pressures. We also continue to advance our Pharmaceutical pipeline. This quarter, we received FDA approval for Carvykti, a CAR-T therapy for the treatment of multiple myeloma developed together with our partner, Legend Biotech. We are partnering with clinics utilizing a phased approach to begin patient dosing, and the feedback to date has been positive. We also filed Teclistamab, our BCMA CD3 bispecific antibody seeking EMA approval, and we also received priority review from the FDA, potentially expanding our multiple myeloma portfolio further. In our Consumer Health business, we remain focused on delivering on our 2022 performance objectives, continuing to achieve above-market growth in our over-the-counter medicines business, while navigating industry-wide supply constraints that have primarily impacted our Skin Health/Beauty business. We continue to be excited about the activity related to the announcement we made in November on the creation of two new industry-leading companies, the new Johnson & Johnson and the new Consumer Health Company. For the new Johnson & Johnson, the portfolio will remain well diversified with 25 brands delivering over $1 billion in sales annually, holding market-leading positions across key therapeutic areas and franchises. The financial hallmarks of Johnson & Johnson will remain the same, including a well-defined capital allocation strategy, a disciplined approach to inorganic growth and a strong balance sheet, while also creating opportunities to sharpen focus on execution and clinically differentiated innovation. The new Consumer Health Company will also have a strong financial profile and be better positioned to drive incremental growth, realizing increased potential in new markets through a more agile operating model. The company will continue to deliver science-backed innovation and enhanced digital consumer-centric solutions. The Consumer Health separation team is making substantial progress related to our efforts in establishing the new independent company. As previously mentioned, we cannot disclose new financial information specific to Consumer Health in order to preserve optionality on the various separation pathways. Our time lines remain unchanged. We anticipate announcing key executive leadership appointments for the new Consumer Health Company in the coming months, with plans to provide the new company name and headquarters location around the middle of this year. In the second half of 2022, we plan to provide the updated path forward and applicable financial information such as refined standup cost estimates and potential short-term dissynergies. Finally, consistent with previous communications, we expect to execute the separation in 2023. You have our ongoing commitment adhering to the regulatory framework to provide transparent updates for material decisions on a timely basis. Turning now to cash and capital allocation. We generated free cash flow for the quarter of nearly $3.4 billion. At the end of the first quarter, we had approximately $30 billion of cash and marketable securities and approximately $33 billion of debt for a net debt position of approximately $3 billion. Our capital allocation priorities remain unchanged. Internal innovation remains critical to our future growth and a top priority. In the first quarter, we increased R&D investment by approximately 9% compared to the first quarter of 2021. We also continue to evaluate opportunities to complement the current portfolio with acquisitions that build upon our capabilities, address portfolio gaps or play in higher-growth markets while yielding solid financial returns. As I mentioned earlier, we were pleased to announce today that our Board of Directors approved an increase in our quarterly dividend for the 60th consecutive year from $1.06 per share to $1.13 per share, an increase of 6.6%. Moving to full year 2022 guidance and key considerations. I'll start with comments on our COVID-19 vaccine and foreign exchange impacts, essentially the only items with updates from our January guidance. As market demand for all COVID-19 vaccines is currently challenged by global supply surplus and vaccine hesitancy in developing markets, we have made the decision to suspend guidance for sales of our COVID-19 vaccine. This will enable investors to focus on the performance of our core businesses, which drive the current and future value for investors. We are maintaining the total adjusted operational earnings per share guidance we provided in January, absorbing, if need be, the modest income impact from the COVID-19 vaccine. Regarding foreign exchange, as you know, we don't offer guidance or predictions on currency movements. But to give you a sense of the impact currency may have on potential full year reported results, utilizing the euro spot rate relative to the US dollar as of last week at 1.08, there is an incremental unfavorable currency impact of $1.1 billion on reported sales and an unfavorable $0.25 for reported adjusted earnings per share versus the calculation related to January's guidance. The full year unfavorable impact is now projected to be $2.5 billion on reported sales and $0.45 on reported adjusted earnings per share. All other line items for which we provide guidance remain the same as communicated in January. To reiterate, we are maintaining our adjusted operational earnings per share guidance. We don't provide quarterly guidance, but do understand that you find value in us providing some qualitative considerations as you update your models. In Consumer Health, we expect supply constraints to continue throughout the year but not to the same extent in the second half. As a result, we anticipate that the back half performance will improve over the first half. For MedTech, while the first quarter demonstrated faster recovery than we anticipated, our full year expectations remain fairly intact. We anticipate continued market recovery and uptake from recently launched products and are monitoring the ever-changing COVID dynamics, particularly the surging cases in China. Similar to Consumer Health, we expect the second half to be stronger than the first half. As a reminder, with respect to growth rates, the second quarter was the strongest quarter for MedTech in 2021. The expectations for the Pharmaceutical base business remain the same. We anticipate delivering another year of above-market adjusted operational sales growth with relatively consistent growth throughout the remainder of the year. In summary, Johnson & Johnson had a solid start to the year despite managing macroeconomic headwinds, and we remain confident in our business. I would like to recognize the continued efforts of our 144,000 global colleagues focused on delivering our innovative healthcare solutions to our credo stakeholders. Their unwavering dedication and support continue to inspire. And on behalf of the executive team, I'd like to extend our gratitude. I am now pleased to welcome to the call, Ashley McEvoy, Thibaut Mongon and Jennifer Taubert, our Worldwide Chairs to address your questions. Kevin, can you please provide instructions and open the line for Q&A? [Operator Instructions] Our first question today is coming from Larry Biegelsen from Wells Fargo. Your line is now live. Good morning. Thanks for taking the question. So many different places to go. But Joe, I'll start with M&A. You know, there were comments on the tape stating that you're eager to deploy cash to M&A, especially for devices. So maybe for you or Ashley, can you add more color to your thinking there and the types of opportunities to consider? You know, you've talked about reaching the top of the peer set in devices. That would seem to require a relatively large deal or a series of small to medium-sized deals to move the needle. Is that a fair way to think about it? Thanks for taking the question. Yes. So Larry, I'll start, and then I'll turn it over to Ashley for some thoughts specific on Medical Devices. But before I answer, Larry, I do want to compliment you and your team for the foreign exchange report that you guys issued back, I think it was on April 13. That was just -- it's a tough topic to really grasp. And you guys did a fantastic job in assessing what it meant for the medical device industry. It was really a fantastic report. So well done. With respect to cash, as you heard us in January, we are reaching our lowest levels of net debt. And we remain very active. You could talk to Thibaut, Jennifer and Ashley, with respect to ideas that they are bringing forth. We continue to have the same principles that we've had historically. We want to make sure there's a strategic fit. And by that, I simply mean we've got capabilities. We've got scientific expertise. Perhaps it's just our scale that adds more value to that asset than where it currently resides. And then we want to make sure that we compensate risk -- compensate shareholders for the risk that we're bearing on their behalf when we do so. I would not get overly locked into size. Johnson & Johnson, quite frankly, have been built through a number of smaller acquisitions, and really the outliers are these larger acquisitions. But we look at really the strategic merit and then the financial value creation and don't get locked in to saying something is too small or too big with respect to adding to our already dynamic internal portfolio and pipeline. Ashley, I don't know if you want to... Yes. No, Larry, maybe before I get to M&A, just kind of some macro thoughts on MedTech in the quarter. I'm pleased with the results of the quarter. We saw positive signs of the market recovery. Clearly, while COVID has not disappeared, health systems around the world are becoming increasingly more resistant with each passing wave. And as we know, the world is -- is a lot more equipped to manage the pandemic, and quite frankly, so is Johnson & Johnson. So encouraged to see in quarter one that we continue to maintain our path to above-market performance. We referenced that this is kind of a growth at scale, if you will, 11, $1 billion platforms, really most of them growing or maintaining share. And we saw robust sales growth across all four of our franchises in all four of our regions. Some standout, encouraging to see both vision surgery and Vision Care, both double-digit performance and growing market share, really fueled by innovation in ACUVUE and TECNIS. We are the world leader in electrophysiology, still a category that has significant under penetration. We've had 11 consecutive years of double-digit performance and really significantly enhanced our share gain. We're the world leader in biosurgery. The business was up almost 10%, really driven by a clinically differentiated portfolio. And then finally, and enthusiastically, I say we had strong performance in joints really by penetrating some new sites of care like ASCs, both with hips and knees. So when I look forward, I'm encouraged by the organic agenda that we see in innovation, like with the likes of the FDA approval on ACUVUE Theravision, the first drug-eluting contact lens. As Joe mentioned earlier, around really shoring up high-growth segments in knees with ATTUNE fixed bearing, and then really with CERENOVUS the launch of EmboGad, the balloon catheter. So continue to advance robotics and digital surgery. You'll hear us talk about MONARCH 14,000 cases with a big pipeline of new indications, and then VELYS completing over 2,000 cases. So when I think about the future of M&A, Larry, we're going to continue to do tuck-ins and to really digitize the patient experience. You heard us talk about CUPTIMIZE as an example around really adding a precise delivery to hit navigation to improve outcomes. You're going to see us continue to penetrate fast-growing segments like what we have in neurovascular, as an example, 90% of our capital deployment has been to $1 billion or more, but we do intend to make sure that we are well positioned to be in the highest growth end state markets. Thank you. Our next question today is coming from Chris Schott from JPMorgan. Your line is now live. Great. Thanks so much. Maybe Ashley, just following up on some of your MedTech comments. Can you specifically comment on China in terms of the impact you're currently seeing to the business and your outlook for that market specifically, given some of the lockdowns that we're seeing there? And then my kind of core question was just on IMBRUVICA. It seems like prescriptions here are really starting to see some erosion. I'm trying to understand the dynamics you're expecting going forward. So is this -- especially maybe in the US market, are you expecting that this erosion continues? Or do you see dynamics in place that we could start to see some of those prescription trends start to stabilize a bit? Thanks so much. Yeah, sure, Chris. So first, we have, I would say, a very strong and healthy business in China. We're the world \\u2013 we are number one in MedTech in China. We have a very diversified portfolio from surgery to orthopedics to interventional as well as vision. We did experience an impact probably in the March time frame due to the recent surge of the viruses happening and the lockdowns, particularly in Shanghai and now other regions. We do anticipate that to continue in April and through the month of May. But like we've seen, I think China might come down a bit faster, but it comes back faster, too. We have very strong leadership there, and there are a lot of patients that need care. I'll turn it to Jennifer maybe to talk about your second question. Great. Thanks a lot. Hi, Chris and hello, everybody. A few comments on the Pharmaceutical business, and then I'll get to the question on IMBRUVICA. First, for our pharm business, I was really proud that we delivered $12.9 billion in worldwide sales. We're definitely above-market adjusted operational growth of 9.3%. And this is our sixth quarter where we achieved worldwide sales exceeding $12 billion. And as I look across the globe, the growth was really broadly based across our portfolio in the regions, with particularly strong growth in EMEA, Asia Pac and Latin America. During the course of the quarter, we really continued to maximize the value of our key brands, so strong double-digit growth across six of them, including DARZALEX, ERLEADA, TREMFYA, INVEGA SUSTENNA, [Privado] (ph) and EDURANT. And we also had a number of important milestones, the first being the FDA approval of Carvykti, which is our first cell therapy for patients with relapsed or refractory multiple myeloma. The teclistamab filing in the EU was mentioned. The FDA approved expanded label indications for CABENUVA to be administered every two months for the treatment of HIV in virologically suppressed adults and adolescents. And we presented great new data on TREMFYA in our approved indications of psoriasis and psoriatic arthritis, as well as from our Phase II studies, where we're evaluating the product in Crohn's Disease and also in UC. So if we take a look at IMBRUVICA more specifically, IMBRUVICA sales did decline for the quarter, 3.9%, and this really was a US story. Outside the US, our sales actually grew 4.5%. In the US, performance was impacted by both competitive factors with a number of new competitors in the market as well as market softness. We haven't seen that market fully rebound to the pre-COVID levels yet. As we take a look at IMBRUVICA, IMBRUVICA has really changed the standard of care for adults with CLL and other B-cell malignancies. And it is the only BTKI that\\u2019s demonstrated overall survival and a high rate of progression-free survival at five years with up to eight years of safety follow-up. So, we remain really confident in the efficacy and safety profile of the product. It's the market share leader and continues to be the most comprehensively studied and prescribed BTKI with over 250,000 patients worldwide. So we continue to work to develop the asset. We do see further growth opportunities through the introduction of new indications and new combination therapies, as we take a look at IMBRUVICA plus venetoclax that we're working to develop and we filed in the EU. We're also taking a look at first line [ph] and CL and really trying to bring that forward. So I think you can anticipate there will continue to be strong competition in that market. We continue to believe in and invest in IMBRUVICA. Thank you. Our next question is coming from Joanne Wuensch from Citi. Your line is now live. Good morning and thank you for taking the question. I'd like to spend a little bit of time talking about the middle of the income statement with all of the multiple headwinds on those factors. How do you think about managing it? What are the levers to pull? And how do you think about raising prices in this environment for each of your key divisions? Yes, good morning, Joanne. Thanks for the question. With respect to operating margins overall, which is really, I think, at the heart of your question, in the front -- the first quarter, I should say, we do tend to adopt a little bit more of an aggressive approach to advertising and promotion and hopes of getting the full year benefit of that promotion to the topline lift throughout the year. And I would say on R&D, it's also a little bit front-end loaded this year, simply from the standpoint of the progression of our pharmaceutical pipeline, as well as digital robotic surgery. So in pharmaceuticals, think about nipocalimab, our RSV vaccine, those had very nice progression. Teclistamab may be moving a little bit faster than we anticipated, as well as being able to launch Carvykti. There was a healthy amount of inflation built into our P&L in the January guidance. What I think our teams have seen in the -- let's say, the first four months of this year is an uptick in that inflationary impact of about 10% or 15%. So still very manageable. Again, as you heard in some of the prepared remarks, we anticipate that that inflationary pressure as well as commodity scarcity will subside a little bit in the second quarter and then hopefully more pronounced in the second half of this year. If it doesn't, it's certainly something that will keep our attention. And we have the resources to adjust accordingly to make sure that we not only meet the needs of long-term value creation, but also meet short-term performance expectations. So we all think it's very manageable at this point in time, but it's something that we're not taking for granted. We're being very active with cost initiative programs. As we look to separate the two companies, we are looking at ways to streamline technology, processes, things that will lead to leverage on the P&L. Thank you. Our next question today is coming from Chris Shibutani from Goldman Sachs. Your line is now live. Thank you. Good morning. Appreciate the opportunity. Perhaps directed at the Pharmaceutical segment for Jennifer. Two products I'd like to focus on, one being STELARA and the other on XARELTO. With STELARA, could you perhaps elaborate a little bit more in terms of some of the underlying dynamics across the various indications, i.e., the derm versus perhaps the IBD in terms of what the growth trends and outlook you're seeing and you expect there? And then for XARELTO, part of your commentary in the prepared segment discussed and mentioned about patient access. Could you just elaborate a little bit further on how that was an impact on the commercial dynamics? Thank you. Sure. Thanks for the question. So let me start off with STELARA. So STELARA sales were $2.29 billion in the first quarter, and that was 9% growth. And we continue to see a lot of strength in STELARA. Ex-US, the product had nearly 18% growth. In the US, what we saw was growth around 3.6%. And what this really was due to, we saw an impact in the US due to the Omicron variant and the impact that it actually had on staffing resources that particularly impacted a number of areas where you had more resource-intensive delivery of care, and GI offices was definitely one. As we take a look at Crohn's Disease and Ulcerative Colitis, our share positions remain strong and with very strong positive momentum. We actually gained over five share points in CD and six share points in ulcerative colitis. So really strong growth and momentum. And with -- in psoriasis, as anticipated with TREMFYA and a very strong growth in psoriasis and psoriatic arthritis, we expected the STELARA sales there to start tailing off, and that's in line with our expectations. So we continue to have a very strong positive outlook for STELARA going through the rest of the year in CD and in Crohn's -- excuse me, Crohn's and ulcerative colitis, where we've really been realizing the growth. And likewise, when you take a look at TREMFYA, we saw 44.5% growth in psoriasis and psoriatic arthritis in the quarter. So together, really, really nice performance there. Question on XARELTO. So XARELTO in the US, we did see sales decline. That was largely driven by a net unfavorable prior period adjustment. And most of this has actually been a positive adjustment that took place in 2021. So when you do the comparable, it was negative. And so that was really due to the vast majority of that. With Xarelto, we continue to see nice share gains and growth at a prescription level across the indications, whether we're talking about CAD and PAD, really the newest indication set, but also across AFib and VTE. And so it really was around the net unfavorable PPA and a little bit of channel mix as well with some of the mix shifting into 340B and Medicaid in some of the lower-priced channels. Thank you. Your next question today is coming from Louise Chen from Cantor Fitzgerald. Your line is now live. Hi. Thanks for taking my question. So I wanted to ask you about CARVYKTI. And what gives you confidence in your ability to meet some of the manufacturing complexity associated with CARVYKTI? And how much capacity do you think you'll be able to bring online this year, both in the US and potentially globally as well? Thank you. Thanks for the question. So we're real proud about our approval and our launch to-date on CARVYKTI. What I can say is that it is going well and it is on track with our expectations. We're real pleased. As you know, this is a customized therapy where the supply chain is literally built around each patient. We've got about a four week to five week period that goes from the collection of the cells, the processing and manufacturing and the return shipment of the final product and then ultimately the infusion back in to the patient at the treatment center. As we have mentioned before we really are taking a thoughtful and a phased approach to scaling this launch, to ensure a predictable and a reliable experience for the patients and for the treatment centers. We really tried to learn from the other launches in the market in this area. And so far, we're off to a really good start there and have been very pleased with the feedback that we're getting back from our customers. So we have activated our initial round of treatment centers. And we did this based on folks who were very well-experienced from our clinical trials and also very broadly dispersed throughout the US and help ensure patient access. We're working through all of the orders and the slots that we have and actually have product now that's been shipped back -- has been manufactured and shipped back to the patients for infusion into the patients. So we're going to continue in a planned and thoughtful responsible approach to this scaling, both in the United States as well as we do -- as we scale outside the US and throughout the world as well. Now we discussed before around lentivirus. Because there is an industry-wide shortage of lentivirus, that is something that we are also working and investing in to scale all of our internal capabilities to be able to meet the demand, both now in our initial launches in the relapsed/refractory setting as well as our ultimate goal to be able to move into first-line setting here. And so we would have an internal control on that as well. So hope this answers your question. Thank you. Your next question is coming from Josh Jennings from Cowen. Your line is now live. Hi. Good morning. Thanks a lot for taking the question. Joe, since Joaquin made some public commentary on his commitment to support Ashley and her team to drive revenue growth acceleration in the Mega Devices unit, your focus has been on M&A opportunities. But how should we think about the level of internal investment to fuel growth of the devices franchise? You don't break out the percentage of R&D spend allocated to devices. But one data point we do have is from the 2019 pharma day when you related $8.4 billion of the $11 billion in R& D expense from 2018 went to pharma initiatives, so that's north of 75%. But just \\u2013 I mean, has that stepped up just the level of investment in the Devices business over the last couple of years? And will that step up even further? And just to be clear, Ashley did not plant this question with our team. I'm going to check the transcript on that, Josh, just to be sure. But listen, I think what you would hear, as Joaquin was sitting here, is that he supports all the businesses with respect to innovation. We realize that our calling card is innovation, and we're going to have growth across all of our franchises when we have products that matter that are differentiated, that are beyond the current standard of care and meeting consumer needs as well. I actually want to credit Ashley and her team for the way they've managed their P&L. They've been conscious about moving more of their investment into R&D. You saw a record number of 20 plus new product launches last year that are considered meaningful. We're going to be very close to probably a very similar number this year. And so that portfolio has taken very much the same approach that I would say Pharmaceuticals did almost a decade ago when the focus is very well understood and where we want to play because we've got a strategic or competitive advantage will be capitalized upon. I don't know, Ashley, if you want to add anything more, but I think that certainly, there is continued support, but a lot of the credit goes to Ashley and her team in terms of managing their levels of investment throughout the P&L. Thanks, Joe. I mean, Josh, I would say that we are investing at a competitive level, and I'm really pleased with the state of execution. We are \\u2013 we have, in our pipeline right now, 27, $100 million-plus eNPV projects. That number three years ago was six. So they continue to focus the pipeline on medium to higher growth segments and really execute and we're off to a good start in 2022. I would maybe underscore too is that gives us the confidence to go out and add in inorganic opportunities when the opportunity presents itself using the criteria of strategic fit as well as financial value creation. So a stronger internal pipeline that gets hopefully success out in the acquisition markets. Just to reference our 10-K, we do provide the breakout of R&D by segment on an annual basis for reference. Thank you. Our next question today is coming from Terence Flynn from Morgan Stanley. Your line is now live. Great. Thanks so much for taking the questions. Jennifer, I was just wondering if you could elaborate a little bit more on the COVID recovery in the Pharma segment. I know you touched on staffing issues on the gas trip [Audio Gap]? Yeah. So I understand Terry's comment really was around the US and what we're seeing in terms of COVID. So as we exited last year, really in the December time frame and entered this year into really January and February, we did see the Omicron variant impact the US business. And what we saw there really, as already mentioned before, we did see staffing shortages because so many people got sick. People weren't able to go into work. And so in a higher \\u2013 more intensive resource settings in some of the markets, we did see slowdown in terms of delayed visits and new patient starts. What we are seeing now is we're looking towards the end of March and in early April, we're seeing nice recovery there. And so this really, hopefully was something really just at the end of last year and the beginning of this year, and it does look to be more specific to the US than to any of the other markets. Thanks. Jennifer. Thibaut, maybe give some insight, too, on the consumer segment and how COVID is impacting. Obviously, it was much more tumultuous I'd say, in 2020 and 2021. But what are you seeing to the early start of this year? Look, clearly, we continue to see the impact of COVID on the life of our consumers. And that has an impact -- the differentiated impact by category. We are looking at China very specifically right now to see how the situation evolves there. What I would say that COVID has really shifted consumer behavior to digital space and digital solutions. And so -- and we see it in the continued growth of our e-commerce channel, representing more and more of our business. So that's what makes all more resilient is ability to count on multiple channels is something that is showing us well in a provident environment. Having said that, we need to continue to monitor how the situation evolves around the world. Thank you. Our next question today is coming from Matt Miksic from Credit Suisse. Your line is now live. Thanks. Thank so much for taking the question. So maybe for Ashley. I was hoping you could provide a little bit more color on med devices in Q1 and the trajectory exiting March. You had pretty impressive growth across the board, so congrats on that. But investors are often trying to think to just figure out the difference between inpatient segments like orthopedics or cardio or advanced surgery and how those are recovering potentially at different rates in the US? And what you might be seeing there? As well as any color you could provide on how, say, Europe and Japan overseas developed markets compared with the recovery trends we've seen in the US? Thanks. Thanks, Matt for the question. And it's April 2022, we're still talking about this, so just huge acknowledgment for our health care workers who are still battling through this. But I would tell you, EMEA really bounced back nicely in quarter one. It was pretty broad-based within EMEA. I would say, Asia with the exception of China recently also bounced back, and then US really gained momentum. I always look at two data points in the US as an example. I look at like, how were diagnostic procedures performing in the US and then how are surgical procedures performing. And probably at our trough when Omicron was hitting in the US in January, we had about flat diagnostic procedures, and we were looking at surgical procedures down near double digit, down 10%. Encouragingly, as we exited March, we started to see diagnostic procedures tick up to high single digit and start to see a flattening of surgical procedures. I expect in the month of April in the US to see it go north of 2019 levels, really driven by cardio cardiac ablation, bariatrics and colorectal surgery. Thank you. Our next question today is coming from Geoff Meacham from Bank of America. Your line is now live. Hey, guys. Good morning. Thanks so much for the question. I just had a couple. Jennifer, in the myeloma market, we'll see REVLIMID generic soon. And I realize that combinations with DARZALEX are standard of care, but what are your expectations for broader market disruption going forward, either from a pricing or share perspective? And then a quick follow-up on the M&A front for Joe. When you think about the P&L or cash flow impact from the consumer separation, to what degree does this inform or impact plans for a larger scale BD or M&A for either a MedTech or Pharma? Thank you. So thanks for the opportunity to talk about our multiple myeloma portfolio in response to your question. So as we take a look at the myeloma market despite the advances to date in therapies, there is still so much unmet need there, given the underlying heterogeneity of the disease. And so it's really important that there are treatment choices. And what we're really trying to do is to have a strong portfolio of highly effected -- highly effective treatments and actually ultimately shoot for a cure. And so as we take a look at the market with DARZALEX -- in DARZALEX FASPRO right now, we're really seeing this as a foundational therapy multiple myeloma. And so irrespective of others and LOE and those types of things, you noted, it's a lot of combination therapy and things like that. That does not fundamentally change the opportunity for DARZALEX and FASPRO. What I'm also really excited about is then you add in CARVYKTI that was recently approved, as we mentioned, for triple refractory multiple myeloma. And we really think that this will ultimately become a preferred treatment for patients with relapsed/refractory multiple myeloma. We also mentioned teclistamab in the filing of teclistamab. And this really is the first-ever BCMA CD3 specific. And we think that this is going to be a great off-the-shelf option and for patients who really are triple-class exposed and who are really not eligible for CARVYKTI or don't have access. And then in the future, we're not stopping there. We're also working on Talquetamab, and this would be the first and potentially best-in-class GPRC5D bispecific that we think could be potentially sequenced combined to help transform outcomes. And so as we take a look at our portfolio, we really think that these assets are additive and complementary versus something where they would be cannibalizing each other. And we really think that these are the important advances that are going to really help transform multiple myeloma in the future and going forward versus any of the older therapies. And Geoff, with respect to cash flow and M&A, I think I'll answer that in two parts. I think short term, we certainly have the credit rating to warrant more firepower should we need it. As you have observed, our cash flow generation over the last couple of years has ticked up to new levels, north of $20 billion or around $20 billion from when we were just maybe $17 billion a few years ago. As the consumer company operates, I think that's going to be actually liberating for both sides. We still have opportunities to improve our cash flow with inventory management and receivables. But as we move to a higher growth segment, we think we'll be able to generate similar cash flow with a higher level of sales growth, managing the P&L appropriately. So I've got every confidence that we'll be able to do small, medium and large scale acquisitions should the right opportunity present itself. I also think it's liberating for the Consumer Health segment because they'll be able to focus their cash flow generation to value-creating opportunities through their particular lens being fit for purpose in a digitized environment that Thibaut spoke to. So whether it's near-term or long-term, I think we're in a very good position to utilize today's cash and hopefully that which should we generate tomorrow. Kevin, maybe we've got time for one more question? Certainly. Our final question today is coming from Danielle Antalffy from SVB Leerink. Your line is now live. Hi. Good morning, everyone. Thanks so much for squeezing me in. This is a question for Ashley. And is the commentary around the ASC penetration. And I'm just curious, Ashley, as that site of care becomes increasingly important, where you guys think you are relative to the market from a penetration perspective? And where you think you can grow meaningful growth driver will your recent success in the ASC be over the next few years? Thanks so much. Well, thank you, Danielle. Appreciate the question and hope you are well. We -- in US, the ASCs, I think, are -- it's still relatively low penetration, I would tell, from a macro US, less than 20%, but I think it's the fastest growing as we know. In a COVID environment, we've seen the model evolve to create a safe, more patient-friendly experience that addresses a patient sentiment of not wanting to go into a hospital setting. Certain procedures have gone there early sooner than later. I'd say hips or migraine and knees, less spine per se, less complicated. Obviously, trauma case is still happening in the hospital setting. We've done a lot of work recently to modify our business model to make it a capital-efficient flow, if you will, in inventory management, on the personalization of care using digital assets to kind of your pre-op and your post-op experience less full of friction. And we're taking a lot of experience in the US ASCs to really what we're doing in China in the Tier 2 and the Tier 3 cities as well as we deliver care. So I'm optimistic that this channel will continue to evolve. I do think that we think we start competitiveness there, and we're making sure that we really have a sustainable business model going forward. Thank you. Thank you, Danielle, and thanks to everyone for your questions and your continued interest in our company. We apologize to those who we couldn't get to because of time, but don't hesitate to reach out to the Investor Relations team as needed. I will now turn the call back to Joe for some brief closing remarks. Great. Thanks, Jess. And as Jess alluded to, we certainly do appreciate your questions and the chance to interact with you. I'd like to remind everybody as we close that we do have the opportunity to engage with shareholders at next week's annual meeting on April 28. Also be on the lookout for an update on our commitments to ESG. On June 8, we will be issuing our Health for Humanity Report, which is an in-depth review on the progress we are making on our 2025 goals. Thank you for your time and your interest in Johnson & Johnson. Have a great day. Thank you. This concludes today's Johnson & Johnson's first quarter 2022 earnings conference call. You may now disconnect.\",\n          \"Nancy Paxton - Apple, Inc. Timothy Donald Cook - Apple, Inc. Luca Maestri - Apple, Inc. Kathryn Lynn Huberty - Morgan Stanley & Co. LLC Shannon S. Cross - Cross Research LLC Steven Milunovich - UBS Securities LLC Kulbinder S. Garcha - Credit Suisse Securities (USA) LLC Antonio M. Sacconaghi - Sanford C. Bernstein & Co. LLC Michael J. Olson - Piper Jaffray & Co. Amit Daryanani - RBC Capital Markets LLC Brian J. White - Drexel Hamilton LLC Good day, everyone, and welcome to this Apple Incorporated Third Quarter Fiscal Year 2017 Earnings Release Conference Call. Today's call is being recorded. At this time for opening remarks and introductions, I would like to turn the call over to Nancy Paxton, Senior Director of Investor Relations. Please go ahead, ma'am. Thank you. Good afternoon and thanks to everyone for joining us. Speaking first today is Apple CEO Tim Cook, and he'll be followed by CFO Luca Maestri. After that, we'll open the call to questions from analysts. Please note that some of the information you'll hear during our discussion today will consist of forward-looking statements, including without limitation those regarding revenue, gross margin, operating expenses, other income and expense, taxes, and future business outlook. Actual results or trends could differ materially from our forecast. For more information, please refer to the risk factors discussed in Apple's Form 10-K for 2016, the Form 10-Q for the first two quarters of 2017, and the Form 8-K filed with the SEC today along with the associated press release. Apple assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates. I'd now like to turn the call over to Tim for introductory remarks. Thank you, Nancy, and good afternoon and thanks, everyone, for joining us. Today we're proud to announce very strong results for our fiscal third quarter, with unit and revenue growth in all of our product categories. We'll review our financial performance in detail, and I'd also like to talk about some of the major announcements we made in June at our Worldwide Developers Conference. It was our biggest and best WWDC ever, and the advances we introduced across hardware, software, and services will help us to delight our customers and extend our competitive lead this fall and well into the future. For the quarter, total revenue was at the high end of our guidance range at $45.4 billion. That's an increase of 7% over last year, so our growth rate has accelerated in three successive quarters this fiscal year. Gross margin was also at the high end of our guidance, and we generated a 17% increase in earnings per share. iPhone results were impressive, with especially strong demand at the high end of our lineup. iPhone 7 was our most popular iPhone, and sales of iPhone 7 Plus were up dramatically compared to iPhone 6s Plus in the June quarter of last year. The combined iPhone 7 and iPhone 7 Plus family was up strong double digits year over year. One decade after the initial iPhone launch, we have now surpassed 1.2 billion cumulative iPhones sold. Services revenue hit an all-time quarterly record of $7.3 billion, representing 22% growth over last year. We continue to see great performance all around the world, with double-digit growth in each of our geographic segments. Over the last 12 months, our Services business has become the size of a Fortune 100 company, a milestone we've reached even sooner than we had expected. We had very positive results for iPad, with broad-based growth in units, revenue, and market share. iPad sales were up 15% year over year and grew across all of our geographic segments. We achieved our highest global market share in over four years based on IDC's latest estimate of tablet market results for the June quarter. And in markets like China and Japan, over half of iPads sold were to people buying their very first iPad. Our iPad product lineup is stronger than ever. The new iPad we launched in March offers great value and performance. And the all-new 10.5-inch iPad Pro, launched in June, features the world's most advanced display with ProMotion technology and is more powerful than most PC desktops. iPad is the perfect tool for teaching in new and compelling ways, and our iPad results were especially strong in the U.S. education market, where sales were up 32% year over year to over 1 million units. We believe that coding is an essential skill that all students should learn. We're thrilled that over 1.2 million students of all ages are now using iPad and Swift Playgrounds to learn the fundamentals of coding. And over 1,000 K-12 schools across the United States plan to use Apple's Everyone Can Code in their curricula this fall. And for high school and community college students who want to pursue careers in the fast-growing app economy, we announced app development with Swift, an innovative full-year curriculum designed by Apple engineers and educators and provided free to schools to teach students to code and design fully functional apps, gaining critical job skills in software development and information technology. I'd like to turn now to Mac, which gained global unit market share and reached new June quarter unit sales records in mainland China and Japan. Mac revenue grew 7% year over year, driven by the strength of the MacBook Pro and iMac despite IDC's latest estimate of a 4% unit contraction in the global PC market. And with the refresh of almost our entire Mac lineup in June, we're off to a great start for the back-to-school season. Sales of Apple Watch were up over 50% in the June quarter, and it's the number one selling smartwatch in the world by a very wide margin. Apple Watch is having a positive impact on people's health and daily lives and motivating them to sit less and move more. With features like built-in GPS and waterproofing, Apple Watch Series 2 is the perfect companion for hiking, running, and swimming. We're also seeing incredible enthusiasm for AirPod, with 98% customer satisfaction based on Creative Strategy's survey. We have increased production capacity for AirPods and are working very hard to get them to customers as quickly as we can, but we are still not able to meet the strong level of demand. We made some big announcements during the June quarter that I'd like to quickly review. We launched a new investment in the future through our Advanced Manufacturing Fund. We've earmarked at least $1 billion for this program, aimed at helping our manufacturing partners develop innovative production capabilities and create high-skill jobs in the United States. We believe this can lay the foundation for a new era of technology-driven manufacturing in the U.S. The first $200 million from the fund has been committed to Corning to support R&D, capital equipment needs, and state-of-the-art glass processing. And as we announced at WWDC, we have a very exciting fall ahead, with stunning advances in iOS 11, macOS High Sierra, and watchOS4. iOS 11 will make iPhones better than ever with Apple Pay peer-to peer payments, an even more intelligent and natural Siri, new expressive messages with full screen effects, richer and more powerful maps, enhanced live photos and memories and portrait mode effects, and much, much more. iOS 11 will also take the iPad experience to a whole new level, with features such as a customizable dock, Multi-Touch drag and drop, powerful new multitasking, more efficient QuickTime, and great new markup and scanning capabilities. One of the most exciting and most promising announcements from WWDC was the introduction of ARKit, a new set of tools for developers to create augmented reality apps. It's still early in the beta period, but it's clear that ARKit has captured the imagination of our developer community. We think ARKit will help the most creative minds in the industry tap into the latest computer vision technologies to build engaging content. We believe AR has broad mainstream applicability across education, entertainment, interactive gaming, enterprise, and categories we probably haven't even thought of. With hundreds of millions of people actively using iPhone and iPad today, iOS will become the world's biggest augmented reality platform as soon as iOS 11 ships. With iOS 11, we're also bringing the power of machine learning to all Apple developers with Core ML, enabling capabilities like face detection, object tracking, and natural language interpretation. Core ML lets developers incorporate machine learning technologies into their apps with all the processing done right on device, so it respects our customers' data and privacy. For Mac, we provided a peek at the immersive gaming, 3D, and virtual reality experiences made possible with the upcoming release of macOS High Sierra and the amazingly powerful new iMac Pro. We're proud to make the best personal computers in the industry and are very excited to deliver even more innovation in the months to come. Apple Watch will become more intelligent than ever this fall with watchOS4, featuring a proactive Siri watch face, personalized activity coaching, and an entirely new music experience. watchOS4 also introduces GymKit, a groundbreaking technology program to connect workouts with cardio equipment. We also previewed HomePod, a breakthrough wireless speaker for the home that delivers amazing audio quality and uses spatial awareness to sense its location in the room and adjust the audio automatically. Visitors to our listening room at WWDC were blown away by the HomePod's incredible sound, which is unlike any other wireless home speaker on the market. With deep knowledge of music, HomePod is designed to work with your Apple Music subscription to help you enjoy the music you already love as well as to discover great new music, based on your personal preferences. As an intelligent home assistant, HomePod is a great way to send messages, set a timer, get updates on news, sports, and weather, or control smart home kit devices by simply asking Siri to turn on the lights, close the shades, or activate a theme. We can't wait to deliver all of these powerful innovations in the months to come. And we might even have some others to share with you later in the year. Now for more details on the June quarter results, I'd like to turn the call over to Luca. Thank you, Tim. Good afternoon, everyone. Revenue for the June quarter was $45.4 billion, up 7% over last year, an acceleration to the growth rate we reported during the first half of our fiscal year. We achieved these results despite a 200 basis point negative impact from foreign exchange on a year-over-year basis, as currency movements, especially in Europe and China, affected our reported results. Our performance was very strong across the board with growth in all our product categories and almost every market around the world. We achieved double-digit revenue growth in many developed markets, including the U.S., Canada, Germany, Spain, Australia, and Korea, and emerging markets outside of Greater China grew 19% over a year ago. Gross margin was 38.5%, at the high end of our guidance range. Operating margin was 23.7% of revenue and net income was $8.7 billion. Diluted earnings per share were $1.67, up 17% over last year, and cash flow from operations was $8.4 billion. During the quarter we sold 41 million iPhones and reduced iPhone channel inventory by 3.3 million units, leaving us with our lowest level of channel inventory in 2.5 years and well within our five-week to seven-week target inventory range. iPhone sales were up year-over-year in most markets we track, with many markets in Asia, Latin America, and the Middle East growing unit sales by more than 25%. We are very pleased with these iPhone results, especially considering the tough comparison to the June quarter last year when we launched iPhone SE. iPhone ASP was $606, up from $595 a year ago, thanks to strong demand for iPhone 7 Plus, which represented a higher percentage of the iPhone mix compared to the Plus model a year ago. The impact of the stronger mix on ASP was partially offset by negative foreign exchange year over year and the reduction in channel inventory, which took place entirely at the high end of the portfolio. Customer interest and satisfaction with iPhone are very strong with both consumers and business uses. In the U.S., the latest data from 451 Research on consumers indicates a 95% customer satisfaction rating for iPhone 7 and 99% for iPhone 7 Plus. Among consumers planning to buy a smartphone, purchase intention for iPhone was nearly three times the rate of our closest competitor. Among corporate smartphone buyers, iOS customer satisfaction was 94%. And of those planning to purchase smartphones in the September quarter, 78% plan to purchase an iPhone. Turning to Services, we set an all-time quarterly record of $7.3 billion, up 22% year over year. The App Store was a major driver of this performance. And according to App Annie's latest report, it continues to be by a wide margin the preferred destination for customer purchases, generating nearly twice the revenue of Google Play. Revenue from our Apple Music streaming service and from iCloud storage also grew very strongly. And across all of our Services offerings, the number of paid subscriptions reached over 185 million, an increase of almost 20 million in the last 90 days alone. The reach, usage, and functionality of Apple Pay continue to grow. We launched Apple Pay in Italy in May. And the UAE, Denmark, Finland, and Sweden are scheduled to go live before the end of this calendar year. Apple Pay is by far the number one NFC payment service on mobile devices, with nearly 90% of all transactions globally. Momentum is strongest in international markets, where the infrastructure for mobile payments has developed faster than in the U.S. In fact, three out of four Apple Pay transactions happen outside the U.S. And with the launch of iOS 11 this fall, our users in the U.S. will be able to make and receive person-to-person payments quickly, easily, and securely. Next, I'd like to talk about the Mac. Thanks to great performance from the new MacBook Pro, we generated 7% revenue growth over last year and gained share in the global PC market based on the latest data from IDC. Customer satisfaction for Mac is very strong at 97% in the most recent survey from 451 Research, and our active installed base of Mac has grown double digits over a year ago. We ended the quarter within our four to five-week target range for Mac channel inventory, and we have a great lineup of Macs for our customers heading into the busy back-to-school season. Turning to iPad, we sold 11.4 million units, up 15% over last year. We were happy to see iPad growth in each of our geographic segments, with strong double-digit increases in key markets such as the U.S., Japan, Germany, France, and Greater China. We exited the quarter within our five to seven-week target range for iPad channel inventory. NPD indicates that iPad had 55% share of the U.S. tablet market in the month of June, including 8 of the 10 best-selling tablets. That's up from 46% share a year ago. And among tablets priced over $200, iPad's share was 89%. In addition, the most recent survey from 451 Research measured business and consumer satisfaction rates ranging from 95% to 99% across iPad models. And among those planning to buy tablets, purchase intent for iPad was over 70%. Our enterprise business continues to expand, and our customers are transforming the way work gets done with iOS and iPad. Walmart will be deploying more than 19,000 iPads for employee training across 50 states, with projections of over 225,000 associates trained on iPad by the end of the year. Initial response from businesses to iOS 11 and the new iPad Pro has been amazing. And companies including Bank of America, Medtronic, and Panera tell us that they will be rolling out the 10.5-inch iPad Pro throughout key areas of their organizations. We're also seeing real traction with our enterprise partners. Just last month, we unveiled the next set of technology announcements in our partnership with Cisco. This new wave adds a whole new category of security features designed to help enterprises and employees defend against growing cyber threats. We believe this investment in our joint security solutions for iOS will make cyber insurance even more attainable for businesses. SAP is making great strides since launching the SAP cloud platform SDK for iOS in March, with a pipeline of hundreds of global opportunities. SAP has also released SuccessFactors Mobile, its first native iOS app for human resources, which will support 47 million iPhone and iPad users worldwide across multiple industries. And our partnership with Deloitte has recently expanded to several more European countries. We're helping clients transform their businesses with iOS. We jointly developed programs such as the Connected Store, a pop-up version of a retail environment, demonstrating iOS tools for sales and demand generation, as well as tailored apps for safe associates, store management, and customers. We also had a tremendous quarter for iPad in education, up 32% year over year. Following the launch of our new iPad in March, an update to our popular Classroom app, and continued enhancements to iOS that make managing iPads in the classroom even easier. The St. Paul Public School District in Minnesota is renewing its One to One program by deploying over 40,000 iPads across every student and teacher in the district. iPad was chosen because of its power and durability, ease of use, multimedia and accessibility features, and the extensive catalog of iOS apps designed specifically for education. The Shawnee Mission School District outside Kansas City recently purchased 19,000 iPads, extending its One to One program started in 2014 thanks to iPad's intuitive interface, superior reliability, and expansive ecosystem of iOS tools for education. It was a very busy quarter for our retail and online stores, which collectively welcomed over 300 million visitors. In addition to our spectacular new store at the Dubai Mall, we opened our first stores in Singapore and in Taiwan during the quarter, expanding our total store footprint to 497 stores. In May, we kicked off Today at Apple, with new in-store programming from music to photography to art and coding. And our stores collectively hosted 87,000 sessions during the quarter. As Tim mentioned last quarter, we have entered a new chapter in retail with unique and rewarding experiences for our customers and some stunning new stores coming in the near future. Let me now turn to our cash position. We ended the quarter with $261.5 billion in cash plus marketable securities, a sequential increase of $4.7 billion. $246 billion of this cash, 94% of the total, was outside the United States. We retired $3.5 billion of debt and issued the equivalent of $10.8 billion in new euro and U.S. dollar-denominated debt during the quarter, including our second green bond, bringing us to $96.4 billion in term debt and $12 billion in commercial paper outstanding. We also returned $11.7 billion to investors during the quarter. We paid $3.4 billion in dividends and equivalents and spent $4.5 billion on repurchases of 30.4 million Apple shares through open market transactions. We launched a new $3 billion ASR program, resulting in initial delivery and retirement of 15.6 million shares, and we retired 3.4 million shares upon the completion of our 10th ASR during the quarter. We have now completed $222.9 billion of our $300 billion capital return program, including $158.5 billion in share repurchases. As we move ahead into the September quarter, I'd like to review our outlook, which includes the types of forward-looking information that Nancy referred to at the beginning of the call. We expect revenue to be between $49 billion and $52 billion. We expect gross margin to be between 37.5% and 38%. We expect OpEx to be between $6.7 billion and $6.8 billion. We expect OI&E to be about $500 million. And we expect the tax rate to be about 25.5%. Also today, our Board of Directors has declared a cash dividend of $0.63 per share of common stock, payable on August 17, 2017 to shareholders of record as of August 14, 2017. With that, I would like to open the call to questions. Thank you, Luca, and we ask that you limit yourself to one one-part question and one follow-up. Rebecca, may we have the first question, please? And that question will come from Katy Huberty with Morgan Stanley. Yes, thanks. Good afternoon. Luca, first question for you, gross margin guidance is strong, but it did tick down from your June quarter guidance, and you also narrowed the range to 50 basis points. I wonder if you can just address. What is the driver of the sequential downtick, and what gives you confidence that you have more visibility than you did three months ago? Katy, sequentially from 38.5% that we just reported, typically we have product transition costs during the September quarter. That's the primary driver. This happens fairly regularly for us. We also have a more difficult memory pricing environment this year than a year ago. And we think that we're going to be able to partially offset this with the positive leverage. As you've seen, we guided up sequentially in revenue. So those are the major puts and takes. In terms of the range that we use for gross margins, we have a fairly good understanding on where we are with our hedging program, and that allows us to mitigate some of the volatility there. So we felt we could guide to a slightly narrower range, which we've done occasionally in the past. Thank you, and maybe a question for both Tim and Luca. As you outlined on this call and at the Developer Conference in June, there is an unprecedented number of products that either ramped volume or launched in the back half of this year. So appreciating you only formally guide a quarter out, I wonder if there's any qualitative commentary you can provide to help us think about the back half of this calendar year and how all those new products that come into the model could impact either revenue seasonality versus past years or could impact just the costs associated with ramping that many products all at once. Thanks. Katy, as Luca mentioned, we did assume some transitional costs in our guidance for the quarter, as is typically the case. And we're looking very much forward to the product rollouts. Thank you, Katy. Could we have the next question, please? We'll go to Shannon Cross with Cross Research. Thank you very much for taking my question. Tim, could you talk a bit about what you're seeing in China? I think obviously, there continues to be strong demand for smartphones. But perhaps mix shift, I think you brought back the iPhone 6 this quarter to be a bit more price aggressive. And then can you just talk a bit about how you see that market developing with the growth of WeChat and some of the other developments that are happening there? Thank you. Yeah. Thanks, Shannon. We were very encouraged by the results this quarter. We improved as we thought we would from the previous quarters a little more than I thought we would. If you look underneath the numbers, mainland China was actually flat year-over-year during Q3. And in constant currency terms, we were actually up 6% in mainland China. And so we're very encouraged about that. iPad grew dramatically more than the market. The Mac grew much more than the market. iPhone was relatively flat year-on-year, similar as the market was. And so we see all of those as very encouraging signs. On top of that, Services grew extremely strongly during the quarter. Hong Kong continued to drag down the total Greater China segment. But on a sequential basis, we're probably at the trough of that, which is nice. With the peg to the dollar there from a currency point of view and tourism being what it is, I don't really know when that market will come back. But what we see on the mainland is definitely much more encouraging. It's interesting to note that upgraders both for the quarter and actually for the full fiscal year to-date was our highest ever, and so that we felt very good about. In terms of WeChat, the way that I look at this is because our share \\u2013 because iOS share is not nearly a majority of the market in China, the fact that a lot of people use that, it makes the switching opportunity even greater. And I think that's more the case than the risk that a lot of folks have pointed out. And so I see Tencent as one of our biggest and best developers. They've done a great job of implementing a lot of iOS features in their apps and we're looking forward to working with them even more to build even greater experiences for our mutual users in China. Great. Thank you. And then can you talk a bit about the composition of the installed base of iPhones at this point, as obviously we're getting close to a refresh? Just you brought in the iPhone SE. You've obviously had strength at the high end. I'm just trying to think about what percent do you think have upgraded in the prior generation, any color you can give us on that? From an absolute quantity point of view, the upgrades for this fiscal year are the highest that we've seen. And so we feel good about that. However, if you look at it from an upgrade rate point of view instead of the absolute number, the rate is similar to what we saw with the previous iPhones, except for iPhone 6, which as we called out in the past had an abnormally high upgrade rate. We do think that based on the amount of rumors and the volume of them that there is some pause in our current numbers. And so where that affects us in the short-term, even though we had great results, it probably bodes well later on. Thank you, Shannon. Could we have the next question, please? Steve Milunovich with UBS. Thank you. I wonder if you wanted to make any comments about switching this quarter. Sure. Switching outside of China was up year-on-year, and so we're happy with that. We continue to see people moving over to iOS and it helped with us making the results that Luca announced earlier, including the channel inventory reduction. Okay, and then a government question. First of all, the President suggested that you may build three big beautiful plants. I wonder if you can comment on if that's a possibility either directly or indirectly. And then in China, I think, we all understand that you have to work within the regulations, but maybe you could comment a bit on how you feel your working relationship is with the government and if there is certain lines that you can't cross. Sure. Starting with the U.S., let me just take this question from what are we doing to increase jobs, which I think is probably where it's rooted. We've created 2 million jobs in the U.S., and we're incredibly proud of that. We do view that we have a responsibility in the U.S. to increase economic activity, including increasing jobs, because Apple could have only been created here. And so as we look at that 2 million, there are three main categories of that, and we have actions going on in each of them to further build on that momentum. The first category is app development. About three-quarters of the 2 million are app developers. And we're doing an enormous amount of things to deliver curriculum to both K-12 with Swift Playgrounds in the K-to-6 area, other curriculum as you proceed beyond grade 6 under the Everyone Can Code area. And just a couple months ago, we announced a new curriculum that's focused on community schools and community colleges, junior colleges, technical colleges, for kids that did not have coding in their elementary and high school years. And so we're excited about that because we think it could increase the diversity of the developer community and the quantity. And I think this area in general and all the things we do for the developer community will be the largest contribution that Apple can make because this is the fastest growing job segment in the country, and I think will be for quite some time. If you look at the second area, we have purchased \\u2013 or we purchased last year about $50 billion worth of goods and services from U.S.-based suppliers. Some significant portion of those are manufacturing-related, and so we've asked ourselves what can we do to increase this. And you may have seen that at the beginning of the quarter, sometime in April I believe, we announced a fund, an Advanced Manufacturing Fund, that we're initially placing $1 billion in. And we've already deployed $200 million of that. And the first recipient is Corning in Kentucky, and they'll be using that money to expand the plant to make very innovative glass. And we purchase that glass and essentially export it to the world with iPhones and iPads. We think there's more of these that we can do. I think there are probably several plants that can benefit from having some investment to grow or expand or even maybe set up shop in the U.S. for the first time, so we're very excited about that. And then the third area is we have about two-thirds or so of our total employee base is in the U.S. despite only a third of our revenues being here, and we'll have some things that we'll say about that later in the year. And so that's what we're doing from a job growth point of view, and we're very, very proud of that. Now turning to China, let me comment on what I assumed is at the root of your question about this VPN issue. Let me just address that head on. The central government in China back in 2015 started tightening the regulations associated with VPN apps, and we have a number of those on our store. Essentially, as a requirement for someone to operate a VPN, they have to have a license from the government there. Earlier this year, they began a renewed effort to enforce that policy, and we were required by the government to remove some of the VPN apps from the App Store that don't meet these new regulations. We understand that those same requirements are on other app stores, and as we checked through that, that is the case. Today there are actually still hundreds of VPN apps on the App Store, including hundreds by developers that are outside China, and so there continues to be VPN apps available. We would obviously rather not remove the apps, but like we do in other countries, we follow the law wherever we do business. And we strongly believe that participating in markets and bringing benefits to customers is in the best interest of the folks there and in other countries as well. And so we believe in engaging with governments even when we disagree. And in this particular case, now back to commenting on this one, we're hopeful that over time the restrictions that we're seeing are loosened because innovation really requires freedom to collaborate and communicate, and I know that that is a major focus there. And so that's what we're seeing from that point of view. Some folks have tried to link it to the U.S. situation last year, and they're very different. In the case of the U.S., the law in the U.S. supported us, which was very clear. In the case of China, the law is also very clear there. And like we would if the U.S. changed the law here, we'd have to abide by them in both cases, that doesn't mean that we don't state our point of view in the appropriate way. We always do that. And so hopefully that's a little bit probably more than you wanted to know, but I wanted to tell you. Thank you. Thank you, Steve. Could we have the next question, please? We'll hear from Kulbinder Garcha with Credit Suisse. Thank you, a question for Tim maybe on the iPhone install base. At various points in the past you've told us the rate at which that was growing. At the end of the first half, what is that up year on year? At what rate is it growing? Can you give us some sense of that? And on upgrade rates over the longer term, there are lots of moving parts, and I get that there's I guess geographic mix shift of your base. There's many new phones that you may or may not bring out. There's how carriers promote your products. But do you think this upgrade rate is sustainable? Do you think it gets faster all the time? How should we think about the major drivers that you want to see for it? Many thanks. I think the upgrade rate is a function of many, many different things, from the size of the installed base, the age of the installed base, the product that is new at the time, the regional distribution, the upgrade plans that are in various markets around the world. And so I think there are many, many factors in that. It's not a simple thing that you can apply a set formula to or one variable or a couple of variable formula in my opinion. But I think in general, because our installed base was up strong double digit once again, there's a lot of factors that are very positive for us. And between the upgraders and the switchers that we see, and the first-time buyer category is still out there too in several countries, including some that you may not think there is, there's still a sizable base in some. Between those three areas, I think we have a lot of opportunity. Thank you. Yes. Thank you, Kulbinder. Could we have the next question, please? Toni Sacconaghi with Bernstein. Yes, thank you. I have one for Luca and one for Tim, please. Luca, typically in the fiscal Q4, Apple builds considerable iPhone channel inventory, like 2 million or 3 million units. You're starting from a very low point at the end of fiscal Q3, as you mentioned on the call, with the drawdown. As we think about what's embedded in your guidance for fiscal Q4 for channel inventory for iPhone, should we be expecting a normal seasonal build, or is it likely to be significantly higher given the very low starting point? As you know, Toni, we do not guide on channel inventory. We've never done that. We are providing a fairly wide range from a revenue standpoint, so obviously that also has an impact on potential channel inventory levels. One thing that I would tell you is that we feel very good about the performance of the business right now. We think that our Services business will continue to grow well. We've got a lot of momentum on iPad and Mac because we refreshed the lineups of those products. Watch and AirPods are doing incredibly well. We're getting a lot of positive customer feedback. And I think in general, even the performance in China, Tim has mentioned it. We think that the performance will continue to improve. So those are the drivers of our guidance range for the quarter. Okay, thanks. Tim, I was wondering if you could maybe talk a little bit about two things that you mentioned in public before. One is television, which you have described as an area of intense interest, but I don't even think there was an update on Apple TV on this call. So perhaps you can talk to us about how you're thinking about content. I know you're doing some original content creation, and how that area is evolving in your thinking. And then recently you talked about how Apple is focusing on autonomous systems for automobiles. And there has been press reports that Apple has been testing autonomous vehicles for potentially up to a year. I was wondering if you could talk a little bit more about Apple's interest in autonomous vehicles and whether self-driving is really likely to be Apple's principal focus in the near to medium-term. On the first part of your question about original content, we have done some original content. It's focused on Apple Music. Currently, we have some more that's launching in a week or so that will be made available on Apple Music. The objective of this is really twofold. One is for our own learning, given that we're new in the video space in terms of creation. And two is to give the Apple Music subscriber some exclusive content and hopefully grow our subscriber base. And we've recently hired two great folks with lots of experience in creating content like Breaking Bad and The Crown and some really top-notch content. And so we'll see how this area goes, but it is still an area of great interest. In terms of autonomous systems, what we've said is that we are very focused on autonomous systems from a core technology point of view. We do have a large project going and are making a big investment in this. From our point of view, autonomy is the mother of all AI projects. And the autonomous systems can be used in a variety of ways and a vehicle is only one. But there are many different areas of it and I don't want to go any further with that. But thank you for the question. Thank you, Toni. Could we have the next question, please? That comes from Mike Olson with Piper Jaffray. Good afternoon. I just have one question for Tim. This may be a hard question to answer in a condensed way, but how would you describe what you expect the most near-term applications will be for developers to target using ARKit? Will it be consumer iPhone and iPad applications, enterprise applications, or I guess some combination of the two? And basically, how does this come to market in the most significant way in the next few quarters as Apple becomes the largest global platform for AR as you've talked about? Thanks. Mike, that is a great question. And I could not be more excited about AR and what we're seeing with ARKit in the early going. And to answer your question about what category it starts in, just take a look at what's already on the web in terms of what people are doing and it is all over the place. From entertainment to gaming, I've seen what I would call more small business solutions. I've seen consumer solutions. I've seen enterprise solutions. I think AR is big and profound and this is one of those huge things that we'll look back at and marvel on the start of it. So I think that customers are going to see it in a variety of ways. Enterprise takes a little longer sometimes to get going. But I can already tell you there's lots of excitement in there. And I think we'll start to see some applications there as well. And it feels great to get this thing going at a level that can get all of the developers behind it, so I couldn't be more excited about it. Thank you. Thanks, Mike. Could we have the next question, please? We'll go to Amit Daryanani. Thanks a lot. Good afternoon, guys. I guess to start off with, on your Services segment, revenues actually I think accelerated by 400 basis points to worse than what you guys had in the first half of this year. Could you just help us understand what's driving this? Is there a way to think about ARPU in a traditional manner within that Services business versus the installed base growing? Amit, Luca. Our Services business is very broad. We've got multiple categories in the Services business, so it's difficult to talk about ARPU in general. It doesn't make a lot of sense. The reason for the acceleration also here is multiple factors. One that is very, very important for us is the fact that the App Store, which is the largest of our Services categories, is seeing an increasingly larger amount of paying accounts. On a year-over-year basis, the number of accounts that are actually transacting and paying on the App Store is growing very, very well. It is happening for a variety of reasons. One of them, for example, is the fact that we are making it easier for customers to pay on the App Store. Outside the United States, in many markets, not every form of payment is accepted. We are making it easier all the time. We launched on Alipay, for example, in China during the December quarter. That has obviously helped a lot with the growth in the number of paid accounts. And we continue to bring more and more forms of payment in the App Store around the world. That's a big reason for that. The other reason why the number of paying accounts is growing is the fact that the quality and the quantity of content continues to improve. And so there's many more ways of experiencing games and entertainment and other apps on the store. We have other businesses like the Apple Music streaming service, which is growing very fast because we just started it a couple of years ago, so we are getting a lot of new subscribers there. Our iCloud storage business continues to grow very, very fast. So it's multiple services. The number of people transacting on our stores continues to grow. In terms of ARPU, maybe I can make a comment on ARPU specifically related to the App Store. What we're seeing and we've seen over a long period of time as we keep track of these cohorts of customers, we see that as customers get on the App Store and start spending on it, we see the spending profile is very similar across generations of customers. People tend to spend more over time. Obviously, you have different spending profiles in different geographies around the world, but in general you see that trend across the board. Got it, that's really helpful. And if I could just follow up, on the iPhone side, there's been a large amount of discussion in blogs and among your component suppliers that the timing this time may be somewhat different and delayed versus past. Your guide almost seems you're more excited about this iPhone launch versus historically because the sequential growth is better. So I guess beyond the fact we probably shouldn't read every blog and believe every blog, what do you think is different with this product launch or product availability through the cycle versus what you've seen historically? We have no comment on anything that's unannounced. Fair enough, I figured it was worth a shot. Thank you. Thank you, Amit. Could we have the next question, please? That will come from Brian White with Drexel. Yes. Tim, growth in the smartphone market is now crawling along at about a low single digit percentage. I know iPhone grew about 2% year over year this quarter, and it looks like you had about a mid-teens market share in units in 2016. So as we look forward maybe three to four years, do you think Apple can expand its unit market share? And if so, what will be the drivers be? And my second question is just about India, general thoughts about India in the quarter. Thank you. The answer to your first question is yes. I do think that we can grow both in units and market share. We don't predict those things, but yes, if you ask me what I think, that's what I think. And so what are the drivers? The installed base is growing. It's still growing very strongly. That will generate more upgrades over time. I feel good about our ability to convince people to switch. And where the developed markets the first-time buyer rates are down other than places like Japan perhaps, the emerging markets, we haven't even gotten started yet, really. From a revenue point of view, we had very strong growth there. Emerging markets ex-China were up 18% year on year. It was a record for us, so we see a lot of opportunity in these markets. We are investing in India. As you mentioned in your second point, we've already launched an app accelerator center. That's on top of working with the channel and looking at expanding our go-to-market in general. And we began to produce the iPhone SE there during the quarter, and we're really happy with how that's going. And so we're bringing all of our energies to bear there. I see a lot of similarities to where China was several years ago. And so I'm very, very bullish and very, very optimistic about India. Great, thank you. Thanks very much, Brian. A replay of today's call will be available for two weeks as a podcast on the iTunes Store, as a webcast on apple.com/investor, and via telephone. And the numbers to the telephone replay are 888-203-1112 or 719-457-0820. Please enter confirmation code 6376964. And these replays will be available by approximately 5:00 PM Pacific Time today. Members of the press with additional questions can contact Kristen Huguet at 408-974-2414. And financial analysts can contact Joan Hoover or me with additional questions. Joan is at 408-974-4570 and I'm at 408-974-5420. Thanks again for joining us. Ladies and gentlemen, that does conclude today's presentation. We do thank everyone for your participation.\",\n          \"Thank you, ladies and gentlemen, for standing by. Welcome to the Q1 2019 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will be given at that time. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our VP of Investor Relations, Kevin Hern. Please go ahead. Thank you. Good morning. Thank you for joining us for Eli Lilly and Company\\u2019s Q1 2019 earnings call. I am Kevin Hern, Vice President of Investor Relations. Joining me on today\\u2019s call are Dave Ricks, Lilly\\u2019s Chairman and CEO; Josh Smiley, our Chief Financial Officer; Dr. Dan Skovronsky, President of Lilly Research Laboratories; Christi Shaw, President of Lilly Bio-Medicines; Anne White, President of Lilly Oncology; and Enrique Conterno, President of Lilly Diabetes and Lilly USA. We are also joined by Kim Macko and Mike Czapar of the Investor Relations team. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on slide three and those outlined in our latest Forms 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions. As we transition to our prepared remarks, a reminder that our commentary will focus on non-GAAP financial measures, which exclude the financial contribution from Elanco during the first quarters of both 2018 and 2019, and present earnings per share as though the full disposition of the exchange offer was complete on January 1, 2018. We believe this view provides insights into the drivers of our underlying business performance as a dedicated pharmaceutical company and provides for cleaner comparisons to future and prior periods. Now, I will turn the call over to Dave for a summary of our progress in Q1. Thanks, Kevin. The Company\\u2019s focus in 2019 is to execute on a broad and exciting range of new products and indication launches, to build and accelerate our pipeline, and continue to improve the focus and competitiveness of our company. We are pleased with the progress on these objectives in Q1 2019. First quarter revenue grew 5% in constant currency, despite a significant decline in U.S. Cialis revenue due to the recent loss of exclusivity. We made significant investments in key commercial and late-stage pipeline products and delivered non-GAAP EPS of 2% putting us on track to meet our full year financial guidance. Our key growth products, which all launched since 2014 contributed meaningfully to our performance and account for 39% of our revenue. While still relatively early in their product life cycles, these products continue to drive growth led by Trulicity, Taltz, Verzenio, and in collaboration with Boehringer Ingelheim, Jardiance and Basaglar. Total volume growth across the entire portfolio was 7% and excluding Cialis was nearly 13%. U.S. diabetes contributed strong volume growth of nearly 17%. Oncology growth accelerated in the U.S., Japan and China. And our international markets grew volume by 9%, as global launches of key brands continue across our major geographies. Excluding the impact of FX on international inventory sold, Q1 non-GAAP operating income as a percent of revenue decreased by nearly 600 basis points versus Q1 2018, reflecting a decrease in gross margin and investment in recent launches and multiple late-stage pipeline opportunities. On the same basis, operating income as a percent of revenue in Q1 increased by nearly 80 basis points versus Q4 2018, reflecting progress toward our 2019 full year margin goal of 28%. We exited Q1 on track with our plans for the full year. We have invested in our future growth, while delivering strong volume growth across the business. Importantly, several pipeline assets achieved milestones this quarter, including the regulatory submission for the Trulicity REWIND study for CV outcomes label in the U.S. and in Europe. The FDA granted priority review for Emgality for cluster headache in the U.S. The submission of Ultra Rapid Lispro for Type 1 and Type 2 diabetes in both Europe and Japan. The U.S. submission of our first connected device, our connected care prefilled insulin pen. And we had several Phase 3 data readouts. We also announced an updated timeline for expected regulatory action timing for nasal glucagon. We received notification. The FDA has extended the review timeline by up to three months to analyze information requested late in that review cycle. We remain confident in nasal glucagon submission package and look forward to FDA action in the coming months. In terms of capital deployment, we continue to utilize our strong operating cash flow to access value creating external innovation, which will enhance our future growth prospects. We completed the acquisition of Loxo Oncology and in key pipeline assets and expanding our presence into precision medicine. We completed the full separation of Elanco Animal Health via an exchange offer, retiring 65 million Lilly shares with approximately $8.2 billion. We entered into a global licensing and research collaboration with ImmuNext, focused on new medicines for autoimmune disease. We announced a global licensing and research collaboration with Avidity, focused on potential new medicines in immunology and select other indications. We announced an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, as well as a manufacturing facility to Eddingpharm, a Chinese-based specialty pharmaceutical company. And we returned an additional $3.5 billion to shareholders via a previously announced accelerated share repurchase program and $600 million in dividends, representing a 15% increase per share versus 2018. Moving on to slides five and six, you will see more details on key events since our February earnings call, including our announcement to introduce Insulin Lispro a low priced version of Humalog in the U.S. Now, I will turn the call over to Josh to review our Q1 results and to provide an update on our post Elanco financial guidance. Thanks Dave. Slide seven summarizes our presentation of GAAP results and non-GAAP measures and slide eight provides a summary of our GAAP results. Looking at the non-GAAP measures on slide nine, you will see revenue increased 30%. Excluding the impact of FX on international inventories sold, gross margin as a percent of revenue was 80.2%, in line with our long-term goals for manufacturing efficiency and profitability. On the same basis, gross margin declined 130 basis points compared to Q1 2018, driven by production timing and lower volumes from post patent products. Total operating expense increased 12%, with marketing selling and administrative expense, increasing 13%, driven primarily by increased investment to support our recent launches, including DTC campaign campaigns to drive awareness from Emgality, Verzenio and Taltz. R&D expense increased 11%, reflecting the ramp up of multiple late-stage pipeline assets, the addition of the Loxo Oncology portfolio and the insight communicating to us that they would no longer co-fund the development of baricitinib, which reduces the royalty we will pay them moving forward. As a result of the investments described above, operating income decreased 8% compared to Q1 2018, which put our operating income as a percent of sales at 26.2% for the quarter. As our recent launches continue to drive revenue and operating leverage, we expect income growth and improvements in operating margin during the remainder of 2019. Other income and expense was income of $86 million this quarter compared to income of $70 million in Q1 2018, driven by over $100 million in gains of mark-to-market of public equities held through venture capital investments and strategic partnerships, partially offset by higher net interest expense. Our tax rate for the quarter was 12.9%, a decrease of 260 basis points compared with the same quarter last year, driven primarily by timing associated with the impact of U.S. Tax Reform. At the bottomline, net income declined 4%, while earnings per share increased 2%, due to a reduction in shares outstanding from share repurchases. Recall that our non-GAAP comparisons remove the 65 million shares retired through the Elanco exchange for both 2018 and 2019. While income declined this quarter versus Q1 2018 we made important progress on several fronts that will drive future growth, as demonstrated by growing revenue despite significant headwinds from the loss of exclusivity of Cialis in the U.S., investing behind key growth brands, such as Emgality, Verzenio, Taltz, Jardiance and Trulicity, and advancing several pipeline assets to the next phase of development, including multiple regulatory submissions. Slide 10 provides a reconciliation between reported and non-GAAP EPS and you will find additional details on these adjustments on slide 23. Moving to slide 11, let\\u2019s take a look at the effective price rate and volume on revenue growth. This quarter, foreign exchange reduced revenue growth by 2 percentage points. As Dave mentioned earlier, worldwide revenue grew 5% on a performance basis, driven by a 7% increase in volume, partially offset by price, Q1 is the ninth straight quarter our business grew volume in each major geography. U.S. revenue increased 3%. Like last quarter Trulicity, Taltz, Verzenio and Basaglar were the key drivers of 6% volume growth, partially offset by price. Excluding Cialis, volume grew nearly 15% in the U.S., highlighted by diabetes products delivering nearly 17% volume growth. Consistent with our 2019 financial guidance U.S. price declined 3%, driven by increased utilization of patient affordability programs, mainly for insulins and Taltaz, adjustments through estimates for rebates and discounts at higher contracted rates, primarily related to Trulicity, which were partially offset by favorable segment mix across the portfolio. Moving to Europe, strong volume growth of 9% was largely offset by the negative effect of foreign exchange and to a lesser extent price. Volume growth was led by Trulicity, Olumiant and Taltz. In Japan, strong volume growth of 7%, driven by Cymbalta, Verzenio and Trulicity, was largely offset by a drag of 6% from price, as a result of the government mandated price decreases that went into effect in 2018. Revenue in the rest of the world increased 9% on a performance basis this quarter, led by volume growth from Humalog, Trulicity, Cialis, Jardiance and the recently launched Tyvyt, a China-only anti-PD1 immunotherapy agent in collaboration with Innovent Biologics. As shown on slide 12, our key growth drivers were once again the engine of our worldwide volume growth. These products drove 14.8 percentage points of volume growth this quarter, an increase of over 100 basis points versus their contribution to growth in Q4 2018. Brands that have experience loss of exclusivity provided a drag of 530 basis points, driven primarily by Cialis. You may recall, the generic versions of the Cialis entered the U.S. market at the end of September last year, and as expected, we have seen a rapid erosion of sales. When excluding LOE, the rest of our products posted robust Q1 volume growth of nearly 16%. Slide 13 provides a view of our key growth products. In total, these brands generated nearly $2 billion in revenue this quarter, representing 39% of revenue. Trulicity continues to post robust growth, having achieved over 45% total share of the U.S. market, in a rapidly expanding class, that grew nearly 30% this quarter. Similarly, Jardiance posted impressive U.S. share gains in volume growth, now capturing 50% and 64% share of market in total and new prescriptions respective. Both products continue to be the market leaders in their classes. Emgality launch trajectory continues to be strong, with nearly 33% share of market for new prescriptions in the U.S., an increase of almost 13 share points from where we finished 2018. We expect increasingly strong performance in the U.S., combined with best-in-class access to drive meaningful sales contribution in the second half of 2019. Continuing with our non-GAAP explanations on Slide 14, foreign exchange rates had a modest impact on our revenue, but a more meaningful impact on cost of sales, due to the effect in last year\\u2019s quarter, resulting in the mid-single digit impact of operating income and EPS. Turning to our 2019 financial guidance on Slide 15, you will see that we maintained non-GAAP-pharma-only expectations we shared in February. And with the Elanco exchange offer complete, are now providing EPS on the same basis. Our non-GAAP earnings per share range is $5.60 to $5.70, an increase of $0.05 versus our previously issued guidance range, which included Elanco. While the line items remain unchanged from the previously communicated pharma-only expectations, I\\u2019d highlight two items that impact our outlook for the remainder of 2019. First, we will manage expenses to deliver within our SG&A range, while investing thoughtfully to drive continued revenue growth. And second in Q1, OID benefited from mark-to-market equity gains and our tax rate benefited from a net discrete item. We are maintaining our full year outlook for these items, however, as these items are highly variable and it is early in the year. Touching briefly on our updated GAAP guidance, we expect earnings per share to be in the range of $8.57 to $8.67, which includes a $3.7 billion gain on the disposition of Elanco recorded in discontinued operations. On Slide 16, we provide an update on our recent activity regarding capital allocation. Consistent with our strategic priorities, we spent over $8 billion on initiatives to drive future growth. In addition to investing in internal R&D, we closed the Loxo Oncology acquisition which augmented our pipeline, and returned over $4 billion of cash to shareholders. As Dave mentioned earlier, we completed the successful divestiture of Elanco this quarter via an exchange offer. We exited Elanco at an attractive price and recognized a $3.7 billion gain on the disposition. In addition, the exchange offer was substantially oversubscribed, and resulted in earnings accretion in 2019, from retiring Lilly shares. As we have returned to growth, our confidence in our business outlook has been reflected in meaningful dividend increases in 2018 and 2019. As we move ahead, our ability to continue to generate strong operating cash flow supports our pursuit of external innovation to enhance our long-term growth and create shareholder value. Now I will turn the call over to Dan to highlight our progress on R&D. Thanks Josh. Slide 17 shows select pipeline opportunities as of April 24. Movement since our last earnings call includes, the regulatory submission of Trulicity rewind data for CV outcomes label in the U.S. and Europe, submission of our Connected Care prefilled insulin pen for Type 1 and Type 2 diabetes in the U.S., submission of a fixed-dose combination of empagliflozin. linagliptin and metformin XR, for type-2 diabetes in the U.S. and submission of Ultra Rapid Lispro from type-1 and type-2 diabetes in Europe and Japan. We also highlight the initiation of Phase 2 testing for our IL-33 monoclonal antibody and immunology. The initiation of Phase 1 testing for three new molecular entities, including our GIP, GLP glucagon tri-agonist, and the attrition of two Phase 2 molecules. With the submission of Ultra Rapid Lispro, we are now on track to deliver 12 NME approvals since 2014. Therefore, a common question I get is, what\\u2019s next? As we replenish our late-stage pipeline, in the past 12 months we have made four big innovation bets with mirikizumab, pegilodecakin, our recently acquired RET inhibitor and tirzepatide. Moving to Slide 18, mirikizumab is our IL-23 in Phase 3 for psoriasis and ulcerative colitis, with expected data readouts in 2020 and 2021 respectively. We see first-in-class potential for ulcerative colitis, a disease with high unmet need in growing incidence, where we saw strong Phase 2 efficacy and clinical response and endoscopic healing. Based on positive Phase 2 data in Crohn\\u2019s disease, which we will be presenting in a few weeks at DDW, we are now moving quickly into Phase 3 for Crohn\\u2019s disease yet this year. Pegilodecakin is our first-in-class PEGylated IL-10 from ARMO Biosciences. We see strong biological rationale and single agent activity in renal cancer. There\\u2019s also an intriguing signal in combination with both chemotherapy and checkpoint inhibitors in several tumor types. We are looking forward to data readouts from the Cypress-1 and Cypress-2 non-small cell lung cancer studies by the end of this year, as well as the Phase 3 pancreatic cancer trial in 2020. We will also be starting a clinical program in renal cell carcinoma this year. Our most recent late stage entry is our potential first-in-class and best-in-class RET inhibitor from Loxo Oncology. Currently in the Phase 2 portion of the LIBRETTO-001 study, we look forward to having both additional data readout and a regulatory submission by the end of this year. This molecule has received breakthrough designation from the FDA for three indications, RET fusion positive non-small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion positive thyroid cancer. We are excited about the data we have seen to-date, which has shown robust response rates and encouraging response durations. We look forward to presenting new data at a medical meeting in the second half of this year. Finally, tirzepatide, our novel first-in-class and best-in-class GIP, GLP dual agonist twincretin, which started its Phase 3 SURPASS program in late 2018, on the heels of presenting impressive Phase 2 results in October at EASD. We believe tirzepatide could provide levels of efficacy not seen with existing products. All SURPASS studies for the global submission should start by the end of the year, with data expected in 2021. We also expect to initiate Phase 3 studies in obesity and a Phase 2 study in NASH later this year. We look forward to presenting new data at ADA in June on tirzepatide, including the additional dose escalation data from a Phase 2 trial in diabetes, data from a Japan clinical trial and new biomarker data from our Phase 2 trial supporting potential efficacy for NASH. We are excited about this cohort of innovative first-in-class, late-stage assets each with the potential to improve the standard of care across immunology, oncology and diabetes. We look forward to what\\u2019s next from these assets as they achieve important milestones and readouts over the next 12 months. Slide 19 shows a tally of a significant progress we have made since our last earnings call on key events we are monitoring for 2019 including submissions across four key line extensions or NMEs that I described earlier, the regulatory submission of Emgality for episodic cluster headache in Europe, positive results from CAROLINA CV outcome study of Trajenta, positive results for a Phase 3 study of Taltz for non-radiographic axial spondyloarthritis. Results from two Phase 3 studies of Tanezumab, the first in patients with chronic lower back pain and the second a long-term safety study in patients with osteoarthritis pain. Positive results from a Phase 3 study of Cyramza for first line EGFR non-small cell lung cancer. We also note that we received notification that for technical reasons the FDA has refused to file the supplemental NDA for Empagliflozin in type 1 diabetes and that we have made a decision to not pursue the development of Olumiant for psoriatic arthritis. In addition to the late-stage highlights I shared with you today, we are growing our early stage pipeline through both enhanced internal productivity and external innovation. We will highlight several examples in upcoming earnings calls. Now I will turn the call back over to Dave for some closing remarks. Thanks, Dan. In the first quarter, we delivered strong volume based revenue growth of 5% on a constant currency basis, driven entirely by our key growth products. We made strategic investments in commercial and late-stage products, which will enhance our future growth prospects. We have seen good pipeline progress this quarter, including a number of regulatory submissions. In addition, we bolstered our early phase pipeline by advancing multiple assets into the clinic and signing research agreements. We also completed two significant transactions that will allow us to simultaneously focus the business and accelerate our pipeline of innovative medicines, the disposition of Elanco and the acquisition of Loxo Oncology. Finally, we returned over $4 billion to shareholders via the dividend and share repurchases. Speaking for the entire team at Lilly, we remain incredibly excited about the prospects in front of us to reach millions of people, who need better medicines for difficult diseases. And we are eager to continue to execute on the growth opportunity in front of the company. This concludes our prepared remarks and now I will turn the call over to Kevin to moderate our Q&A. Thanks, Dave. We would like to take questions from as many callers as possible. So we ask that you limit your questions to two or to a single question with two parts. Karen [ph], please provide the instructions for the Q&A session. And then we are ready for the first caller. [Operator Instructions] We will go to the line of Chris Schott from JPMorgan. Please go ahead. The first one from me was just elaborating a little bit more on Trulicity dynamics this quarter, particularly as you think about price as well as to make sure I heard the comments in the prepared remarks properly. But how should we be thinking about net pricing and the overall pricing environment for Trulicity in 2019? And were there any one-time impacts or true-ups of rebates for Trulicity this quarter? My second question is really quick one on Emgality, and just how we should we be thinking about where net pricing is going to shake out for this one. And should we think about second quarter results reflecting maybe more normalized gross to net then we saw with the Q1 result? Thanks very much. Thanks, Chris we will go to Enrique for Trulicity and then Christi for Emgality. Chris, thank you for your question allow me to provide some color on Trulicity\\u2019s overall performance. We continue to be very excited about the underlying business fundamentals of the product. When we look at volume growth, we are basically the beneficiary of very strong share growth. We are now sitting at 46%, which is an all time high for Trulicity and with the tailwind of very significant class growth now sitting at 30%. Something to note is that when we look at sequentially volume while scripts basically increased for Trulicity from Q4 of 2018 to Q1 of 2019 by about 5%/6%, our actual shipments declined by 7%. So I want to make sure that we are looking at the underlying business fundamentals and not necessarily just some shift in retail or wholesale inventory dynamics. When it comes to pricing, there hasn\\u2019t been a step change, when it comes to pricing. I think of course, we see pricing pressures across all diabetes categories. But it\\u2019s important to note that our price this quarter was comparable to our price in Q4 of 2018. Now what we basically see in terms of pricing is relative to Q1 of 2018 is higher rates, when it comes to managed care and rebates. Growth in highly rebated segments, whether it\\u2019s the Department of Defense,VA and so forth. And then we also had a negative impact due to changes in the estimates for rebates and discounts. And Chris on Emgality, your question on net pricing and will be more normalized on Q2, what we saw in Q1, first of all, on-demand, very excited about the fact that we are now the number two CGRP passing a JV in both new prescriptions and total prescriptions. And we are on track in Q2 to pass Aimovig in new prescriptions. As we look at the net, we saw a higher than typical free goods as reimbursement was coming on. To give you a little bit of flavor the first quarter had a 57% of commercial claims were reimbursed. We exited Q1 at 67 or two out of every three prescriptions are claims -- commercial claims being reimbursed. So as the reimbursement comes on in Q2, we should see an improvement in that. Next we will go to the line of Jason Gerberry, Bank of America. Please go ahead. Christi, just to follow up on the Emgality comment I know that a lot of companies in the space of kind of frame second half payer environment is a little bit fluid. So is your comment that where you exited 1Q, should we be thinking about that as a linear trend. Are there any puts and takes going on changes in the reimbursement of CGRP biologics just wanted to get a better sense there. And I guess my follow up probably staying with you AbbVie\\u2019s SKYRIZI got pretty good early access. And so I am just sort of curious, your thoughts winners and losers there either be the established novel interleukins or do you see this as more cannibalization of AbbVie\\u2019s own Humira franchise. Thanks. Sure so, continuing on Emgality in terms of access. First of all, we saw very good receptivity by the payers for this class really given doctors and patients choice. And also not having many if any real restrictions for primary care prescribing. So on the reimbursement side we see the payers coming on board and more and more are coming on board right now our access ending Q1 is 82%. So we do expect that to get better and better over the course of the year. So I hope that answers your question there. On SKYRIZI, the data on SKYRIZI is as expected and as we look at tolerability to compete, the competitive landscape that we environment that we are in really doesn\\u2019t change access is very similar SKYRIZI and Taltz all of the newer agents really coming to market and helped increase the expectations of patients and doctors should have on really skin clearance. And so it\\u2019s a competitive marketplace, but we like our chances because with Taltz in the dermatology office we know clear skin, very fast and it lasts up to five years, we have seen data that sustained and no new safety signals. And we also have the head to head versus an IL-23 that will be coming out this year which will demonstrate that speed and clearance at 12 weeks and 24 weeks for the IL-23 really show their peak efficacy. So we are looking forward to that and in rheumatology we will continue to compete there as we just released our head-to-head data versus Humira showing superiority and then later this year, being able to look at the regulatory approval of AxSpA. So the competition is fierce, but our chances and our add with Taltz are extremely good. And we don\\u2019t care huge difference in the landscape because of really coming in. Seamus Fernandez from Guggenheim. Please go ahead. I am sorry. One moment. Yes go ahead please. So just a couple of quick questions. As we think about the evolving competitive landscape in the insulin space. We have seen Humalogtake up quite a bit of share in a short period of time. And then there\\u2019s also the threat of potential biosimilars reaching the market in the next couple of years. The evolving landscape and how that potentially impacts your portfolio as it relates to Humalog or also for the long-acting insulins going forward. And then just a second quick question for Dan. You guys have some data on your ERK inhibitor at ASCO, just hoping that you could give us your thoughts on data coming at ASCO for that product and perhaps any other datasets, that you think we should be watching for. Thanks. Thank you, Enrique, if you want to answer the insulin question we will go to Dan. Sure. Clearly, there\\u2019s -- there are new competitors in the insulin space, I think, in the case of EADVI think it\\u2019s important to reflect that their most of their share gains really have been driven and managed Medicaid outside more look and Humalog of management are -- our overall script are basically flat, clearly there is an evolving landscape, when . it comes to insulin with the potential entry of other insulins follow-ons. As you know the insulin categories are going to be transitioning to BLAs in the 2020 timeframe. Clearly, there\\u2019s questions about interchangeability and when is that going to play out as we said in the past, we don\\u2019t view interchangeability or something imminent. We eventually think, this is going to happen, but it needs to be more clarity. So this is likely something that won\\u2019t happen before 2021. Now, it\\u2019s difficult for us to predict when insulin follows up will come into the market in particular in the U.S., given that some of these products have expressed certain expectation when it come to launch timelines, but have been delayed. Importantly, to note as well is that we continue to evolve our overall instrument strategy and we like to say that we are reimagining insulin systems and an insulin delivery with by basically bringing in a connected care platforms to be able to improve patient outcomes in a much more meaningful way. So we are excited about our overall innovations with systems connected care, but also bringing new insulin like our Ultra Rapid Insulin Lispro that we are developing. Yes, thanks for the question on our ERK inhibitor. This is a Phase 1 program, but it\\u2019s still very early, but we are pretty excited about it. The reason that we are excited about this pathway is because the MAP Kinase pathway is implicated in driving about 30% of solid tumors. So it\\u2019s a great opportunity to drive that pathway. At ASCO, we have a couple of presentations on the ERK inhibitor, including some of the early Phase 1 data in a variety of patients and some data in lung cancer patients as well. So we look forward to being able to share that, but again it\\u2019s a early program. I think we have a few other disclosures ASCO, but we are excited about, turn it over to Anne to comment on late-phase disclosure. Yes. So one of the disclosure that we are very excited about at ASCO is the results of our EGFR mutation positive first-line lung cancer study in CYRAMZA. So this is the RELAY Study and we shares top line data in March that the study was positive and met the primary endpoint of progression-free survival. So we will be submitting to regulators globally midyear and approval on this would make the six indication that we have achieved for Cyramza. Importantly, we are excited about the data and we look forward to this oral presentation at ASCO. Also there\\u2019s currently the standard of care in this setting and we know that our magnitude of benefit must be competitive with that. We look forward to providing more answers for patients in the setting and also providing more options for physicians as they look to sequence therapy for the best outcomes for their patients. So we look forward to sharing more with you at ASCO. And next we will go to Tim Anderson with Wolfe. Please go ahead. On the rewind data for Trulicity coming up at ADA without running the data. Can you just talk about your level of excitement and if this is the data where once just presented you think the prescriber community is going to say well, that\\u2019s really a game changer? And then second question on Tanezumab, I think a lot of investors see this program is probably dead based on the latest data disclosure from you and Pfizer. Can you just share your perspective? So we will go to Enrique on rewind, and then Dan, you want to talk about the tanezumab results. Yes. We continue to be excited about the rewind results for Trulicity. I am going to -- I have a plug here for my Investor Relations colleagues that we have an investor, we are planning on in new investor call at the ADA post disclosure of rewind we saw. Also, we hope to either see you there. Hope there you can either connector be there in person. Yes. Great, thanks for the question on tanezumab. Before I address your question on the future tanezumab, I think it\\u2019s important to comment on why we entered into this partnership with Pfizer and why we have pursued this program. It\\u2019s obviously because of the dramatic unmet medical need here. There are nearly 60 million Americans suffering with chronic pain from osteoarthritis and chronic lower back pain, many of whom have moderate to severe disease and aren\\u2019t getting relief from currently available therapies. When you put that in the context of the drawbacks of the therapies that are currently available, including in many cases opioids, you can just understand how important it is to have new non-opioid mechanisms to address pain. So that\\u2019s why we entered into this program and as we said before, we entered in, with a high level of confidence on the efficacy of this mechanism. But what we saw to discharge was the safety risk through this program. And so that brings us to the final study, which of course was designed to fully understand the safety risk of this mechanism that reason in the study enrolled a different population of patients and we enrolled in the others, we wanted to compare to NSAIDs and therefore we had to enroll patients, who were getting some measure of relief and it is tolerate chronic NSAIDs. So we are continuing to analyze the results from that study from 10.58, we are looking at that so in the context of all of the available data on tanezumab. Our plan then is to discuss the totality of the data with regulators in the coming months and that will help us decide on what the next steps are, and then we will be able to share an update with you when that\\u2019s globally. Next we will go to the line of Geoff Meacham from Barclays. Please go ahead. For Dan on the Olumiant and atopic derm, what do you guys see as differentiation in the data so far among the JAKs. I know you still have some data coming up. And in this indication is your view from the field how attractive oral options are versus injectables. And then just a real quick one for Enrique on Trulicity, just wanted to ask your view of the class growth differences in the U.S. versus O-US and how durable says, I know this has been a big driver in independent of the share gains that Trulicity has gotten over the years. Thank you. Thanks, Geoff. So Dan and then we will go to Christi. Okay, maybe I will start with the comment on differentiation and toss it to Christi for the commercial insights on patient interest and in an oral here. Although I should just say it\\u2019s premature to speculate differentiation versus other molecules where we haven\\u2019t seen the full data from theirs or even ours. But we are excited about the opportunity to be first year in atopic derm. Christi? Yes, exactly, right now DUPIXENT is available, but it\\u2019s an injectable for the more severe type of atopic derm and there\\u2019s so many more patients out there suffering millions of patients. In fact, our dermatologist tell us atopic derm space reminds them of the psoriasis space about 15, 20 years ago. So we do think it\\u2019s a large opportunity and we do plan to be the first JAKs to market. We have released on the fact that our first two studies were positive. You probably saw that we have three more studies to read out this year and then based on the totality of that data, if they continue to be positive. We will be submitting next year. So when it comes to Trulicity class or GLP-1class growth, I think we see the same dynamics in most markets, the drivers are similar, which is the updated guidelines that having recently released. So when we look outside of the U.S., we are GLP-1class growth is in the mid \\u201820s, given the maturity of the class in the U.S., it is impressive that the growth in the U.S. is even higher than that, but it\\u2019s very exciting to see and as a corollary to that, I think the Trulicity\\u2019s performance is very consistent across many markets. Next we will go to the line of Andrew Baum from Citi. Please go ahead. Just going back to SKYRIZI for the first question. What\\u2019s your first-line market share for Taltzin psoriasis and do you expect to be able to grow it now that\\u2019s SKYRIZI has been introduced into the market. I am obviously referencing Avi\\u2019s enormous rebates influence as well as the profile of that drug and what it may mean for the contraction of the more refractory lines of therapy? And then second, perhaps Dave could comment on the timing and the impact of the proposed rebate reform on your diabetes business expressly on the near-term impact for realized pricing because of the Medicare math, assuming it does get implemented at the beginning of next year. Many thanks. Thanks, Andrew, so we will go to Christi for the comment on SKYRIZI and then, Enrique, if you want to talk about the impact on diabetes so then proposed rebate Safe Harbor world. Yes, so in dermatology specifically, our total prescriptions are a little over 15% and we do see growth continuing absolutely, we see actually with the new therapies that have come to market. It actually has increased the market growth, so right now the market is growing at 13%. And the more of the newer agents coming to market, I think the more, you will see the older TNFs be used for short periods of time or potentially not used first line in the future. And so we do see our growth coming from the fact also our ability to compete in dermatology. So the SKYRIZI versus Taltztop to head will be another place for us to go five year data sustained efficacy and we really are the only one that\\u2019s had been able to show not only clear positive 100, but the ability to do it fast and one to two weeks and that sustainability. So our growth continues and we continue to see have very high confidence that growth will continue. The biggest impact from the proposed rule is really at the patient level, because patients will have access to medicine side to more affordable prices. And if you take that threat forward, I think what you will basically see is better appearance, and I think that\\u2019s something that we all want when it comes to healthcare, which is better appearance to medicine. So the impact that is not often talked about is really, when it comes to maybe an impact on volume. When it comes to some of the mechanics and so forth honestly, I view pretty neutral overall. Let me just jump in Andrew, on both of those points. I think it\\u2019s important to note in psoriasis two things, one that there\\u2019s four stepping through TNFs for almost every patient, if that were to change, I think that\\u2019s a big positive for the newer innovation, so the doctors can select appropriate therapy for patients with psoriasis noting that TNFs don\\u2019t work nearly as well as in the new classes and amongst those we think tells us the best profile. Also within derm, there\\u2019s a lot of switching anyway, so the front-line market is versus the total is much smaller than other immunology indications. That\\u2019s an important thing to keep in mind. On the rebate rule we do, we are planning for implementation January 1, I think Enrique rightly notes that the volume upside, the thing I would worry about is rate compression because presumably you would have more facial transparent pricing. But I think across our portfolios, because of the hike consolidation on the payer side, the rates are pretty compressed already. There aren\\u2019t big differences between what the payers are paying. So that\\u2019s why we lean into this one, we think it\\u2019s the right policy answer to help seniors with medication costs and to shift the debate from list pricing to net pricing, which we see as our long-term interests. Thanks for your questions, Andrew, next caller please. I will go to Vamil Divan from Credit Suisse. Please go ahead. Hi. Great. Thanks for taking the questions. So just first on Olumiant, I think, I asked this question before, but just the U.S. opportunity there against our limited sales this quarter. I think you said in your prepared remarks, you are not going to be filing for psoriatic arthritis, just correct me if I miss heard that? And I am just, I guess, on how you think about getting the 4-milligram to the market and so the opportunity in the U.S. for that product and also the implications from the data of Pfizer recently released from their long-term trial showing some additional question on thrombosis? And then the second one, just following up on the psoriasis questions, you mentioned mirikizumab and the data there in psoriasis, I know you said you will be first in GI, I am just curious what the differentiation of any would be in psoriasis for that product or is it really more just a GI focus we should think about? Thanks. Thanks, Vamil. We will go to Christi for Olumiant Americas questions. Okay. So for Olumiant, yeah, I think, what we see in the U.S. is it will be slow and steady in Olumiant 2 milligrams RA. Your question about psoriatic arthritis, you did hear correctly, as we look at the opportunities for us to be best-in-class, first-in-class and really enter market with unmet need. In psoriatic arthritis in the ankylosing spondylitis non-radiographic expire as well. We already have Taltz and Taltz has shown very remarkable results and so we feel very good with that play as we look to study Olumiant and other indications like atopic dermatitis. Remember Lupus got Fast Track designation in December. We are studying both 2 milligrams and 4 milligrams in that indication, as well as atopic dermatitis and we have our alopecia areata study where Phase 2 will readout later this year and if positive we will move to Phase 3. So we are still very big on the opportunity of baricitinib as a whole, the RA 2 milligrams will be slow and steady growth and 4-milligram is being studied and we looked at CD efficacy results there and bring it to market if they are positive. In regards to the Pfizer question about what readout in their Jack high dose. So we -- as we look at the data that we have and 55 countries that have approved Olumiant, we haven\\u2019t seen unusual safety signals in DTEs and we continue to study, obviously, post marketing research that we are doing in collaboration with agreement with FDA both on real world evidence and in randomized clinical trials, those will continue as well. So no news on -- no unusual news on our Taltz and Olumiant like the Pfizer announcement. And then lastly on mirikizumab, so, yes, we are in Phase 3 studies with both psoriasis and ulcerative colitis, we are very excited about the GI space because mirikizumab should be the first IL-23 to ulcerative colitis. We also finished our Phase 2 data on Crohn\\u2019s disease that data will be released at DDW in just a few weeks here in May. So look for that. And then, yes, in psoriasis we are doing a Phase 3 clinical trial with some competitive endpoints in head-to-head data. So when that study reads out we will be looking to see if we can have stronger and more sustained results then current IL-23 in the market. Vamil, thanks for your questions. Next caller please. And next we will go to Umer Raffat from Evercore. Please go ahead. Hi. Thanks so much for taking my questions. First, can you quantify for us what percentage of TRx are paid versus free on Taltz, as well as Emgality? And secondly, I noticed one of the trials reading out for you this fall, the IL-10 plus Opdivo trial in second-line lung has been shrunk from 100 down to 50 patients. Is that simply a function of increasing Keytruda use in first-line or is there another dynamic here as well? Thank you very much. Okay. Thank you. We will go to Christi for the questions around Taltz and Emgality and then Enrique will talk about pegilodecakin. Sure. First of all, Lilly believes in really open access and giving choice to patients and physicians. So we continue to work with payers on access with Taltz. In spite of that, we -- the barriers that we have had -- we had very good uptake with Taltz and as we look at our programs, patient specific, copay cards, et cetera, being able to allow patients on drug and then transition to insurance coverage, we see that two-thirds of patients in the market on Taltz are paid for. On Emgality, as I said before, the commercial claims that have been submitted, we see in Q1 that 57% of those have been reimbursed. And as we exited Q1, we saw that in the mid \\u201860s, two out of every three patients that submitted a claim we had reimburse coverage for. Thanks, Christi. Yes. On the question on pegilodecakin, this is the Cyprus 2 study referring to. So this is a second-line lung study, its Phase II study IO-naive patients. So following first-line treatment, but not in immunotherapy and then it\\u2019s in combination with Opdivo in low expressers. And what we are finding, as you know, well, is that IO-naive patients in the second-line are becoming increasingly rare. So what we decided to do was analyze that data and have that inform the next steps for the program. But not continued to further enrolled patients in this somewhat diminishing population. We have remain confident that the greatest opportunities for pegilodecakin remain in lung cancer, both in the first-line setting and in later lines, and also in renal cell cancer. So as Dan mentioned, we will be starting a renal cell study later this year. But we look forward to readouts in lung at the end of this year and then also in pancreatic cancer early next year and remain confident in the opportunities for pegilodecakin across those tumor types. So I look forward to hearing more towards the end of the year, both on Cyprus 2 and on the Cyprus 1 study, which is in the first-line setting. Thanks, for the questions Umer. Next caller, please. And we will go to David Risinger, Morgan Stanley. Please go ahead. Yes. Thanks very much. I have two questions. The first is for Dave. I am hoping that you can help us understand a little bit better, how you are thinking about the forthcoming HHS action on the elimination of rebates and how that will negatively impact companies that use volume based discounts such that a product like Taltz will be able to step up on the formulary and maybe move into a formulary position that another larger player held in psoriasis? And then second, Enrique, with respect to Trulicity, just hoping that you can help us with a little bit more of a bridge. So you said that, Rx increased sequentially by 5% to 6%, actual shipments declined by 7%. So does that mean there was an inventory work down of 12% to 13% and could you also quantify the negative dollar change in reserves? Thank you. Thank you, Dave, and then Enrique. Yes. Thanks, Dave. So on the rebate rule, again, we are planning for this January 1, of course, it\\u2019s Part D, there are some legislative efforts to look at regulating commercial market. I guess, at this point, my speculation would be that looks more challenging either for political or practical reasons. But I do think once Part D changes and I think we are, as I said, planning toward that, you will start to see increased interest from payers that are not in the government systems or commercial payers to have similar benefits provided to their beneficiaries, particularly in chronic disease where list price effects have a lot of distortion and increased out-of-pocket costs and we have all heard the upgrade around that really centered on insulin, frankly. So I think your logic is the right one in the sense that today with rebates which are not share with patients and confidential payers have a strong incentive to keep those confidential and use those to compete on premiums, that\\u2019s the way it works. I think in the future world where that can\\u2019t be the way they use those rebates, they will need compete for premiums in other ways, efficiency, presumably, and patients will have a choice at the counter based on net pricing. I would assume the doctors are informed about those net prices and that also becomes an influence on prescribing. So for new innovative therapies hypothetically one in specialty market or in a general practitioner market like Emgality, I think that will be an important part of any company\\u2019s strategy to understand the net price that will officially be there for the consumer. The final comment is, of course, Part D is senior program. So the demographics will affect us mostly in our diabetes franchise initially and that\\u2019s where a lot of our planning is focused right now. Thanks, Dave. Enrique? Whenever we look at sequential growth you -- there\\u2019s a lot -- what I call the colloquially a double whammy effect. So we could be double counting here is not to simply add up. One good way to think about it is just if we were to shift 5% of the units from Q4 to Q1 that that explains 10 percentage points of difference, but in reality we are only shipping 5% of units from one quarter to another. That\\u2019s a long way of saying that, I will have your estimate likely the -- we don\\u2019t have full visibility into the retail inventories, but my assessment is about 6 points. Thank you. Dave, thanks for the questions. Next caller please. And next we will go to Steve Scala from Cowen. Please go ahead. Thank you. I have a couple of questions. We were expecting Verzenio data in 2019 from MONARC Her and MONARCH plus. I am wondering if there still on track. And then, secondly, Enrique, one of the concerns with the upcoming rewind readout is that the benefit might be driven by the 30% or so of patients in the trial with pre-existing cardiovascular disease and that the remaining patients add little to the overall outcome. So, overall, the benefit might be a solid but unspectacular 20% or so reduction in risk, which won\\u2019t offer opportunity for differentiation. I am just wondering, can you tell us not to be concerned about this point? Thank you. All right. We will go to Anne for the question on Verzenio and then Enrique on rewind. Yeah. So you are correct. So we are looking to deliver our new data to drive additional growth in one of them the HER-2 positive study, which we will report results on towards the end of the year at a medical meeting. The MONARCH 2 overall survival data will readout as we had communicated in the past in 2020. And then we also have importantly the adjuvant study reading out in 2021. And I appreciate asking about Verzenio because there has been an encouraging start to the year. The revenue grew 30% over Q4 and we also are seeing nice uptake across Japan and European markets. So we look forward to these additional data readouts helping contribute to that message. But look forward to those readouts coming as we had communicated in the past. Thanks, Anne. Enrique? We are unable to provide additional comments on rewind, but look -- we look forward to seeing you at the conference call. Thanks, Steve. Next caller, please. Thank you. Next we will go to the line of Alex Arfaei, BMO. Please go ahead. Okay. Thank you and good morning. On tirzepatide, your -- good to see the program formally, I guess, extended in obesity and NASH. Regarding your Phase 3 obesity trial, could you give us a little bit more color in terms of the outcomes you are looking forward the competitor are you using and the potential readout? And you mentioned you have dose titration data at ADA, can you comment on the extent to which that data shift you dosing for the Phase 3 trials, particularly the high dose? Thank you. Enrique? Yeah. So we are very excited about the tirzepatide and being able to start our Phase 3 Type 2 diabetes study and basically pursuing both obesity in Phase 3 and NASH in Phase 2. We are not providing additional color on the specific obesity trials that we are conducting -- that we plan to conduct. Clearly we need to have the appropriate discussions with the FDA as we engage in this Phase 3 trial, but we plan to do sometime -- that sometime in the future. And as far as the titration question, yes, we do plan to have presentation at ADA, looking at some of the additional titration data for separate thing. Thanks for the questions, Alex. Next caller, please. Thank you. Next we will go to Louise Chen, Cantor. Please go ahead. Hi. Thanks for taking my questions. So my first question is on mirikizumab, you had mentioned that you will likely be the first to IL-23 to marketing you see in Crohn. I am just curious in addition to that, what are the competitive advantages do you see as it relates to other ILs and about and also Jack? And then the second question I had was on LOXO-292, you showed very good ORR median duration percentage of patients on therapy. How do you think that will hold up into the Phase 2 readout and how do you think you might compare with other RET inhibitors in development? Thank you. Thanks. We will go to Christi for mirikizumab and then Anne on RET inhibitor. Thanks Louise for the question on miri. So, to be clear, we expect to be first in to the market on ulcerative colitis and first of a couple to market on Crohn\\u2019s disease. So, you never know, we have been speeding up the Phase 2 trial and look forward to entering the next, but that\\u2019s where we are on GI. We are very excited, because our studies are set up to be best-in-class and so if they read out positively, we expect to not only be first-in-class or best-in-class in ulcerative colitis and Crohn\\u2019s disease. Thanks, Christi. Anne? Yes. When we have thoughts on the Loxo question, when we start to move into precision medicine and to obtain a RET inhibitor, we really thoroughly survey the landscape and selected the molecule in the portfolio that we believe to be first and best-in-class, and we continue to believe that today. We intend to submit in the U.S. by the end of the year end in Europe shortly thereafter. So to answer your question, we remain very confident in the efficacy, safety profile and the duration of our RET inhibitor. And we will continue to expect that will deliver first in both lung and thyroid cancer. So we are actually be having -- we are presenting an update on the registrational data in the second half of 2019 at a major -- a couple of major medical meetings in advance of that potential regulatory filing. And importantly, as you look at this data set, we now have over 400 patients enrolled across tumor types with RET fusion or mutations. And so we fully expect the data to continue to bear out what we saw last year, which is in response rates, as you said, from 60% to 80%, with well over 90% of patients remaining on study. This is the data reported last year and then we will provide an update later this year. Thanks, Anne. Louise, thanks for your questions. Next caller, please. Certainly. [Operator Instructions] Next we will go to Navin Jacob from UBS. Please go ahead. Hi. Thanks for taking my questions. So, number one, I just wanted to -- I am sorry to beat a dead horse on GLP-1 pricing. But Enrique, if you could just dig in a little bit further, just wanted to understand in Q1 of this year, how much of the lower price was related to Medicare Part D on whole changes versus other rebate related changes, because you mentioned that there was rebate estimate adjustments, I want to understand is that a one-time impact for accrual accounting related issues or is it something that we should be thinking about as continuing on going forward. And so, overall, just wanted to understand, where is the GLP class going in terms of pricing, is there going to be continued pricing pressure over the next couple of years? And then, secondly, just on op margins, if you could help us understand longer term where the op margin profile for the human health business will look like. Can we expect margins to reach mid-to-high \\u201830s in line with some of your other peers? Appreciate the help. Thanks, Navin. We will go to Enrique for Trulicity. Then Josh on the op margin question. Yeah. So I just first to address the question about the doughnut hole. The doughnut hole becomes a little more important in Q2, I don\\u2019t have the numbers in front of me, but in the case of diabetes medicines maybe Q1 is maybe only about 10% of the overall doughnut hole from an accounting perspective, what we are going to see throughout the year. So when we think about Trulicity, while there was some impact of the doughnut hole. It was not material to the pricing results. As we -- as I mentioned, when we look at Trulicity, we do have high rebates in managed care and so forth relative to Q1 of last year, the change is due to estimates -- change in estimates for rebates and discounts. That -- yes, that is basically changing because of how we had accrued them based on a full review of the claim that we received later basically changes the information that we have on hand and we need to account for that as soon as we know that information. So, yes, that is a particular impact that was from other quarters that basically is impacting this particular quarter. So that\\u2019s probably as much detail as I can provide. Thanks, Enrique. Josh? I mean on operating margins for the quarter, we were slightly above 26%, our guidance for the year is to be at 28% we are confident we will get there. I think you will see through the remainder of the year that we will see if power guidance topline growth netting out currency effects similar to what we are seeing this quarter and we will see sort of the operating expenses at a more constant absolute level than what we are seeing in Q1. So we are confident in our 28% for the year. And then for 2020 our goal is 31% and we are confident as well in achieving that. That\\u2019s for pharma only, so that\\u2019s on our new basis excluding Elanco. We see good opportunity to get to the 31%. So we are no change there. I think if you look past 2020, we would expect margin expansion to continue. We have a limited patent expirations in the first half of the next decade and we still have the new products that we are launching now will still be in their growth phase. So we definitely see margin expansion opportunities post 2020. But we haven\\u2019t given a specific goal. Thanks, Josh. Next caller, please. There are no further questions in queue at this time. Dave Ricks, please go ahead. All right. Thank you. Thank you all for joining us and we appreciate your participation in today\\u2019s earnings call and your interest in the Eli Lilly and Company. We began 2018 with a lot of momentum and we made meaningful progress in our first quarter. Although, Q1 was a period of investment, we remain committed to our revenue and profitability goals for 2019 and 2020. We continue to advance our innovation-based strategy to progressing internally discovered medicines, augmented with external innovation. We completed two transformative transactions this quarter as well, with the full separation of Elanco and the addition of Loxo Oncology. With a robust pipeline and volume driven revenue growth Lilly continues to be a compelling investment. Thanks again for dialing in. Please follow up with our IR team if you have additional questions that were not addressed on today\\u2019s call. Have a great day. Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"vader_mean\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.05544049760476355,\n        \"min\": 0.08683901689708141,\n        \"max\": 0.375169176882662,\n        \"num_unique_values\": 314,\n        \"samples\": [\n          0.3060629473684211,\n          0.26113011494252875,\n          0.27128275154004106\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"vader_pos_share\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.06581522211558521,\n        \"min\": 0.3526490066225166,\n        \"max\": 0.7110332749562172,\n        \"num_unique_values\": 311,\n        \"samples\": [\n          0.4626865671641791,\n          0.5228310502283106,\n          0.5819935691318328\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"vader_neg_share\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.033975243027520405,\n        \"min\": 0.0029411764705882353,\n        \"max\": 0.19246861924686193,\n        \"num_unique_values\": 308,\n        \"samples\": [\n          0.08670520231213873,\n          0.0958904109589041,\n          0.06109324758842444\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"vader_neu_share\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.05398752381536704,\n        \"min\": 0.24168126094570927,\n        \"max\": 0.5827814569536424,\n        \"num_unique_values\": 311,\n        \"samples\": [\n          0.41914893617021276,\n          0.3812785388127854,\n          0.35691318327974275\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"avg_sentence_length\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1.9124029282932797,\n        \"min\": 12.62251655629139,\n        \"max\": 31.266025641025642,\n        \"num_unique_values\": 314,\n        \"samples\": [\n          19.004210526315788,\n          17.55862068965517,\n          20.72689938398357\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 16
        }
      ],
      "source": [
        "#Computing features on `content_full` and attaching to the same DataFrame\n",
        "features = (\n",
        "    df_calls['content_full']\n",
        "    .apply(compute_key_features)\n",
        "    .apply(pd.Series)\n",
        ")\n",
        "\n",
        "df_final = pd.concat(\n",
        "    [df_calls.reset_index(drop=True),\n",
        "     features.reset_index(drop=True)],\n",
        "    axis=1\n",
        ")\n",
        "\n",
        "df_final.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 440
        },
        "id": "U6-vDfZtAzKi",
        "outputId": "5d3393ad-8678-41cf-e5a6-646537151901"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "(353, 23)\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "  symbol   shortName chosen_sector           yf_industry  market_cap_billion  \\\n",
              "0   AAPL  Apple Inc.    Technology  Consumer Electronics             4039.41   \n",
              "1   AAPL  Apple Inc.    Technology  Consumer Electronics             4039.41   \n",
              "2   AAPL  Apple Inc.    Technology  Consumer Electronics             4039.41   \n",
              "3   AAPL  Apple Inc.    Technology  Consumer Electronics             4039.41   \n",
              "4   AAPL  Apple Inc.    Technology  Consumer Electronics             4039.41   \n",
              "\n",
              "  report_date  fiscal_year  fiscal_quarter  \\\n",
              "0  2025-10-30         2025               4   \n",
              "1  2025-07-31         2025               3   \n",
              "2  2025-05-01         2025               2   \n",
              "3  2025-01-30         2025               1   \n",
              "4  2024-10-31         2024               4   \n",
              "\n",
              "                                         transcripts transcripts_id  ...  \\\n",
              "0  [{'paragraph_number': 1, 'speaker': 'Suhasini ...           <NA>  ...   \n",
              "1  [{'paragraph_number': 1, 'speaker': 'Suhasini ...           <NA>  ...   \n",
              "2  [{'paragraph_number': 1, 'speaker': 'AI Insigh...           <NA>  ...   \n",
              "3  [{'paragraph_number': 1, 'speaker': 'Suhasini ...         506955  ...   \n",
              "4  [{'paragraph_number': 1, 'speaker': 'Suhasini ...         455679  ...   \n",
              "\n",
              "  vader_neg_share  vader_neu_share  avg_sentence_length        day0  \\\n",
              "0        0.059497         0.416476            17.558352  2025-10-30   \n",
              "1        0.062212         0.394009            18.069124  2025-07-31   \n",
              "2        0.088937         0.381779            16.869848  2025-05-01   \n",
              "3        0.071594         0.318707            17.618938  2025-01-30   \n",
              "4        0.076037         0.283410            17.709677  2024-10-31   \n",
              "\n",
              "   price_return_1day  price_return_3day price_return_5day  bench_return_5day  \\\n",
              "0           0.006303           0.001261          0.000259          -0.024848   \n",
              "1          -0.007080          -0.029323          0.052523          -0.003483   \n",
              "2           0.003859          -0.065835         -0.070635           0.018971   \n",
              "3          -0.007395          -0.027406         -0.025652           0.007494   \n",
              "4          -0.018209          -0.028901         -0.011386           0.026896   \n",
              "\n",
              "       CAR5  volume_change  \n",
              "0  0.025107       0.367998  \n",
              "1  0.056007       0.773104  \n",
              "2 -0.089606       0.097142  \n",
              "3 -0.033146       0.223633  \n",
              "4 -0.038282       0.367514  \n",
              "\n",
              "[5 rows x 23 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-5a71879a-b835-4732-9668-134a56918be4\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>symbol</th>\n",
              "      <th>shortName</th>\n",
              "      <th>chosen_sector</th>\n",
              "      <th>yf_industry</th>\n",
              "      <th>market_cap_billion</th>\n",
              "      <th>report_date</th>\n",
              "      <th>fiscal_year</th>\n",
              "      <th>fiscal_quarter</th>\n",
              "      <th>transcripts</th>\n",
              "      <th>transcripts_id</th>\n",
              "      <th>...</th>\n",
              "      <th>vader_neg_share</th>\n",
              "      <th>vader_neu_share</th>\n",
              "      <th>avg_sentence_length</th>\n",
              "      <th>day0</th>\n",
              "      <th>price_return_1day</th>\n",
              "      <th>price_return_3day</th>\n",
              "      <th>price_return_5day</th>\n",
              "      <th>bench_return_5day</th>\n",
              "      <th>CAR5</th>\n",
              "      <th>volume_change</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>Apple Inc.</td>\n",
              "      <td>Technology</td>\n",
              "      <td>Consumer Electronics</td>\n",
              "      <td>4039.41</td>\n",
              "      <td>2025-10-30</td>\n",
              "      <td>2025</td>\n",
              "      <td>4</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'Suhasini ...</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>...</td>\n",
              "      <td>0.059497</td>\n",
              "      <td>0.416476</td>\n",
              "      <td>17.558352</td>\n",
              "      <td>2025-10-30</td>\n",
              "      <td>0.006303</td>\n",
              "      <td>0.001261</td>\n",
              "      <td>0.000259</td>\n",
              "      <td>-0.024848</td>\n",
              "      <td>0.025107</td>\n",
              "      <td>0.367998</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>Apple Inc.</td>\n",
              "      <td>Technology</td>\n",
              "      <td>Consumer Electronics</td>\n",
              "      <td>4039.41</td>\n",
              "      <td>2025-07-31</td>\n",
              "      <td>2025</td>\n",
              "      <td>3</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'Suhasini ...</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>...</td>\n",
              "      <td>0.062212</td>\n",
              "      <td>0.394009</td>\n",
              "      <td>18.069124</td>\n",
              "      <td>2025-07-31</td>\n",
              "      <td>-0.007080</td>\n",
              "      <td>-0.029323</td>\n",
              "      <td>0.052523</td>\n",
              "      <td>-0.003483</td>\n",
              "      <td>0.056007</td>\n",
              "      <td>0.773104</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>Apple Inc.</td>\n",
              "      <td>Technology</td>\n",
              "      <td>Consumer Electronics</td>\n",
              "      <td>4039.41</td>\n",
              "      <td>2025-05-01</td>\n",
              "      <td>2025</td>\n",
              "      <td>2</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'AI Insigh...</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>...</td>\n",
              "      <td>0.088937</td>\n",
              "      <td>0.381779</td>\n",
              "      <td>16.869848</td>\n",
              "      <td>2025-05-01</td>\n",
              "      <td>0.003859</td>\n",
              "      <td>-0.065835</td>\n",
              "      <td>-0.070635</td>\n",
              "      <td>0.018971</td>\n",
              "      <td>-0.089606</td>\n",
              "      <td>0.097142</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>Apple Inc.</td>\n",
              "      <td>Technology</td>\n",
              "      <td>Consumer Electronics</td>\n",
              "      <td>4039.41</td>\n",
              "      <td>2025-01-30</td>\n",
              "      <td>2025</td>\n",
              "      <td>1</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'Suhasini ...</td>\n",
              "      <td>506955</td>\n",
              "      <td>...</td>\n",
              "      <td>0.071594</td>\n",
              "      <td>0.318707</td>\n",
              "      <td>17.618938</td>\n",
              "      <td>2025-01-30</td>\n",
              "      <td>-0.007395</td>\n",
              "      <td>-0.027406</td>\n",
              "      <td>-0.025652</td>\n",
              "      <td>0.007494</td>\n",
              "      <td>-0.033146</td>\n",
              "      <td>0.223633</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>Apple Inc.</td>\n",
              "      <td>Technology</td>\n",
              "      <td>Consumer Electronics</td>\n",
              "      <td>4039.41</td>\n",
              "      <td>2024-10-31</td>\n",
              "      <td>2024</td>\n",
              "      <td>4</td>\n",
              "      <td>[{'paragraph_number': 1, 'speaker': 'Suhasini ...</td>\n",
              "      <td>455679</td>\n",
              "      <td>...</td>\n",
              "      <td>0.076037</td>\n",
              "      <td>0.283410</td>\n",
              "      <td>17.709677</td>\n",
              "      <td>2024-10-31</td>\n",
              "      <td>-0.018209</td>\n",
              "      <td>-0.028901</td>\n",
              "      <td>-0.011386</td>\n",
              "      <td>0.026896</td>\n",
              "      <td>-0.038282</td>\n",
              "      <td>0.367514</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>5 rows Ã— 23 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-5a71879a-b835-4732-9668-134a56918be4')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-5a71879a-b835-4732-9668-134a56918be4 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-5a71879a-b835-4732-9668-134a56918be4');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-a272342d-ba4d-4c62-b49b-80d99ef34f1b\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-a272342d-ba4d-4c62-b49b-80d99ef34f1b')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-a272342d-ba4d-4c62-b49b-80d99ef34f1b button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_big"
            }
          },
          "metadata": {},
          "execution_count": 17
        }
      ],
      "source": [
        "#Events table: one row per (symbol, report_date)\n",
        "events = df_final[['symbol','report_date']].dropna().copy()\n",
        "events['report_date'] = pd.to_datetime(events['report_date'])\n",
        "\n",
        "#Yahoo formatting (BRK.B -> BRK-B)\n",
        "events['yahoo_symbol'] = events['symbol'].astype(str).str.replace('.', '-', regex=False)\n",
        "\n",
        "#Tickers & benchmark\n",
        "tickers = sorted(events['yahoo_symbol'].unique().tolist())\n",
        "if 'SPY' not in tickers:\n",
        "    tickers.append('SPY')\n",
        "\n",
        "#Download window (buffer so +5 days always exists)\n",
        "dmin = events['report_date'].min() - pd.Timedelta(days=20)\n",
        "dmax = events['report_date'].max() + pd.Timedelta(days=20)\n",
        "\n",
        "#Download prices once\n",
        "data = yf.download(\n",
        "    tickers,\n",
        "    start=dmin,\n",
        "    end=dmax,\n",
        "    progress=False,\n",
        "    auto_adjust=True\n",
        ")[['Close','Volume']]\n",
        "\n",
        "close = data['Close']     #columns = tickers\n",
        "vol   = data['Volume']    #columns = tickers\n",
        "\n",
        "#Compute event-window returns for one row\n",
        "def event_metrics(row):\n",
        "    sym = row['yahoo_symbol']\n",
        "    dt  = row['report_date']\n",
        "\n",
        "    #skip if ticker missing\n",
        "    if sym not in close.columns or 'SPY' not in close.columns:\n",
        "        return pd.Series({\n",
        "            'day0': pd.NaT,\n",
        "            'price_return_1day': np.nan,\n",
        "            'price_return_3day': np.nan,\n",
        "            'price_return_5day': np.nan,\n",
        "            'bench_return_5day': np.nan,\n",
        "            'CAR5': np.nan,\n",
        "            'volume_change': np.nan\n",
        "        })\n",
        "\n",
        "    p = close[sym].dropna()\n",
        "    b = close['SPY'].dropna()\n",
        "    v = vol[sym].dropna()\n",
        "\n",
        "    #Align event date to next trading day\n",
        "    i0 = p.index.searchsorted(dt)\n",
        "    if i0 >= len(p):\n",
        "        return pd.Series({\n",
        "            'day0': pd.NaT,\n",
        "            'price_return_1day': np.nan,\n",
        "            'price_return_3day': np.nan,\n",
        "            'price_return_5day': np.nan,\n",
        "            'bench_return_5day': np.nan,\n",
        "            'CAR5': np.nan,\n",
        "            'volume_change': np.nan\n",
        "        })\n",
        "\n",
        "    i_m1 = max(0, i0 - 1)\n",
        "    i_p3 = min(len(p) - 1, i0 + 3)\n",
        "    i_p5 = min(len(p) - 1, i0 + 5)\n",
        "\n",
        "    #Stock returns (relative to t-1)\n",
        "    r1 = (p.iloc[i0]  / p.iloc[i_m1]) - 1\n",
        "    r3 = (p.iloc[i_p3]/ p.iloc[i_m1]) - 1\n",
        "    r5 = (p.iloc[i_p5]/ p.iloc[i_m1]) - 1\n",
        "\n",
        "    #Benchmark return over same window\n",
        "    b_aligned = b.reindex(p.index).ffill()\n",
        "    rb5 = (b_aligned.iloc[i_p5] / b_aligned.iloc[i_m1]) - 1\n",
        "\n",
        "    #CAR5\n",
        "    car5 = r5 - rb5\n",
        "\n",
        "    #Volume change on day0 vs day-1\n",
        "    v_aligned = v.reindex(p.index).ffill()\n",
        "    vol_chg = (v_aligned.iloc[i0] / v_aligned.iloc[i_m1]) - 1 if v_aligned.iloc[i_m1] != 0 else np.nan\n",
        "\n",
        "    return pd.Series({\n",
        "        'day0': p.index[i0].date(),\n",
        "        'price_return_1day': float(r1),\n",
        "        'price_return_3day': float(r3),\n",
        "        'price_return_5day': float(r5),\n",
        "        'bench_return_5day': float(rb5),\n",
        "        'CAR5': float(car5),\n",
        "        'volume_change': float(vol_chg)\n",
        "    })\n",
        "\n",
        "#Compute metrics & merge into df_final\n",
        "metrics = events.apply(event_metrics, axis=1)\n",
        "events_with_returns = pd.concat([events[['symbol','report_date']], metrics], axis=1)\n",
        "\n",
        "df_final['report_date'] = pd.to_datetime(df_final['report_date']).dt.normalize()\n",
        "events_with_returns['report_date'] = pd.to_datetime(events_with_returns['report_date']).dt.normalize()\n",
        "\n",
        "#Merge onto df_final\n",
        "df_big = df_final.merge(events_with_returns, on=['symbol','report_date'], how='left')\n",
        "\n",
        "#Adding firm metadata from universe\n",
        "if 'universe' in globals():\n",
        "    meta_cols = ['ticker','shortName','chosen_sector','yf_industry','market_cap_billion']\n",
        "    df_big = df_big.merge(\n",
        "        universe[meta_cols].rename(columns={'ticker':'symbol'}),\n",
        "        on='symbol',\n",
        "        how='left'\n",
        "    )\n",
        "\n",
        "    #Move key id columns to front\n",
        "    front = ['symbol','shortName','chosen_sector','yf_industry','market_cap_billion','report_date']\n",
        "    rest = [c for c in df_big.columns if c not in front]\n",
        "    df_big = df_big[front + rest]\n",
        "\n",
        "print(df_big.shape)\n",
        "df_big.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "vLcWTF68Jq6F"
      },
      "outputs": [],
      "source": [
        "def _safe_chunks(text):\n",
        "    \"\"\"Return 3 text chunks: start/middle/end (keeps it simple + avoids 512 token limit bias).\"\"\"\n",
        "    if not isinstance(text, str) or not text.strip():\n",
        "        return []\n",
        "    n = len(text)\n",
        "    if n < 2000:   #Short transcript: just score once\n",
        "        return [text]\n",
        "    return [text[:2000], text[n//2 - 1000:n//2 + 1000], text[-2000:]]\n",
        "\n",
        "def _finbert_probs(text):\n",
        "    \"\"\"FinBERT probs: pos, neg, neu.\"\"\"\n",
        "    inputs = tokenizer(str(text), return_tensors=\"pt\", truncation=True, max_length=512)\n",
        "    inputs = {k: v.to(device) for k, v in inputs.items()}\n",
        "\n",
        "    with torch.no_grad():\n",
        "        logits = model(**inputs).logits\n",
        "        p = torch.softmax(logits, dim=1).detach().cpu().numpy()[0]\n",
        "\n",
        "    #model order: [positive, negative, neutral]\n",
        "    return float(p[0]), float(p[1]), float(p[2])\n",
        "\n",
        "def finbert_features(text):\n",
        "    chunks = _safe_chunks(text)\n",
        "    if not chunks:\n",
        "        return pd.Series({\n",
        "            \"finbert_pos_avg3\": np.nan,\n",
        "            \"finbert_neg_avg3\": np.nan,\n",
        "            \"finbert_neu_avg3\": np.nan,\n",
        "            \"finbert_score_avg3\": np.nan,\n",
        "            \"finbert_score_std3\": np.nan,\n",
        "            \"finbert_confidence\": np.nan,\n",
        "            \"finbert_entropy\": np.nan\n",
        "        })\n",
        "\n",
        "    scores = []\n",
        "    probs_list = []\n",
        "\n",
        "    for c in chunks:\n",
        "        pos, neg, neu = _finbert_probs(c)\n",
        "        probs_list.append([pos, neg, neu])\n",
        "        scores.append(pos - neg)\n",
        "\n",
        "    probs_arr = np.array(probs_list)\n",
        "    pos_avg, neg_avg, neu_avg = probs_arr.mean(axis=0)\n",
        "\n",
        "    score_avg = float(np.mean(scores))\n",
        "    score_std = float(np.std(scores)) if len(scores) > 1 else 0.0\n",
        "\n",
        "    #Confidence & entropy from averaged probs\n",
        "    conf = float(max(pos_avg, neg_avg, neu_avg))\n",
        "    p = np.array([pos_avg, neg_avg, neu_avg])\n",
        "    ent = float(-(p * np.log(p + 1e-12)).sum())\n",
        "\n",
        "    return pd.Series({\n",
        "        \"finbert_pos_avg3\": float(pos_avg),\n",
        "        \"finbert_neg_avg3\": float(neg_avg),\n",
        "        \"finbert_neu_avg3\": float(neu_avg),\n",
        "        \"finbert_score_avg3\": score_avg,\n",
        "        \"finbert_score_std3\": score_std,\n",
        "        \"finbert_confidence\": conf,\n",
        "        \"finbert_entropy\": ent\n",
        "    })"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "m0LHcfxJRn6m",
        "outputId": "a6c2d6ad-489e-4b3f-f5f4-b9fd1462aa9c"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "BertForSequenceClassification(\n",
              "  (bert): BertModel(\n",
              "    (embeddings): BertEmbeddings(\n",
              "      (word_embeddings): Embedding(30522, 768, padding_idx=0)\n",
              "      (position_embeddings): Embedding(512, 768)\n",
              "      (token_type_embeddings): Embedding(2, 768)\n",
              "      (LayerNorm): LayerNorm((768,), eps=1e-12, elementwise_affine=True)\n",
              "      (dropout): Dropout(p=0.1, inplace=False)\n",
              "    )\n",
              "    (encoder): BertEncoder(\n",
              "      (layer): ModuleList(\n",
              "        (0-11): 12 x BertLayer(\n",
              "          (attention): BertAttention(\n",
              "            (self): BertSelfAttention(\n",
              "              (query): Linear(in_features=768, out_features=768, bias=True)\n",
              "              (key): Linear(in_features=768, out_features=768, bias=True)\n",
              "              (value): Linear(in_features=768, out_features=768, bias=True)\n",
              "              (dropout): Dropout(p=0.1, inplace=False)\n",
              "            )\n",
              "            (output): BertSelfOutput(\n",
              "              (dense): Linear(in_features=768, out_features=768, bias=True)\n",
              "              (LayerNorm): LayerNorm((768,), eps=1e-12, elementwise_affine=True)\n",
              "              (dropout): Dropout(p=0.1, inplace=False)\n",
              "            )\n",
              "          )\n",
              "          (intermediate): BertIntermediate(\n",
              "            (dense): Linear(in_features=768, out_features=3072, bias=True)\n",
              "            (intermediate_act_fn): GELUActivation()\n",
              "          )\n",
              "          (output): BertOutput(\n",
              "            (dense): Linear(in_features=3072, out_features=768, bias=True)\n",
              "            (LayerNorm): LayerNorm((768,), eps=1e-12, elementwise_affine=True)\n",
              "            (dropout): Dropout(p=0.1, inplace=False)\n",
              "          )\n",
              "        )\n",
              "      )\n",
              "    )\n",
              "    (pooler): BertPooler(\n",
              "      (dense): Linear(in_features=768, out_features=768, bias=True)\n",
              "      (activation): Tanh()\n",
              "    )\n",
              "  )\n",
              "  (dropout): Dropout(p=0.1, inplace=False)\n",
              "  (classifier): Linear(in_features=768, out_features=3, bias=True)\n",
              ")"
            ]
          },
          "metadata": {},
          "execution_count": 19
        }
      ],
      "source": [
        "import torch\n",
        "\n",
        "device = torch.device(\"cuda\" if torch.cuda.is_available() else \"cpu\")\n",
        "model = model.to(device)\n",
        "model.eval()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 204
        },
        "id": "gO9Y-VLVWBHD",
        "outputId": "d013ff8b-7d61-45df-b122-6af452d80e62"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "  symbol chosen_sector report_date  vader_mean  finbert_score_avg3  \\\n",
              "0   AAPL    Technology  2025-10-30    0.245773            0.346798   \n",
              "1   AAPL    Technology  2025-07-31    0.251060            0.266943   \n",
              "2   AAPL    Technology  2025-05-01    0.216898            0.331313   \n",
              "3   AAPL    Technology  2025-01-30    0.276358            0.346382   \n",
              "4   AAPL    Technology  2024-10-31    0.294967            0.268895   \n",
              "\n",
              "   finbert_confidence  finbert_entropy  sentiment_disagreement  \n",
              "0            0.622190         0.727678                0.101025  \n",
              "1            0.583298         0.875443                0.015883  \n",
              "2            0.627497         0.739914                0.114415  \n",
              "3            0.621829         0.729095                0.070024  \n",
              "4            0.693248         0.687532                0.026073  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-3c834788-3cb6-484b-b94a-d5d133af308f\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>symbol</th>\n",
              "      <th>chosen_sector</th>\n",
              "      <th>report_date</th>\n",
              "      <th>vader_mean</th>\n",
              "      <th>finbert_score_avg3</th>\n",
              "      <th>finbert_confidence</th>\n",
              "      <th>finbert_entropy</th>\n",
              "      <th>sentiment_disagreement</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>Technology</td>\n",
              "      <td>2025-10-30</td>\n",
              "      <td>0.245773</td>\n",
              "      <td>0.346798</td>\n",
              "      <td>0.622190</td>\n",
              "      <td>0.727678</td>\n",
              "      <td>0.101025</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>Technology</td>\n",
              "      <td>2025-07-31</td>\n",
              "      <td>0.251060</td>\n",
              "      <td>0.266943</td>\n",
              "      <td>0.583298</td>\n",
              "      <td>0.875443</td>\n",
              "      <td>0.015883</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>Technology</td>\n",
              "      <td>2025-05-01</td>\n",
              "      <td>0.216898</td>\n",
              "      <td>0.331313</td>\n",
              "      <td>0.627497</td>\n",
              "      <td>0.739914</td>\n",
              "      <td>0.114415</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>Technology</td>\n",
              "      <td>2025-01-30</td>\n",
              "      <td>0.276358</td>\n",
              "      <td>0.346382</td>\n",
              "      <td>0.621829</td>\n",
              "      <td>0.729095</td>\n",
              "      <td>0.070024</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>AAPL</td>\n",
              "      <td>Technology</td>\n",
              "      <td>2024-10-31</td>\n",
              "      <td>0.294967</td>\n",
              "      <td>0.268895</td>\n",
              "      <td>0.693248</td>\n",
              "      <td>0.687532</td>\n",
              "      <td>0.026073</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-3c834788-3cb6-484b-b94a-d5d133af308f')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-3c834788-3cb6-484b-b94a-d5d133af308f button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-3c834788-3cb6-484b-b94a-d5d133af308f');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-5719777e-d839-4844-aaa1-06ffc90148d9\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-5719777e-d839-4844-aaa1-06ffc90148d9')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-5719777e-d839-4844-aaa1-06ffc90148d9 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"]]\",\n  \"rows\": 5,\n  \"fields\": [\n    {\n      \"column\": \"symbol\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"AAPL\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chosen_sector\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Technology\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"report_date\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2024-10-31 00:00:00\",\n        \"max\": \"2025-10-30 00:00:00\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"2025-07-31 00:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"vader_mean\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.029940457894133184,\n        \"min\": 0.21689804772234275,\n        \"max\": 0.29496705069124424,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          0.2510599078341014\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"finbert_score_avg3\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.040786574548558927,\n        \"min\": 0.26694286863009137,\n        \"max\": 0.3467975997676452,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          0.26694286863009137\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"finbert_confidence\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.03973251045444513,\n        \"min\": 0.5832982957363129,\n        \"max\": 0.6932484209537506,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          0.5832982957363129\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"finbert_entropy\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.07186191938791622,\n        \"min\": 0.6875318682722277,\n        \"max\": 0.8754429791491313,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          0.8754429791491313\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"sentiment_disagreement\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.04385072211626753,\n        \"min\": 0.015882960795989942,\n        \"max\": 0.11441530282600407,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          0.015882960795989942\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 20
        }
      ],
      "source": [
        "#flatten the existing dict\n",
        "finbert_symbols = [t for lst in sector_tickers.values() for t in lst]\n",
        "\n",
        "#keep only these 10 companies for FinBERT\n",
        "df_finbert = df_big[df_big[\"symbol\"].isin(finbert_symbols)].copy()\n",
        "\n",
        "#run FinBERT only on this subset\n",
        "fb = df_finbert[\"content_full\"].apply(finbert_features)\n",
        "\n",
        "df_finbert = pd.concat(\n",
        "    [df_finbert.reset_index(drop=True), fb.reset_index(drop=True)],\n",
        "    axis=1\n",
        ")\n",
        "\n",
        "#Disagreement between FinBERT and your VADER sentence-mean\n",
        "df_finbert[\"sentiment_disagreement\"] = (\n",
        "    df_finbert[\"finbert_score_avg3\"] - df_finbert[\"vader_mean\"]\n",
        ").abs()\n",
        "\n",
        "#Quick check\n",
        "df_finbert[[\n",
        "    \"symbol\",\"chosen_sector\",\"report_date\",\n",
        "    \"vader_mean\",\n",
        "    \"finbert_score_avg3\",\"finbert_confidence\",\"finbert_entropy\",\n",
        "    \"sentiment_disagreement\"\n",
        "]].head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "u7i_nYuZZKIW"
      },
      "outputs": [],
      "source": [
        "finbert_cols = [\n",
        "    \"symbol\",\"report_date\",\n",
        "    \"finbert_score_avg3\",\"finbert_confidence\",\"finbert_entropy\",\n",
        "    \"finbert_score_std3\",\"sentiment_disagreement\"\n",
        "]\n",
        "\n",
        "df_big = df_big.merge(df_finbert[finbert_cols], on=[\"symbol\",\"report_date\"], how=\"left\")"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "hpqGGxPG7koc"
      },
      "source": [
        "## Key Variables\n",
        "\n",
        "- **Identifiers & Firm Metadata:**  \n",
        "  `symbol`, `shortName`, `chosen_sector`, `yf_industry`, `market_cap_billion`,  \n",
        "  `report_date`, `fiscal_year`, `fiscal_quarter`\n",
        "\n",
        "- **Transcript Content:**  \n",
        "  `content_full`, `transcripts`, `transcripts_id`\n",
        "\n",
        "- **VADER-Based Sentiment & Style:**  \n",
        "  `vader_mean`, `vader_pos_share`, `vader_neg_share`, `vader_neu_share`,  \n",
        "  `avg_sentence_length`\n",
        "\n",
        "- **FinBERT-Based Sentiment (Deep NLP):**  \n",
        "  `finbert_score_avg3`, `finbert_confidence`, `finbert_entropy`,  \n",
        "  `finbert_score_std3`\n",
        "\n",
        "- **Hybrid Linguistic Feature:**  \n",
        "  `sentiment_disagreement`  \n",
        "  *(absolute difference between FinBERT sentiment and VADER sentiment)*\n",
        "\n",
        "- **Market Reaction Variables:**  \n",
        "  `price_return_1day`, `price_return_3day`, `price_return_5day`,  \n",
        "  `bench_return_5day`, `CAR5`, `volume_change`\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "mQLlLhWqZM2_",
        "outputId": "29184236-2dd5-4f00-83b8-b4f0c21f71c0"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Index(['symbol', 'shortName', 'chosen_sector', 'yf_industry',\n",
              "       'market_cap_billion', 'report_date', 'fiscal_year', 'fiscal_quarter',\n",
              "       'transcripts', 'transcripts_id', 'content_full', 'vader_mean',\n",
              "       'vader_pos_share', 'vader_neg_share', 'vader_neu_share',\n",
              "       'avg_sentence_length', 'day0', 'price_return_1day', 'price_return_3day',\n",
              "       'price_return_5day', 'bench_return_5day', 'CAR5', 'volume_change',\n",
              "       'finbert_score_avg3', 'finbert_confidence', 'finbert_entropy',\n",
              "       'finbert_score_std3', 'sentiment_disagreement'],\n",
              "      dtype='object')"
            ]
          },
          "metadata": {},
          "execution_count": 22
        }
      ],
      "source": [
        "df_big.columns #all the columns in the big DataFrame"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "50yHuNZvQg4h"
      },
      "source": [
        "#Research Questions\n",
        "\n",
        "1. Can sentiment extracted from earnings call language predict short-term abnormal stock returns?\n",
        "\n",
        "- Can earnings calls be used to predict whether CAR5 is positive or negative?\n",
        "\n",
        "- Does sentiment have more predictive power for 1-day vs 5-day returns?\n",
        "\n",
        "- Does model performance improve when combining VADER + FinBERT features?\n",
        "\n",
        "2. Are some firms and sectors more sentiment-sensitive than others in terms of market reaction?\n",
        "\n",
        "- Does sentiment predict returns better in Technology and Consumer Discretionary than in Financials?\n",
        "\n",
        "- Does firm size (market cap) dampen or amplify sentiment effects?\n",
        "\n",
        "- Are sentiment-based predictions more accurate for certain sectors?\n",
        "\n",
        "3. Does communication style and emotional intensity improve predictions beyond sentiment polarity alone?\n",
        "\n",
        "- Do emotionally intense earnings calls (high confidence / low entropy) lead to stronger market reactions?\n",
        "\n",
        "- Does disagreement between FinBERT and VADER signal uncertainty that markets react to?\n",
        "\n",
        "- Are clearer, simpler earnings calls more predictable than complex ones?"
      ]
    }
  ],
  "metadata": {
    "accelerator": "GPU",
    "colab": {
      "gpuType": "T4",
      "provenance": []
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}